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ABSTRACT
This dissertation is a critical examination of the relationship between sleep problems and/or
disorders, particularly Obstructive Sleep Apnea (OSA) and Alzheimer Disease (AD). First, I conducted an
exhaustive systematic review of existing literature, and identified gaps in research that led to specific
research aims. For the first aim, I conducted the first ever-published meta-analysis examining sleep,
cognitive decline and AD, providing an aggregate effect of sleep on AD. Second, focusing on OSA, I
conducted a study examining OSA’s effect on longitudinal changes on AD biomarkers in cognitive
normal, MCI and AD subjects, using data from the Alzheimer Disease Neuroimaging Initiative (ADNI).
Lastly, I conducted a review, integrating over 3 decades of research examining OSA and cognition; OSA
and subsequent cognitive decline; and OSA and AD; with particular focus in appreciating the
heterogeneity of OSA and its outcomes in distinct age groups.
Results and implications from my research indicate that ample evidence exists linking sleep
impairments and circadian regulating mechanisms directly to clinical symptoms in AD. Sleep problems
and/or disorders increases your risk of cognitive decline and AD. OSA is associated with increased AD
biomarker burden over time, and effects longitudinal changes in these biomarkers, such that OSA subjects
progress faster than non-OSA subjects do. OSA may be age-dependent in older adults (60 – 70 years old)
and the elderly (70 years and above) and is associated with neurodegenerative diseases particularly,
cognitive decline and AD. Intermittent hypoxia and sleep fragmentation are two main processes by which
OSA induces neurodegenerative changes. Therefore, clinical interventions aimed at OSA, such as
treatment with CPAP or dental appliances, in cognitive normal and MCI patients, could possibly slow the
progression of cognitive impairment to AD.
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SECTION 1
SYSTEMATIC REVIEW: SLEEP AND ALZHEIMER’S DISEASE
Note to the Reader:
Portions of this section have been previously published in SLEEP journal, 2017, Jan 1; 40(1). doi:
10.1093/sleep/zsw032 and have been reproduced with permission from Oxford University Press.
ABSTRACT
Background/Objective: Alzheimer’s disease (AD) is a neurodegenerative disorder with expected
incidence of approximately a million people each year, and a total estimated prevalence of 11 to 16
million people by 2050 in the United States. Mounting evidence implicates sleep as one of the risk factors
for AD with an association between sleep disruption, cognitive ability, and neurodegenerative disease.
We systematically reviewed all available studies examining any association and/or relationship and/or
biologic plausibility between sleep and its related problems/disorders and Alzheimer’s disease, cognitive
decline or dementia and evaluated the evidence for a causal association.
Methods: Original published literature assessing any association of sleep and its related
problems/disorders with AD, cognitive decline or dementia was identified by searching four bibliographic
databases, namely PubMed, Embase, Web of Science, and Cochrane library (i.e., the Cochrane Central
Register of Controlled Trials). Searches on all databases were from the onset of the archives until and
including November, 2014. The terms Alzheimer, Mild Cognitive Impairment, Sleep, Sleep Disorders
and Circadian Rhythm were identified as MeSH terms. Other MeSH search headings related to sleep and
various study types including cross-sectional, case control, cohort (retrospective and prospective),
Randomized Clinical Trials (RCTs) were also identified. Articles identified from the search were first
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screened using titles and abstracts of the publications and eligible articles for this review had to meet
certain inclusion and exclusion criteria.
Results: Seventy-two publications that met the selection and final inclusion criteria were identified by the
literature search: 18 studies and 12 studies used a cross-sectional analysis and case-control design
respectively, to examine the association of sleep alterations/disturbances, circadian rhythm abnormalities,
and/or sleep disorders with AD, cognitive decline and/or dementia; 22 studies were prospective studies
examining the relationship between sleep and cognitive outcomes; 4 RCTs examined cognitive effects of
treating sleep and its related problems/disorders in AD; and 16 experimental studies examined the
associations between sleep and AD pathology and/or AD biomarkers. Altogether, there is substantial
evidence providing support that sleep is associated with cognitive decline and/or AD/AD pathology.
Prospective studies provide support that sleep problems precede the onset of cognitive impairment,
including AD and dementia, and experimental studies provide the most compelling evidence of the
plausibility of causal associations between sleep deprivation and AD pathology and/or AD biomarkers.
Conclusion: There is growing experimental and epidemiological evidence for a reciprocal interaction
between cognitive decline and sleep alteration. Ample evidence exists linking sleep impairments and
circadian regulating mechanisms directly to clinical symptoms in AD. However, long-term longitudinal
studies are needed to determine the relationship of chronic sleep deprivation, circadian rhythm/sleepwake abnormalities, sleep-disordered breathing and sleep disorders with cognitive decline.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder with an incidence in the United States
expected by 2050 to be of a million new cases yearly, and a corresponding prevalence of 11 to 16 million
people.1 In 2013, approximately 5.2 million Americans had Alzheimer’s Disease (AD), including an
estimated 5 million age 65 and older.2 AD and other dementias cause significant morbidity and mortality
to those afflicted, with an enormous socio-economic impact: an estimated US$604 billion worldwide,
constituting about 1% of the aggregated global gross domestic product.3 Preventive and/or therapeutic
measures targeted at delaying or curing AD are therefore imperative.4 Advancing age is the most
significant risk factor for AD with most individuals with AD diagnosed at age 65 or older. Various risk
factors for AD including family history,5-7 Apolipoprotein E epsilon4 allele (APOE-ε4 gene),8,9
smoking,10-12 diabetes,13-15 obesity in midlife,16-20 high cholesterol in midlife,17,21 hypertension in
midlife,22-24 physical activity,25-28 education,29,30 head circumference,31,32 head trauma,33,34 brain reserve35
and social and cognitive engagement,36-38 have been identified in epidemiological studies and additional
risk factors are being investigated.39 Mounting evidence implicates sleep as one of these factors.
Sleep and Normal Aging
Structural alterations of sleep, including sleep maintenance difficulty, sleep latency increase,
frequent nighttime and early morning awakenings, occur as part of the normal aging process.40 Various
sleep stages also show some level of alteration with increasing age including a reduction in slow wave
sleep (SWS) and a compensatory increase in sleep stages 1 and 2.40 Rapid-eye movement (REM) sleep
changes are less distinct and seem to appear later with increasing age.41,42 Microstructural alterations such
as decrease in K complexes and sleep spindles are also observed.43 Apart from these structural alterations
of sleep, sleep-wake rhythm disturbances have also been described in the elderly. Greater tendency for
daytime sleep and increased propensity to phase advancing are observed frequently.41 Circadian sleepwake rhythm disorders do not result from behavioral factors alone but also from neuro-hormonal
modifications, especially melatonin whose plasma concentration declines with age.44 Psychiatric and
3

somatic pathologies, pharmacological treatments, decrease in physical activity and exposure to light also
play a role in the origin of sleep disturbances in normal aging.40 Sleep disorders such as sleep-related
breathing disorders (SRBD), restless legs syndrome (RLS) and periodic limb movements in sleep (PLMS)
also increase significantly with age.41
Sleep and Demented older adults
Demented older adults exhibit significant sleep disturbance and degenerate sleep patterns,
including shorter sleep duration and fragmented sleep,43,45-47 altered circadian rest/activity patterns,45 and
elevated rates of sleep disordered breathing (SDB).48,49 It is estimated that about 45% of AD patients have
sleep disturbances.50,51 When symptoms appear at an early stage of the disease, they are frequently
associated with a more severe cognitive decline.50,52 Both circadian rhythm disruptions and sleep
disturbances have a major impact on the quality of life of patients and their caregivers.53-56 They have
been conventionally thought of as complications of various psychiatric co-morbidities50,57 secondary to
disease pathology. However, researchers have begun to examine whether sleep and its related problems
contribute to the risk of AD.58 Sources of sleep disturbance in AD are thought to include degeneration of
neural pathways that regulate sleep-wake patterns and sleep architecture.50,57 Sleep disorders may also
exacerbate cognitive symptoms through impairment of sleep-dependent memory consolidation
processes.59,60 Interestingly, circadian and sleep disorders may have a causal role in the pathophysiology
of AD, and could be critical to the goal of preventing AD, because effective interventions exist to
improve sleep.61
Previous narrative reviews
There are few narrative review articles,40,62-64 that have examined this association with focus on
different aspects of sleep disturbances and/or neurologic diseases. Palma et al.,62 focusing on sleep
deprivation, reviewed how sleep loss constitutes a risk factor for various neurologic diseases including
AD. In discussing sleep loss and AD, they concluded that it was necessary to distinguish between the
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possibility that the risk of AD is influenced by changes in rest activity patterns and sleep-wake cycles,
through their effects on underlying neurodegenerative processes or the alternative explanation that rest
activity and sleep-wake patterns are just markers of a subclinical neurodegenerative process. Slats et al.,63
focusing on the role of hypocretin and melatonin, described the impairments of both sleep regulating
systems and circadian rhythms in AD and their link to clinical symptoms. They further discussed how
sleep regulating systems, especially neurotransmitters such as melatonin and hypocretin, could affect AD
pathophysiology. They concluded that there is substantial evidence of impairments in both sleep and
circadian regulating mechanisms in AD pathophysiology, which may be linked directly to clinical
symptoms in AD patients. Peter-Derex et al.,40 did a thorough clinical review of sleep and Alzheimer’s
disease, observing that micro-architectural sleep alterations, nocturnal sleep fragmentation, decrease in
nocturnal sleep duration, diurnal napping and inversion of the sleep-wake cycle are the main disorders
observed in patients with AD. Further, they noted that there is growing experimental and epidemiological
evidence for a close reciprocal interaction between cognitive decline and sleep alterations.
Objective of this systematic review
To the best of our knowledge, there are no systematic review articles on sleep and AD or
Dementia. In this context, we conducted a broad systematic review of all available studies examining any
association of sleep and its related problems/disorders with Alzheimer’s disease, cognitive decline or
dementia, and evaluated the evidence for a causal association. Recommendations for future directions of
research are also proposed.
METHODS
We conducted this systematic review in accordance with the exemplified step-by-step guide for
systematic reviews and meta-analysis by Pai et al.,65 and for the purpose of reporting, we adhered to the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement by
Moher et al.66 We also consulted the Cochrane handbook for systematic reviews of interventions.67
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Identification of Eligible Studies
Electronic search
An extremely sensitive search strategy was developed and assisted with identification of all
eligible published articles in scientific (medical, psychological and epidemiological) journals for all years
up to November 2014. The electronic search strategy combined terms characterizing AD/AD
pathogenesis, as the outcome variable, Sleep, as the exposure variable, and a third set specified various
study types. All terms within each set were combined with the Boolean operator OR, and then all three
sets were then combined using AND.
Original published literature assessing associations of sleep and its related problems/disorders
with Alzheimer’s disease, cognitive decline or dementia were identified by searching four bibliographic
databases on November 21, 2014, namely:
•

Medline (through PubMed; all years 1946 - present)

•

Embase (through www.embase.com by Elsevier B.V. 2011; all years from 1947 - present)

•

Web of ScienceTM (Thomson Reuters 2014; all years from 1900 – present)

•

Cochrane library (i.e., the Cochrane Central Register of Controlled Trials; all years from 1900 present).

The terms Alzheimer, Mild Cognitive Impairment, Sleep, Sleep Disorders and Circadian Rhythm were
identified as MeSH terms. Other MeSH search headings related to sleep included sleep loss, sleep
deprivation, sleep apnea, sleep disruption, excessive daytime sleepiness, Obstructive Sleep Apnea (OSA),
Sleep-Disordered Breathing, Rapid Eye Movement Behavioral Disorder, melatonin, and hypocretin.
Search terms related to Alzheimer’s disease and AD pathogenesis included amyloid beta, amyloid
cascade hypothesis, Amyloid Precursor Protein (APP) and APOE-ε4. MeSH terms associated with
various study types included cross-sectional, case control, cohort (retrospective and prospective),
Randomized Clinical Trials (RCTs), literature reviews, systematic reviews, and ecological studies.
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Articles written in other languages other than English were also considered and screened with the help of
Google translator.
In PubMed, a search using Alzheimer’s disease and AD pathogenesis MeSH terms yielded
136,119 articles; and a search using sleep and its related problems/disorders MeSH terms yielded 185,925
articles. The combination of the Alzheimer’s disease and AD pathogenesis MeSH terms and sleep and its
related problems/disorders MeSH with MeSH terms associated with various study types, yielded a total of
904 publications. The PubMed search was adapted to searching the other databases. Table 1.1 provides a
list of the search terms used. The complete search strategy including the saved search histories in the
various databases is available on request.
Searching other sources
To locate additional relevant studies, the reference lists of articles identified through database
searches and the Bibliographies of narrative review articles were examined. We also hand-searched the
previous year’s issues (November 2013 to November 2014) of high ranking journals that published more
than one relevant identified article during the initial search, including Sleep Medicine Reviews,
Neurology, JAMA (Journal of American Medical Association), Sleep Medicine, American Journal of
Alzheimer’s Disease and other Dementias, Sleep, Journal of Sleep Research, Journal of clinical sleep
medicine, Journal of Alzheimer’s Disease, Brain, and Neurobiology of Aging.
Selection criteria
Type of study
Original articles from observational studies (cross-sectional, case-control and
retrospective/prospective cohort), Randomized Controlled Trials (RCT), and Animal Experimental
studies were included in this systematic review. Articles identified in the search were first screened using
titles and abstracts of the publications. Eligible studies for this review had to meet the following final
study inclusion criteria: (1) They reported a primary or secondary data analysis using an appropriate
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epidemiologic study design of any association of sleep and its related problems/disorders with
Alzheimer’s disease, cognitive decline or dementia; (2) The diagnosis of Alzheimer's
disease/dementia/cognitive decline was based on a self-reported diagnosis, on meeting standardized
criteria (e.g. International Classification of Disease-9 (ICD -9), Diagnostic Statistical Manual-IV (DSMIV)) or objective measures of Alzheimer pathology (e.g., Positron Emission Tomography (PET) scan); (3)
The finding of sleep and its related abnormalities/disorders was based on self-reported diagnosis or
standardized criteria/questionnaires (e.g., PQSI Pittsburg Sleep Quality Index (PQSI),68 Epworth
Sleepiness Scale (ESS)) or objective measures (e.g., wrist actigraphy69 or polysomnography (PSG)), (4)
Inclusion of a comparison group with or without varying levels of sleep disturbances/disorders or
cognitive decline/dementia/AD, whichever is applicable, and (5) The study provided a valid measure of
association between sleep and its related problems/disorders and Alzheimer’s disease, cognitive decline
or dementia with 95% confidence intervals and/or p-values. Exclusion criteria included the following: (1)
case series/reports, systematic and/or literature reviews, abstracts or editorials, (2) articles that did not
examine an association between sleep and its related problems/disorders and Alzheimer’s disease,
cognitive decline or dementia, and (2) any RCT that did not examine the cognitive effects of treating
sleep and its related problems/disorders in AD.
Sleep abnormalities and/or disorders
Sleep abnormality and/or disorder was considered as the risk factor of interest in this systematic
review. The international Classification of Sleep Disorders (ICSD-2)70 aptly describes and classifies sleep
disorders, however, previous studies71,72 examining the association between sleep and workplace injuries
made use of various concepts to define sleep problems in order to fit their study design. Accordingly, in
this systematic review, we classified sleep based on the measured sleep parameter and eligible studies in
this review were grouped on this basis. Sleep parameters including duration, quality, efficiency and/or
disturbance were classified as sleep depth problems; circadian rhythm abnormalities, and excessive
daytime sleepiness (EDS) were classified as sleep-wake cycle abnormalities; the apnea hypopnea index
8

(AHI) that measures hypoxia levels in sleep was used to refer to Sleep Disordered Breathing (SDB),
Sleep Apnea (SA) and/or Obstructive Sleep Apnea Syndrome (OSAS); and lastly other sleep disorders
referred to insomnia and Restless Leg Syndrome (RLS). Studies that examined multiple sleep parameters
e.g., circadian rhythm abnormalities and Insomnia, were reviewed under the various sleep categories,
however, were still counted as one study.
Cognitive decline and/or Alzheimer’s disease Dementia
The outcome of interest in this review was Cognitive Decline and/or Alzheimer’s disease.
Eligible studies were expected to have diagnosed cognitive decline and/or Alzheimer's disease based on a
self-reported diagnosis that met standardized criteria (e.g. International Classification of Disease-9 (ICD 9), Diagnostic Statistical Manual-IV (DSM-IV)) or on objective measures of Alzheimer pathology (e.g.,
Positron Emission Tomography (PET) scan). AD is the most common form of Dementia accounting for
up to 50-80% of dementia cases,1 as such studies that had dementia as an outcome were also considered.
Studies that solely looked at specific forms of dementia other than AD e.g., vascular, Lewy body,
frontotemporal dementia were excluded.
Data Extraction
An independent assessment of all the titles and abstracts of all eligible study identified by the
search strategy was performed by two authors (OB, SS) using EndNote X6. Potential articles for the study
were retrieved and examined for possible inclusion by the same two authors. Discordances that were
unresolved in unison were referred to a third author (AB). Excel spreadsheet and extraction sheets created
in Access (Microsoft Office version 2010) was then used for the data extraction. This was independently
done by two reviewers (OB, JM), and extracted categories included the study design, study population,
exposure assessment, outcome assessment, statistical methods and tests used, covariates as well as the
main results of the study. Differences in the information extracted were resolved by a third author (MD)
Reviewers were not blinded to the funding, authors, or institutions.
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Assessment of study quality
Study quality was assessed using an adaptation from previous systematic reviews73,74 and the
modified version of the Newcastle-Ottawa scale (NOS) for quality assessment of the observational
studies,75,76 with addition of new items relevant to this review (Table 1.2). Two review authors (OB, JM)
assessed each included study separately. Any disagreement between the two review authors was settled
by consensus, or where necessary, by a third party (YW). Parameters used for the quality assessment
included well specified hypothesis, study design type, appropriately described sample population, sample
size, definition of sleep and its related abnormalities, definition of Alzheimer's disease/dementia/cognitive
decline, statistical analytical methods, and inclusion or approach used to adjust for potential confounders.
The quality rating scale was adapted to specific study design, and each category had specific maximum
number of awarded stars (Tables 1.3 – 1.6). Quality scores were awarded such that the minimum number
of stars a study can get was 5. For cross-sectional studies, 16 stars was the maximum possible; for casecontrol, cohort studies and RCTs 20 stars was the maximum possible, and for animal experimental studies
15 stars was the maximum possible. Quality indicators of most significance for this review (given the
highest weights) included appropriate definition of sleep and its related abnormalities, study population
and adjustment for potential confounders (such as age, years of education, marital status, forced
expiratory volume (FEV) in one second based on spirometry, self-reported history of physician’s
diagnosis of asthma, number of hours of sleep and napping, and use of benzodiazepines, Chronic
Obstructive Pulmonary Disease (COPD), nonfatal coronary heart disease including myocardial infarction,
stroke, the ankle-brachial index, Apolipoprotein E-epsilon4 (APOE-ε4) genotype, Body Mass Index
(BMI) and Depression). Studies were divided into three categories: low quality (< 50% of the maximum
number of stars), medium quality (≈ 55-70% of the maximum number of stars), and high quality (75% or
more of the maximum number of stars) (Tables 1.3 – 1.6).
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Risk of Bias in Individual Studies
Studies were thoroughly reviewed and the risk of bias within individual studies was assessed by
examining the appropriateness of the study design as it relates to the study hypothesis, how each study
defined and/or ascertained their exposure and/or outcome, and whether appropriate comparison was done
with the unexposed participants. Appropriate identification and/or selection of study participants to
minimize selection bias risk was also important. It was essential that diagnoses were properly assessed
and/or validated, and that studies reported which diagnosis or symptomatology was utilized, and if using
various databases, how overlapping data was handled. Study data were also assessed to determine if
completeness and potential publication/reporting bias could be evaluated.
Observational data from studies
Evidence from the reviewed studies was harmonized and integrated using a narrative synthesis77
and reported data is presented making use of accepted and recognized conventional guidelines78

RESULTS
Study Selection
A total of 2341 publications were identified doing a literature search in PubMed, Embase, Web of
Science, and Cochrane library (i.e., the Cochrane Central Register of Controlled Trials), with each
yielding 904, 1026, 305 and 106 publications respectively (Figure 1.1). One thousand, one hundred and
twenty duplicates were identified and removed of which 90% were from PubMed, and Embase. After
duplicates were removed, 1221 publications were screened for titles resulting in the exclusion of 180
publications because titles did not reflect an examination of an association between sleep and Alzheimer’s
disease. The remaining 1041 publications were screened using the published abstracts resulting in the
exclusion of 840 publications that were removed because they were either case series/reports or were
systematic and/or literature reviews, abstracts or editorials. Two hundred and one full text articles were
assessed for eligibility and 130 publications were further excluded, of which 105 publications identified
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were excluded because they did not address an association between sleep and its related
problems/disorders and Alzheimer’s disease, cognitive decline or dementia or did not estimated a measure
of association that included 95% confidence intervals or p-values. Twenty-five RCTs were excluded
because they did not examine cognitive effects of treating sleep and its related problems/disorders in AD.
One study was included from a search of the reference lists of articles identified through database
searches. Seventy-two articles met all eligibility criteria.
Study Characteristics (Design and Quality)
Among the 72 studies identified, 18 studies51,79-95 and 12 studies96-107 used a cross-sectional
analysis and case-control design respectively, to examine the association of sleep alterations/disturbances,
circadian rhythm abnormalities, and/or sleep disorders with AD, cognitive decline and/or dementia; 22
studies108-129 were prospective studies examining the relationship between sleep and cognitive outcomes;
4 RCTs130-133 examined cognitive effects of treating sleep and its related problems/disorders in AD; and
16 experimental studies134-149 examined the associations between sleep and AD pathology and/or AD
biomarkers (Table 3). One110 of the prospective studies examining the relationship between sleep and
cognitive outcomes was in Polish; the remaining studies were in English. In total 36 studies were assessed
to be of high quality (16 experimental studies,134-149 3 RCTs,130,132,133 14 prospective studies,109,111,112,114116,118,119,121,122,124,126-128

and 3 cross-sectional studies79,83,86); 22 studies were assessed to be of medium

quality (1 RCT,131 6 prospective studies,108,117,120,123,125,129 7 case-control studies,97-99,101,105-107 and 8 crosssectional studies51,84,85,88-90,93,94); and 14 studies were assessed to be of low quality (2 prospective
studies,110,150 5 case-control96,100,102-104 and 7 cross-sectional studies80-82,87,91,92,95) (Table 1.3 – 1.6). Type of
study, selection bias related to sampling, measurements of sleep and/or AD solely based on self-reporting,
and insufficient adjustment for core confounders, were the main shortfalls.
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Participants and setting
The 72 studies included in the systematic review were published between 1998 and 2014. Human
participants of the included studies were middle aged and elderly adults of both sexes with age ranging
from 40 – 91 years cutting across North America (38 studies), Europe (22 studies), Australia (1 study),
Asia (7 studies) and collaborations between continents (5 studies). Participants were drawn from settings
that included communities (32 studies), hospital/patient population (20 studies), institutions e.g., nursing
home residents (4 studies), and brain autopsies (1 study). In total, 50 studies included both sexes, 6
studies were based on females, and three studies were based on males only. Fifteen experimental studies
that made use of AD transgenic mice were also included.
Sleep abnormalities and/or disorders
There was a considerable amount of variation in the methods used by the studies to assess for
sleep problems. Most studies (n=35) utilized objective measures (e.g., wrist actigraphy69 or
polysomnography (PSG), while 11 studies utilized standardized questionnaires including the Pittsburg
Sleep Quality Index (PQSI),68 Epworth Sleepiness Scale (ESS), Berlin questionnaire,151 Behavioral
pathology in AD rating scale, the BEHAVE-AD,152 Women’s Health Initiative Insomnia Rating Scale
(WHIIRS),153 and the International RLS Study Group questionnaire.154,155 Only five studies utilized selfconstructed questionnaires while 4 studies made use of Fluorescence Immuno Assays (FIA) to determine
melatonin/hypocretin concentrations. The experimental studies (n=16) conducted cell culture, transfection
and hypoxic treatment tests or utilized immuno-assays, Enzyme Linked Immuno-sorbent Assay (ELISA),
Western Blot tests to determine melatonin concentrations and/or forced experimental mice into states of
wakefulness. In total, 30 studies (i.e., 10 cross-sectional,51,79,80,82,84,85,88,92-94 5 case-control,96,98-100,105 9
prospective cohort,109-111,116,118,120,122,125,126 1 retrospective cohort,123 4 experimental studies136,138,142 and 1
RCT133) examined sleep depth parameters, 23 studies examined sleep-wake /circadian rhythm
abnormalities (i.e., 5 cross-sectional,87,89,91,95,102 4 case-control,97,101,106,107 6 prospective
cohort,108,118,119,124,127,129 7 experimental studies134,135,137,140,143-145 and 1 RCT131), 16 studies examined
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hypoxia states (AHI) in sleep apnea/sleep disordered breathing (i.e., 4 cross-sectional,81,83,86,90 1 casecontrol,103 3 prospective cohort,125,128,150 1 retrospective cohort,112 2 RCTs,130,132 and 5 experimental
studies139,141,147-149), 6 studies (i.e., 2 cross-sectional87,92 and 4 prospective cohort studies114,115,117,121)
examined sleep as insomnia and 3 studies (i.e., 2 cross-sectional84,92 and 1 case-control104) examined
sleep as RLS.
Cognitive decline and/or Alzheimer’s disease Dementia
There was also great variability in the methods used to diagnose cognitive decline and/or
Alzheimer’s disease Dementia. Most studies made use of self-reported diagnosis that met standardized
criteria (e.g. International Classification of Disease-9 (ICD -9),156 Diagnostic Statistical Manual-IV
Revised Text (DSM-IV TR),157 National Institute of Neurological and Communicative Disorders and
Stroke/Alzheimer’s Disease and Related Disorders Association (NINCS–ARDRA).158 Mild Cognitive
Impairment (MCI) was mostly diagnosed using the Petersen criteria. 159 Cognitive function was assessed
by a battery of neuropsychological tests (mostly with the Mini Mental State Examination (MMSE), 160
California Verbal Learning Test (short form),161 Rey-Osterrieth complex figure,162 Verbal Fluency,
Wechsler Adult Intelligence Score (digit symbol, digit span).163 Emotional state was mostly assessed with
the Geriatric Depression Scale164 and functioning in daily living with Functional Activities
Questionnaire,165 and dementia severity was mostly assessed using the Clinical Dementia Rating Scale
(CDR). Objective measures of Alzheimer pathology (e.g., Positron Emission Tomography (PET) scan for
amyloid load (Aβ), Polymerase Chain reaction (PCR) for APOE genotyping), were also done.
Study findings
A. Sleep depth and cognitive decline and/or Alzheimer’s disease dementia
In total, 30 studies (i.e., 10 cross-sectional,51,79,80,82,84,85,88,92-94 5 case-control,96,98-100,105 9
prospective cohort,109-111,116,118,120,122,125,126 1 retrospective cohort,123 4 experimental studies136,138,142 and 1
RCT133) examined the association between sleep depth (i.e., sleep quality, duration, sleep latency, sleep
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efficiency and/or disturbance), and cognitive decline and/or Alzheimer’s disease Dementia. Table 1.7
presents the results of the descriptive study characteristics, statistical methods and main findings of the
studies.
A.1 Cross-sectional studies
Nebes et al88 examined the association between sleep quality (i.e., sleep duration, sleep latency
and sleep efficiency) and cognitive performance while controlling for the effects of some common
confounding conditions including anticholinergic drug burden and found that sleep quality was associated
with cognition. The association was not explained by confounding factors such as cerebrovascular
disease, depression, or medication usage. Blackwell et al79 (2006) examined the association between
objectively measured fragmented sleep and decreased cognitive function in a cohort of 2,242 communitydwelling women 65 years old or older with a baseline Cognitive Abilities Screening Instrument (CASI)
score of >=74 points. The CASI is a composite of the Hasegawa Dementia Screening Scale, the Folstein
Mini-Mental State Examination,160 and the Modified Mini-Mental State Test.166 They found that women
with <70% sleep efficiency had a 61% higher risk of cognitive impairment when compared with women
with sleep efficiency >=70%. Higher sleep latency was also associated with higher risk of cognitive
impairment as was higher Wake after Sleep Onset (WASO). There was no significant relationship for
total sleep time. Saint Martin et al93 examined the association between sleep quality, subjective
cognitive complaints, and neuropsychological performance in a cohort of 272 healthy elderly subjects
(mean age 74.8 ± 1.1 years) recruited from a population-based cross-sectional study on aging and
cardiovascular morbidity, and found that in healthy elderly subjects subjective sleep quality and duration
was not associated with subjective and objective cognitive performances, except for attention. However,
in this study, sleep duration and quality were self-reported and the authors had no information on sleep
structure and sleep fragmentation, two factors implicated in self-reported cognitive deficits.
Guarnieri et al84 described the frequency and characteristics of sleep disturbances in a large
cohort of persons with mild cognitive impairment or dementia and found that over 60% of the participants
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had one or more sleep disturbances, almost invariably associated with each other but without any evident
and specific pattern of co-occurrence. Persons with AD and those with MCI had the same frequency of
any sleep disorder. This study suffered from considerable selection bias issues as patients were enrolled
consecutively and selected for specific characteristics including the presence and type of sleep disorders.
Moran et al51 using 215 attendees at a memory clinic who were diagnosed with AD found the prevalence
of sleep disturbance in the sample to be 24.5%. Sleep disturbance in AD patients was also associated with
other behavioral symptoms, notably aggressiveness. Pistacchi et al92 enrolled 236 patients (78 men and
158 women) with different subtypes of dementia and investigated the frequency and characteristics of
sleep disorders in the sample. Patients with MCI had a frequency of sleep disturbances of any type equal
to that of patients with AD. Fetveit et al82 aimed to describe the characteristics of 24-hour sleep patterns
in nursing home patients with dementia and to determine whether various degrees of dementia have any
influence on total sleep duration. They found that sleep duration was positively correlated with the
severity of dementia in nursing home patients.
Studies that examine sleep associations with Alzheimer’s disease pathology or Alzheimer’s
disease biomarkers are extremely important to help clarify and consolidate efforts at establishing that AD
pathology might link poor sleep to cognitive outcomes. Since AD biomarkers are evident early in the
Alzheimer’s disease process, such findings might help foster directed preventive efforts at a time when
prevention may still be feasible.167 Spira et al94 examined the association between self-reported sleep
variables and Aβ deposition in 70 community-dwelling older adults who were part of the Baltimore
Longitudinal Study of Aging cohort. Participants underwent [11C]-Pittsburgh compound B PET (PiB
PET) amyloid imaging and completed self-report sleep measures. The investigators found that selfreported shorter sleep duration and poorer sleep quality both were associated with greater Aβ burden
according to a cortical (i.e. global) measure of PiB uptake, and a measure of uptake in the precuneus – a
region in which Aβ aggregates early in the Alzheimer’s disease course.168 Ju et al85 determined whether
Aβ deposition in preclinical AD, prior to the appearance of cognitive impairment, is associated with
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changes in quality or quantity of sleep in 142 cognitively normal middle-aged and older adults. They
found that amyloid deposition was associated with poorer sleep quality, specifically poorer sleep
efficiency (% time in bed that was spent asleep), compared to those without amyloid deposition. On the
contrary, sleep quantity (i.e., total sleep time) did not vary between groups. Napping also frequently was
associated with amyloid deposition.
Craig et al80 investigated the monoamine-A-oxidase promoter polymorphism that may impact
sleep/wake control by balancing the availability of serotonin, a precursor of melatonin. The authors found
that the high-activity 4-repeat allele of the monoamine-A-oxidase variable number tandem repeat
promoter polymorphism conferred increased susceptibility to sleep disturbance (p = .008). Nevertheless,
it is worth noting that allelic variations in this gene have been associated with behavioral and personality
traits in other contexts, which may explain this association.169 A quantitative sleep disturbance score was
signiﬁcantly higher in the patients possessing MAO-A 4-repeat allele genotypes. APOE had no inﬂuence
on the development of an altered sleep
A.2 Case-control studies
Hita-Yañez et al98 determined whether changes in polysomnographic (PSG) sleep patterns
accompany subjective sleep complaints in patients with mild cognitive impairment (MCI), whether
meaningful changes in objective sleep physiology are predicted by self-reported sleep measures in MCI
patients, and whether incipient neurodegeneration contributes to exacerbate sleep misperception. Both
PSG and self-reported sleep measures confirmed that sleep is altered in patients with MCI. Whereas
subjective sleep responses predicted fragmentation of slow wave sleep (SWS) in healthy elderly (HE)
individuals, this relationship was not evident in MCI patients. Furthermore, patients with MCI showed
significant discrepancies in the estimation of sleep onset latency when compared with HE subjects. This
study compared PSG sleep data recorded in 1 night with subjective sleep quality over the past few months
to establish relationships between objective and subjective sleep in HE subjects and patients with MCI.
This approach implicitly assumes that PSG data obtained from one single night is representative of a
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typical night in the past few months. PSG sleep studies were performed without previous adaptation of
participants to the sleep laboratory. As such, authors note that results might have been affected by the
first-night effect (i.e., differences observed on the first PSG sleep recording in comparison with
consecutive ones), which has previously been demonstrated to affect older patients more than younger
ones.170-172
The ApoE4 allele is a known susceptibility gene for AD,9,173-177 especially in homozygous
cases.178 In another study, Hita-Yañez et al99 determined if impaired sleep patterns appear years before
AD diagnosis and whether changes in sleep patterns parallel memory decline as well as its relationship
with the Apolipoprotein E (APOE) e4 genotype in 25 Mild Cognitive Impairment (MCI) patients (7
females, mean age: 70.5 ± 6.8 yr) and 25 healthy old (HO) volunteers (13 females, mean age: 67.1 ± 5.3
yr). The study results showed a significant shortening of rapid eye movement (REM) sleep together with
increased fragmentations of slow-wave sleep in MCI patients relative to healthy elders. Reduction of
REM sleep in MCI patients with APOE e4 was more noticeable than in e4 non-carriers. Changes in sleep
patterns were not correlated with memory performance in MCI patients. Instead, increased REM sleep
was associated with enhanced immediate recall in MCI e4 non-carriers.
Chen et al96 investigated changes in muscular activity, which may indicate a deficiency of
Acetylcholine (ACh), among patients with cognitive impairment, and recruited 9 controls without
dementia, 6 patients with mild cognitive impairment (MCI), and 6 patients with mild Alzheimer's disease
(AD). None of the participants had sleep complaints, and all AD patients were receiving cholinesterase
inhibitors. All participants underwent PSG examination using surface electromyographic (sEMG)
recording of both legs. A one-way analysis of variance (ANOVA) test was used to analyze the differences
in root mean square (rms) amplitude, peak frequency, and mean frequency among the three groups and
the results showed that all rms, mean frequencies, and peak frequencies increased significantly (p<0.05)
in MCI patients. The authors concluded that a deficiency of Ach may result in an increase sEMG activity
in MCI patients, and that because cholinesterase inhibitors are capable of suppressing sEMG activity in
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AD patients, an increase in sEMG activity is associated with a deficiency of Ach, which could be an early
indicator of dementia. Hot et al100 examined relationships between episodic memory deficits and
electroencephalography [EEG] abnormalities occurring during sleep in patients with early AD.
Polysomnographic sleep acquisition was performed and included continuous recordings of EEG. Results
showed that relative to age-matched controls, AD patients presented faster mean theta frequency in both
REM sleep and slow wave sleep [SWS]. In AD patients, a correlative analysis revealed that faster theta
frequency during SWS was associated with better delayed episodic recall. Authors concluded that the
results suggest that changes in theta rhythm during REM and SWS are a relevant index of brain
impairments in the early stage of AD whereas sleep architecture is not, and that changes in theta activity
during SWS are related to episodic memory performance.
Sanchez-Espinosa et al105 examined associations between changes in physiological sleep and
plasma Aβ concentrations in 21 healthy old (HO) adults and 21 amnestic Mild Cognitive Impairment
(aMCI) subjects. They further assessed whether these two factors were associated with cortical volume
loss in each group. Sleep parameters were assessed with PSG. The investigators found significant
relationships between disrupted slow-wave sleep (SWS) and increased plasma levels of Aβ42 among
aMCI, but not HO subjects. They also found correlations between shortened rapid-eye movement (REM)
sleep in aMCI and thinning of the posterior cingulate, precuneus, and post-central gyrus; whereas higher
levels of Aβ40 and Aβ42 accounted for grey matter (GM) loss of posterior cingulate and entorhinal
cortex, respectively.
A.3 Cohort studies
Keage et al118 investigated the effect of self- reported sleeping behaviors and incidence of
cognitive impairment over two and 10 years in two healthy aged English populations. Napping behavior
was found to be negatively associated with incident cognitive impairment, with those who napped more
being less likely to be cognitively impaired at two years (OR = 0.38, 95% CI 0.22–0.67) and 10 years
(OR = 0.48, 95% CI 0.29–0.78). Short night time sleep duration (<= 6.5 h) increased the risk of incident
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cognitive impairment over 10 years (OR = 2.02, 95% CI 1.17–3.48). The effect of long sleep duration (>=
9 h) failed to reach significance at both two and 10 years. The study did not account for relationships
between sleep and cognition with medication, cardiovascular factors, and metabolic diseases (other than
BMI). In addition, only cognitively healthy individuals were included at baseline so that the prognostic
effect of these sleep measures in those cognitively impaired or demented at baseline cannot be
extrapolated. Tworoger et al125 examined the association of sleep duration, snoring, and difficulty
sleeping with cognitive function in a cohort of community-dwelling women. Results showed that women
sleeping ≤5 hours/night scored worse than women sleeping 7 hours/night (mean difference on global
score combining all cognitive tests = 0.15 standard units, 95% CI: -0.28, -0.02). Women who regularly
had difficulty falling or staying asleep scored 0.11 units lower on the global score (95% CI: -0.22, 0.01)
compared with those who rarely had difficulty sleeping. These differences were equivalent to the mean
differences in score observed between participants who were 4 to 5 years apart in age. Authors found no
associations with snoring or with any of the sleep variables and cognitive decline over 2 years. In a
unique study, Virta et al126 investigated the association between midlife sleep characteristics (mean age
52 years) and late life cognitive function and dementia 18–26 years later in 2,336 members of the Finnish
Twin cohort who were at least 65 years of age, and found that reports of short (<7 h) and long (>8 h)
sleep duration, poor sleep quality, and use of hypnotic medications for more than 60 days per year were
associated with lower cognitive composite scores in old age; with long sleep being associated with
roughly 1.8 times the odds of developing AD. In this study, questionnaire data from 1981 were used in
the assessment of sleep characteristics, use of hypnotics, and covariates at baseline and between 1999 and
2007, and participants were assigned a linear cognitive score with a maximum score of 51 based on a
telephone interview (mean score 38.3, SD 6.1). Some of the associations differed by participant
characteristics, including Apolipoprotein E (APOE) e4 allele status, sex, and age, suggesting that poor
sleep may differentially affect cognition in different populations. The study revealed an association
between midlife sleep length and cognitive performance and AD based on medical records. With a mean
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follow-up time of above 20 years, temporality can be assessed between sleep disturbance and cognitive
outcomes, thereby providing evidence of a potential causal link from poor sleep to cognitive decline.
Song et al122 examined the associations between sleep stage distributions and subsequent decline
in cognitive function in community-dwelling men aged 67 or older (n = 2,601) who were free of probable
dementia at the time of sleep evaluation. Follow-up averaged 3.4 years. Sleep stages were identified by
in-home polysomnography at the initial sleep visit. The average percent of time spent in stages of sleep
were as follows: N1, 6.7% ± 4.1%; N2, 62.6% ± 9.5%; N3, 11.3% ± 8.9%; and R, 19.4% ± 6.6%. The
authors found that increased time in Stage N1 and less time in Stage R were associated with worsening
cognitive performance in older men over time. Blackwell et al111 (2014) examined associations of
objectively- and subjectively-measured sleep with subsequent cognitive decline over 3.4 ± 0.5 y in 2,822
cognitively intact community-dwelling older men (mean baseline age 76.0 ± 5.3 y). Diminished
actigraphic sleep efficiency (i.e. spending a lower proportion of time in bed asleep), greater nighttime
wakefulness, greater number of long wake episodes, and poor self-reported sleep quality measured by a
score greater than 5 on the Pittsburgh Sleep Quality Index (PSQI) were all associated with subsequent
cognitive decline. However, there was no association between sleep duration and cognition.
Sterniczuk et al123 examined whether self-reported sleep problems in individuals who were not
demented at baseline, are early independent markers of risk for developing AD or dementia over an
approximately 4-year period. Data on four sleep variables (sleeping problems and fatigue in past 6
months, sleep medication use, and ‘recent trouble sleeping or a change in pattern’) were collected, and the
authors created a composite ‘sleep disturbance index’ from those items. The authors found a 23% greater
odds of dementia or Alzheimer’s disease among participants with higher scores on the sleep disturbance
index compared to those with lower scores after adjusting for age, sex, education, body mass index
(BMI), and cognition. Also, individual sleep items independently predicted AD or dementia and mortality
within ~4 years. Benito-León et al109 using a population-based study of 3,857 people without dementia
aged 65 years and older (NEDICES [Neurological Disorders in Central Spain]) examined whether long
sleep duration was associated with increased risk of dementia mortality. In a Cox model that adjusted for
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numerous demographic factors and comorbidities, the hazard ratio for dementia mortality in long sleepers
was 1.63 (p = 0.03). Hahn et al116 examined a subjective report of change (reduced duration and/or
depth) in sleep pattern in relation to subsequent risk of incident all-cause dementia and Alzheimer disease
(AD) over a 9-year follow-up. Participants included 214 Swedish adults aged 75 and over who were
dementia-free both at baseline and at first follow-up (3 years later). Results showed that reduced sleep
was associated with a 75% increased all-cause dementia risk (hazard ratio: 1.75; 95% confidence interval:
1.04-2.93; Wald = 4.55, df = 1, p = 0.035) and double the risk of AD (hazard ratio: 2.01; 95% confidence
interval: 1.12-3.61; Wald = 5.47, df = 1, p = 0.019) after adjusting for age, gender, education, lifestyle and
vascular factors. However, results did not hold after adjusting for depressive symptoms, which was
measured with only one self-reported item. Findings are limited by the fact that the study did not include
objective longitudinal data on sleep. Bidzan et al110 found that patients in the preclinical period of
dementia were more likely to experience sleep disturbances and with greater intensity. The study was
conducted in Poland using 150 care centers residents age 55 and older. The presence of dementia was
excluded in the participants. After a follow-up period of 7 years, diagnosis of AD was established in 25
participants, while 111 people formed the control group.
Lim et al120 examined whether better sleep consolidation attenuates the relationship of the APOE
genotype to the risk of incident AD and the burden of AD pathology, in 698 community-dwelling older
adults without dementia (mean age, 81.7 years; 77% women) of the Rush Memory and Aging Project.
Participants were followed for up to 6 years. They found that better sleep consolidation attenuated the
effect of APOE genotype on incident AD and development of neurofibrillary tangle pathology, and
concluded that assessment of sleep consolidation may identify APOE+ individuals at high risk for
incident AD, and interventions to enhance sleep consolidation should be studied as potentially useful
means to reduce the risk of AD and development of neurofibrillary tangles in APOE ε4+ individuals.
A.4 Experimental studies
Mander et al142 determined whether regional brain atrophy, reduced slow wave activity (SWA)
during non–rapid eye movement (NREM) sleep and impaired long-term retention of episodic memories,
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independently recognized features of aging, are inter-related. The authors found that “age-related medial
prefrontal cortex (mPFC) gray-matter atrophy was associated with reduced NREM SWA in older adults
and statistically mediated the impairment of overnight sleep–dependent memory retention. Moreover, this
memory impairment was further associated with persistent hippocampal activation and reduced taskrelated hippocampal-prefrontal cortex functional connectivity, potentially representing impoverished
hippocampal-neocortical memory transformation”. Together, these data support a model in which agerelated mPFC atrophy diminishes SWA, the functional consequence of which is impaired long-term
memory. Such findings suggest that sleep disruption in the elderly, mediated by structural brain changes,
represents a contributing factor to age-related cognitive decline in later life. At a translational level, data
from this study endorses the possibility that improvements of SWA in older adults, through physiological,
behavioral or pharmacological means may represent a treatment target for minimizing the cognitive
decline associated with deficient long-term memory retention in later life.
Studies in AD mouse models support an association between sleep deprivation and AD
pathology. Kang et al138 in their study used in-vivo micro-dialysis in amyloid precursor protein (APP)
transgenic (Tg2576) mice (i.e. mice that overexpress mutant familial AD APP genes) and demonstrated
that both acute and chronic sleep deprivation alters brain interstitial fluid (ISF) Aβ diurnal rhythm. The
study also provided evidence of effects of hypocretin signaling on Aβ metabolism in studies of humans.
Circadian rhythm mean peak levels between 7 p.m. and 9 p.m. in human CSF Aβ levels were 28% higher
than the mean trough levels, which occurred between 9 a.m. and 11 a.m. A similar rhythm was found in
mice, with increased Aβ levels in brain interstitial fluid (ISF) while awake, compared to the sleep, both in
wild type C57BL6 mice and human APP transgenic mice, Tg2576. After being sleep deprived, mice spent
more time sleeping resulting in reductions in ISF Aβ levels. This suggests an association between
wakefulness, and increased ISF Aβ. Moreover, infusing the ventricle with a dual hypocretin receptor
antagonist resulted in suppressed ISF Aβ levels and the natural diurnal variation of Aβ was abolished. In
addition, hypocretin infusion led to significant decreases in ISF Aβ levels. The amount of ISF Aβ also
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significantly increased during acute sleep deprivation and during orexin infusion in multiple sub-regions
of the cortex. Remarkably, systemic treatment with infusion of a dual orexin receptor antagonist once
daily for 8 weeks decreased the Aβ plaque formation in aged, sleep deprived, APP transgenic mice. This
finding suggests that Aβ diurnal rhythm is related to sleep/wake regulation and that sleep deprivation
increases Aβ levels and promotes subsequent Aβ plaque formation in APP transgenic mice. Rothman et
al146 compared male AD transgenic mice that were subjected to 6-hours/day sleep for 6-weeks to controls
(>7-hour/day sleep). Biochemical (immunoblot) outcomes were compared to mice undergoing daily cage
transfers (large cage control; LCC) as well as control mice that remained in their home cage (control;
CTL). Mice subjected to 6-hours/day sleep displayed a non-significant increase of ∼80% and a two- fold
increase of both Aβ and P-Tau levels respectively in the cortex (P <0.22). Significant positive correlations
between cortical Aβ and p -Tau levels and circulating corticosterone were seen and possibly indicate a
potential role for glucocorticoids in mediating behavioral and biochemical changes observed after sleep
restriction in a mouse model of AD. Di Meco et al136 evaluated the functional and biological
consequences on 3xTg mice that underwent 4 hours sleep restraint per day for 8 weeks. Starting at the age
of 8 months, mice were randomized to 2 groups, one underwent a 20/ 4-hour light and/or dark cycle for 2
months (4 males and 5 females), the other was kept on a normal light and/or dark cycle, as controls (5
males and 4 females). Compared to controls, behavioral assessment showed that sleep deprived mice had
a significant decline in their learning and memory. Differences in the levels of soluble amyloid-b peptides
between the groups were not observed, however reductions in tau phosphorylation, with a significant
increase in its insoluble fraction was observed. Sleep deprivation also resulted in lower levels of
postsynaptic density protein 95 and increased glial fibrillary acidic protein levels. Finally, although total
levels of the transcription factor cellular response element binding protein were unchanged, its
phosphorylated form was significantly diminished in brains of sleep-deprived mice when compared with
controls. The authors noted that their mice were relatively young in age and that the observed absence of
effect on the Aβ levels provides support for their hypothesis that sleep deprivation is not a simple
biomarker of the underlying neurodegenerative disease, but a direct contributor to its pathogenesis.
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A.5 Randomized Controlled Trials
Ooms et al133 conducted an RCT to determine the effect of 1 night of total sleep deprivation on
cerebrospinal fluid Aβ42 protein levels in healthy middle-aged men. Participants were cognitively normal
middle-aged men (40-60 years of age) with normal sleep (n = 26) recruited from the local population.
Participants were randomized to 1 night with unrestricted sleep (n = 13) or 1 night of total sleep
deprivation (24 hours of wakefulness) (n = 13). Sleep was monitored using continuous polysomnographic
recording from 3 PM until 10 AM. Cerebrospinal fluid samples were collected using an intrathecal
catheter at defined times to compare cerebral Aβ42 concentrations between evening and morning. A night
of unrestricted sleep led to a 6% decrease in Aβ42 levels of 25.3 pg/mL (95% CI [0.94, 49.6], P = .04),
whereas sleep deprivation counteracted this decrease. A difference of 75.8 pg/mL of Aβ42 was shown
between the unrestricted sleep and sleep deprivation group (95% CI [3.4, 148.4], P = .04) when
accounting for the individual trajectories of Aβ42 over time. Individual evening and morning trajectories
of Aβ42 concentrations varied between the sleep deprivation and unrestricted sleep groups (P = .04) in
contrast to stable Aβ40, tau, and total protein levels.
B. Sleep wake-cycle/circadian rhythm and Cognitive decline and/or Alzheimer’s disease Dementia
Table 1.8 presents the results of the descriptive study characteristics, statistical methods and main
findings of studies that examined the association between sleep-wake /circadian rhythm abnormalities and
cognitive decline and/or AD. In total, there were 23 studies (i.e., 5 cross-sectional,87,89,91,95,102 4 casecontrol,97,101,106,107 6 prospective cohort,108,118,119,124,127,129 7 experimental studies134,135,137,140,143-145 and 1
RCT131).
B.1 Cross-sectional studies
Oosterman et al89 examined whether nocturnal sleep and the circadian organization of the sleepwake rhythm had predictive value for cognitive functioning in home-dwelling elderly people and found
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an association between the rest-activity rhythm and cognitive performance independent of age. Restactivity was assessed using actigraphy, and mental speed, memory, and executive function were evaluated
using a battery of standardized cognitive tests. The authors noted that majority of the subjects suffered
from at least one cardiovascular risk factor. Merlino et al87 examined the relationship between disturbed
sleep and cognitive impairment in the elderly and found that among sleep disturbances, excessive daytime
sleepiness was independently associated with the presence of dementia. In addition, the frequency of
excessive daytime sleepiness increased progressively across the different categories of cognitive decline,
as measured by means of MMSE and Global Deterioration Scale (GDS)179 scores.
Pat-Horenczyk et al91 examined differences in hour-by-hour sleep/wakefulness profiles between
severely and mild to moderately demented patients and assessed how many elderly patients remained
almost fully asleep or nearly fully awake in each hour of a 24-hour period. They found that patients with
mild to moderate dementia showed a disproportionate amount of wakefulness during the night, in contrast
to patients with severe dementia showing a disproportionate amount of sleepiness during the day. They
also found that with the progression of dementia both the capacity to maintain sleep and the capacity to
maintain wakefulness were impaired, resulting in almost complete fragmentation of sleep/wakefulness
during the night and day. Sleep/wakefulness patterns were recorded using actigraphy and levels of
dementia were assessed by the Mini-Mental State Examination (MMSE). This study suggests that sleep
disturbances parallel the severity of dementia\. However, patients were not evaluated for type of
dementia nor were records available to check whether patients had Alzheimer’s disease or dementia of
other types. Yesavage et al95 examined indices of sleep/wake function collected from individuals with
AD in relation to relevant polymorphisms in circadian clock-related genes in two cohorts of AD
participants. [Cohort 1 (n=124): individuals with probable AD recruited from the Stanford/Veterans
Affairs NIA Alzheimer’s Disease Core Center (n=81) and the Memory Disorders Clinic at the University
of Nice School of Medicine (n=43). Cohort 2 (n=176): individuals with probable AD derived from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) data set]. Adjusting for multiple tests, none of the
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candidate gene SNPs were significantly associated with the amount of wake after sleep onset, a marker of
sleep consolidation, and no relationships likely to be of clinical relevance were detected. The authors
therefore concluded that it was unlikely that a relationship with a clinically meaningful correlation exists
between the circadian rhythm-associated SNPs and WASO in individuals with AD.
A pacemaker located in the suprachiasmatic nucleus (SCN) which serves as a master clock180,181
organizes circadian regulation of sleep and wakefulness mechanisms. Melatonin, N-acetyl-5methoxytryptamine, is one of the most important timing signals generated by the SCN and is mostly
known for its relation to circadian rhythms and sleep. Naismith et al102 examined whether patients with
mild cognitive impairment (MCI) had significant alterations in the timing of melatonin secretion onset
and amount as well as changes in sleep architecture. They found that patients with MCI had advanced
timing of their melatonin secretion onset relative to controls, but the levels of melatonin secreted did not
differ between groups. The MCI group also had greater wake after sleep onset (WASO) and increased
rapid eye movement sleep latency. There were differential associations between dim light melatonin onset
and cognition between the two groups, with earlier dim light melatonin onset being associated with poorer
memory performance in MCI patients. Participants’ sleep-wake behavior for the 14-nights prior to
commencing the in-laboratory portion of the protocol was assessed using actigraphy and sleep diaries.
Assessment of circadian function (melatonin rhythm timing and levels) and sleep architecture were
examined using melatonin and polysomnographic (PSG) assessments on separate nights.
B.2 Case-control studies
Two studies conducted in the Netherlands investigated the circadian rhythm of hypocretin-1
(Hypocretin-1 and -2 are hypothalamic neuropeptides, also known as orexins, that form an important
regulating system acting on the sleep–wake cycle182,183) in Alzheimer’s disease. Fronczek et al97
assessed whether the neurodegenerative process of AD affects hypothalamic hypocretin/orexin neurons.
Investigators quantified the total number of hypocretin-1 immuno-reactive neurons in postmortem
hypothalami of AD patients (n = 10) and matched controls (n = 10) and measured hypocretin-1
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concentrations in postmortem ventricular cerebrospinal fluid (CSF) of 24 AD patients and 25 controls.
The numbers and levels of hypocretin-1 immunoreactive neurons and cerebrospinal fluid (CSF)
hypocretin-1 respectively, were significantly lower (i.e., 40% decreased cell number, and 14% lower CSF
hypocretin-1 levels respectively) in AD patients compared to controls. (p = 0.038). These findings
indicate that the hypocretin system is affected in advanced AD. Slats et al107 examined the association
between Hypocretin-1 and Amyloid-β42 CSF levels in 6 patients with AD (59-85 yrs., MMSE 16-26) and
6 healthy volunteers (64-77 yrs.). The authors could show no difference in CSF hypocretin-1 circadian
rhythm between AD and controls. However, lower mean CSF Aβ42 levels were significantly associated
with lower hypocretin-1 levels. The authors postulated that this finding might suggest a relationship
between AD pathology and hypocretin disturbance, which could hold possibilities for treatment of AD
related sleep disorders.107
Schmidt et al106 investigated cerebrospinal fluid (CSF) levels of melanin-concentrating hormone
(MCH) and hypocretin-1 (HCRT-1, orexin-A) in patients with Alzheimer’s disease (AD) and Healthy
subjects (HS) and the potentially causal relationship between these polypeptides and CSF levels of the
AD marker total Tau (T-tau), hyper phosphorylated tau (P-tau) and Ab42, cognitive performance and
behavioral symptoms in AD. The study was carried out in 33 patients with mild to severe AD and 33
subjects without any psychiatric or neurological disorder (HS). A significant main effect of diagnosis
(p=0.01) on MCH levels was found between AD and HS. MCH correlated with T-tau (p=0.01) and P-tau
(p=0.05) in the AD but not in the HS. CSF-MCH correlated negatively with MMSE scores in the AD
(p=0.05) and was increased in more severely affected patients (MMSE≤20) compared to HS (p=0.001)
and BPSD-positive patients compared to HS (p=0.05). For CSF-HCRT- 1, a significant main effect of sex
(p=0.05) with elevated levels in females was found whereas diagnosis and the sex*diagnosis interaction
were not significant. These results should stimulate additional research on the role of the hypothalamus in
AD pathogenesis and development of behavioral disturbances in AD. Future studies should include
repeated MCH/HCRT-1 level measurements in combination with sleep-wake-actigraphy and assessment
of sleep by standardized questionnaires, histochemical determinations of MCH in animal and post28

mortem tissues. Liu et al101 analyzed data from 85 patients with AD (mean age, 75 ± 1.1 yr) and 82 agematched controls (mean age, 76 ± 1.4 yr), to determine melatonin levels in postmortem cerebrospinal
fluid in relation to aging, AD, and APOE ε4 genotype. They found that melatonin levels in AD patients
expressing APOE e3/4 was significantly higher than that in patients expressing APOE e4/4 (p = 0.02).
CSF melatonin levels were significantly lower and about half of those in control subjects (p=.00126).
B.3 Cohort studies
Walsh et al127 using a study cohort of 1,287 community-dwelling older women (82.8 ± 3.1 y)
who were free of dementia at the baseline visit and were followed for 5 years, found that weaker circadian
activity rhythms (CAR) patterns were associated with lower cognitive function, especially poorer
executive function. Keage et al118 found that daytime sleepiness was significantly associated with
incident cognitive impairment over 10 years (OR = 2.43, 95% CI 1.24–4.75). Anderson et al108 also
examined the association between subjective and objective measures of sleep and wakefulness and other
health parameters in a 421 men and women, aged 87–89. The study was nested in the Newcastle 85+
Study, a population-based longitudinal study of health and ageing in the very old. Sleep-wake parameters
were assessed subjectively with the Pittsburgh Sleep Questionnaire Inventory (PSQI) and the Epworth
Sleepiness Score (ESS), while wrist actigraphy was used as an objective measure. The authors found that
impaired sleep–wake cycles were significantly associated with cognitive impairment, disability,
depression, increased number of falls, body mass index and arthritis but not with any other specific
disease markers or decreased survival. The subjective sleep questionnaires did not differentiate well
between objectively determined disturbance of sleep–wake cycles and those with normal cycles. Tranah
et al124 studied whether measured circadian activity rhythms are prospectively associated with incident
dementia or mild cognitive impairment (MCI) in 1,282 community-dwelling older women. They found
that older women with decreased circadian activity rhythm amplitude and robustness and delayed rhythms
had a higher likelihood of developing dementia or MCI when comparing those in the lowest quartile of
amplitude (OR =1.57, 95% CI, 1.09–2.25) or rhythm robustness (OR=1.57, 95%CI, 1.10–2.26) compared
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to women in the highest quartile. An increased risk of dementia or MCI (OR=1.83, 95% CI, 1.29–2.61)
also was found for women whose timing of peak activity occurred later in the day (after 3:51PM) when
compared to those with average timing (1:34PM–3:51PM). Lim et al119 tested the hypothesis that sleep
fragmentation is associated with incident Alzheimer’s disease (AD) and the rate of cognitive decline
among 737 older adults without dementia at baseline, and reported that those with significant actigraphic
sleep fragmentation (in the 90th percentile) had a 1.5-fold increased risk of developing AD as compared
with those with low sleep fragmentation (10th percentile). A Cox regression model controlling for age,
sex, and education, also revealed that a higher level of sleep fragmentation was associated with an
increased risk of incident AD (HR = 1.22, 95%CI 1.03-1.44, P = 0.02 per 1 SD increase in sleep
fragmentation). In an earlier prospective study Yesavage et al129 determined if sleep parameters in AD
patients change over time as a function of APOE carrier status in 44 subjects, of which 25 were APOE ε4
carriers and 19 were non-ε4 carriers. Participants had been assessed at least during 2 stages of cognitive
impairment, defined as a decline from one stage of AD to another. They found that among APOE ε4
carriers, wake after sleep onset was associated with lower cognitive function; for non-ε4 subjects,
increases in WASO and declines in total sleep time, sleep efficiency, and the amplitude of the rest/activity
circadian rhythm over time were associated with lower cognitive function.
B.4 Experimental studies
Craig et al134 explored the effects of acute and chronic disruption of circadian rhythms on
memory using a phase shifting schedule that can continually challenge the rats’ circadian system by using
repeated phase shifts and recovery sessions. Twenty-four male Long Evans hooded rats (300–400 g)
obtained from Charles River (Saint-Constant, PQ) were used for all studies. They were divided into three
groups: acutely phase shifted rats (acute; n = 8), chronically phase shifted rats (chronic; n = 8), control
rats for water maze testing (control; n=7) and control rats for fear conditioning (control; n = 14). The
authors demonstrated a significant learning and memory deficit on a spatial version of the water maze
task (used for behavioral testing in the animals) in the chronically phase shifted, but not in the acutely
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phase shifted animals. Moreover, they did not find any impairment in fear conditioning suggesting that
chronic phase shifting predominantly affects hippocampal memory. They proposed that chronic circadian
disruption may play a role in the development of age-related cognitive deficits and dementia in the
elderly. Jyoti et al137 characterized sleep, electroencephalogram (EEG) disturbances and cognitive
dysfunction in transgenic mice carrying transgenes for amyloid-protein precursor (APPswe) and
presenilin 1 (PSEN1A246E) at 5 (pre-plaque) and 20 months, relative to PSEN1 and wild-type (WT)
mice, using a novel wireless microchip device. The study findings suggested that APP/PSEN1 mice
exhibit abnormalities in activity and sleep architecture preceding amyloid plaque deposition as well as
age-related changes in cortical EEG power. Though not fully recapitulating the profile of AD patients,
this suggests activity and EEG recordings are sensitive and translational biomarkers in murine models.
Several anti-amyloidogenic effects of melatonin have been demonstrated in vitro and in animal
studies. Pappolla et al144 examined the interactive ability of melatonin with Aβ1–40 and Aβ1–42 to
determine whether melatonin inhibits the progressive formation of β-sheets and amyloid fibrils. These
investigators found that melatonin crosses the blood-brain barrier, is relatively devoid of toxicity, and
concluded that it may constitute a potential new therapeutic agent in Alzheimer’s disease. Olcese et al143
examined the potential for long-term melatonin treatment to protect Alzheimer’s transgenic mice against
cognitive impairment and development of β-amyloid (Aβ) neuropathology. Authors administered
melatonin (100 mg/L drinking water) to AD transgenic (Tg) mice from 2–2.5 months of age to their
killing at age 7.5 months. Findings revealed that melatonin suppresses Aβ aggregation in brain
homogenates. Inflammatory cytokines such as tumor necrosis factor (TNF)-α were decreased in
hippocampus (but not plasma) of Tg+ melatonin mice. Finally, the cortical mRNA expression of three
antioxidant enzymes (SOD-1, glutathione peroxidase, and catalase) was significantly reduced to non-Tg
levels by long-term melatonin treatment in Tg mice. Lahiri et al140 examined the effects of dietary
melatonin on brain levels of nitric oxide synthase, synaptic proteins and amyloid beta-peptides (Aβ) in
mice. They found that dietary melatonin supplementation led to a significant reduction in levels of toxic
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cortical Aβ of both short and long forms that are involved in amyloid deposition and plaque formation in
Alzheimer's diseases. However, melatonin supplements did not significantly change cerebral cortical
levels of nitric oxide synthase or synaptic proteins such as synaptophysin and SNAP-25.
Deregulation of protein kinases/protein phosphatases is responsible for tau hyper
phosphorylation. Among them, glycogen synthase kinase-3 (GSK-3) is a known tau kinase that plays a
crucial role in AD pathology.184 In-vivo and in-vitro tau phosphorylation can be undertaken by GSK-3
and over-expression of GSK-3 leads to tau hyper phosphorylation.185,186 In an Alzheimer’s-affected brain,
GSK-3 is activated in pretangle neurons and accumulates in paired helical filaments.187 Under the above
premise, Deng et al135 carried out an in-vitro study on N2a (Neuro-2a: a fast growing neuroblastoma cell
line) cells that were grown and differentiated in 96-well culture plates at density of 1.5×105 cells in 100
μL. Cells were exposed to various concentrations of wortmannin (an indirect GSK-3 activator) for 2 h at
37 ºC in the presence or absence of a 12-h-preincubation with melatonin 25, 50, and 100 μmol/L or
Vitamin E (VE). The authors explored the underlying mechanism of tau hyper phosphorylation in an
Alzheimer's affected brain and the possible arresting strategies. One of the findings of the study was that
preincubation of the cells with melatonin or vitamin E attenuated differentially wortmannin induced
oxidative stress as well as GSK-3 over-activation and tau hyper phosphorylation. The authors concluded
that wortmannin might be an effective tool for reproducing AD-like tau hyper phosphorylation cell model
and that melatonin/vitamin E can effectively protect the cells from wortmannin-induced impairments.
Contrary to the above findings on the possible therapeutic value of melatonin on cortical Aβ level
reduction, Quinn et al145 examined the effect of chronic melatonin therapy initiated after the appearance
of plaques in Tg2576 mice and failed to demonstrate any effect, as chronic melatonin therapy did not alter
amyloid burden or oxidative damage after 4-months of treatment. Variations in melatonin dose, age of
treatment initiation, and species of Aβ measured could possibly have accounted for the different results.
Quinn et al. noted that one of the prior studies used a lower dose and still found an effect at this dose
could not have accounted for the different result. The age at treatment initiation varied across the studies
and might possibly explain the different results. Another study188 using similar Tg2576 mice initiated
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treatment at 4 months of age (prior to the appearance of hippocampal and cortical plaques) also found
diminished Aβ and nitrotyrosine at 7–8 months, but no significant difference in histologically detectable
Aβ or brain nitrotyrosine in animals at 15 months of age. The Quinn et al study initiated treatment at 14
months.
B.5 Randomized Controlled Trial
Asayama et al131 conducted a double blind study to examine the effects of melatonin on the
sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type of dementia. The subjects
were 9 persons given a placebo (PLA), and 11 given melatonin (3 mg) (MLT). The drugs were given at
8:30pm each day for 4 weeks. Melatonin administration improved sleep time and night activity
significantly, but had no significant effect with regard to improving daytime naps and activity. Melatonin
administration improved cognitive and non-cognitive functions significantly. Melatonin seemed to be
useful for care of the Alzheimer type of dementia patients
C. Hypoxia (Apnea Hypopnea Index) and Cognitive decline and/or Alzheimer’s disease
Sixteen studies (i.e., 4 cross-sectional,81,83,86,90 1 case-control,103 3 prospective cohort,125,128,150 1
retrospective cohort,112 2 RCTs,130,132 and 5 experimental studies139,141,147-149) examined hypoxia states
(AHI) in sleep apnea/sleep disordered breathing and its association with cognitive decline and/or AD.
Table 1.9 presents the results of the descriptive study characteristics, statistical methods and main
findings of the studies.
C.1 Cross-sectional studies
Kadotani et al86 conducted a cross-sectional study to determine whether genetic variation at the
level of APOE is associated with Sleep Disordered-Breathing (SDB) in a probability based sampling of
791 middle-aged adults, mean age of 49 and age range 32-68. They found that independent of age, sex,
body mass index, and ethnicity, participants with APOE epsilon4 had a significantly higher risk of
moderate-to-severe Sleep Disordered-Breathing (apnea-hypopnea index (AHI) ≥15%) (P =.003).
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Participants with APOE epsilon4 also had a significantly higher mean (SEM) apnea-hypopnea index
(p=.01). These effects increased with the number of APOE epsilon4 alleles carried. In a similar study,
Gottlieb et al83 examined the association of the APOE e4 allele with Obstructive Sleep Apnea/Hypopnea
(OSAH) in a community-dwelling cohort, exploring age dependency of the association. The investigators
conducted a genetic association study, nested within a prospective cohort study of the cardiovascular
consequences of OSAH. APOE e4 allele was associated with increased odds of OSAH (OR 1.41, 95% CI
1.06 to 1.87, p = 0.02) after controlling for age, sex and body mass index (BMI). The effect was greater in
subjects < 75 (OR 1.61, CI 1.02 to 2.54) as in those ≥75 years old (OR 1.32, CI 0.91 to 1.90). Exploratory
analyses revealed that the strongest effect of APOE e4 was in subjects age <65 (OR 3.08, CI 1.43 to
6.64), and was stronger in those with hypertension or cardiovascular disease than in those without. The
authors therefore concluded that the APOE e4 allele is associated with increased risk of OSAH,
particularly in individuals under age 65.83 Osorio et al90 examined the interaction between sleepdisordered breathing and Apolipoprotein E genotype on cerebrospinal ﬂuid biomarkers for Alzheimer’s
disease in a total of 95 cognitively normal elderly participants who were analyzed for SDB severity.
Among the 95 participants, 25 were considered free of SDB (apnea and/or hypopnea with 4% O2desaturation index (AHI4%) < 5) and were included as normal controls, 51 had mild SDB (AHI4% 514.99), and 19 had moderate to severe SDB (AHI4% > 15). Results showed that in ApoE3+ subjects,
significant differences were found between sleep groups for p-tau and t-tau (p=0.017, p = 0.043
respectively), and the AHI4% was significantly correlated with p-tau (p = 0.023), t-tau (p = 0.021), and
Aβ-42 (p = 0.021). In ApoE2+ subjects, the AHI4% was significantly correlated with lower levels of CSF
Aβ-42 (p = 0.004), identical to ApoE4+ subjects where there was also a trend toward lower CSF Aβ-42
levels.
Lastly, Djonlagic et al81 examined the effect of aging on sleep-dependent motor memory
consolidation in patients with and without OSA. Participants included 44 patients (19–68 years) who had
been referred by a physician for a baseline polysomnography (PSG) evaluation and were assigned either
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to the OSA group (AHI>5/h), or control (Non-OSA) group (AHI<5/h). All subjects performed the
Psychomotor Vigilance Task (PVT) and the Motor Sequence Learning Task (MST) in the evening and
again in the morning after their PSG. Results showed that healthy sleepers displayed a greater degree of
sleep-dependent overnight improvement on the MST, an effect not diminished by increasing age. The
existence of untreated obstructive sleep apnea was associated with an aging-related cognitive deficit,
otherwise not present in individuals without OSA. Other research has linked OSA to a greater risk of
developing dementia. Future studies are therefore necessary to determine if the restriction of memory
consolidation is tied to or has a role to play in the onset of neurodegenerative disease.
C.2 Case-control studies
O’Hara et al103 investigated the relationship between obstructive sleep apnea/hypopnea (OSAH)
and cognition in 36 older adults, i.e., 18 APOE epsilon4 carriers, and 18 non-carriers. These authors
found that higher levels of AHI were associated with lower memory scores in the APOE epsilon4 carriers
only. Minimum oxygen saturation (MinSaO2) did not differ significantly between the groups, but was
lower than 90% in both, indicative of the occurrence of hypoxia. MinSaO2 was not associated with
cognition, although there was a non-significant trend for minSaO2 to negatively impact memory in the
APOE epsilon4 carriers only.
C.3 Cohort studies
Cohen-Zion et al150 examined changes in cognitive function associated with Sleep Disordered
Breathing (SDB) in 46 participants aged 65 and older who completed visits 3 and 4. The original cohort
included community-dwelling elders age 65 and older with high risk for SDB studied from 1981 through
1985 and then followed every 2 years. The study results suggest that declining cognitive function is
associated primarily with increases in daytime sleepiness. Although cognitive decline was also associated
with increases in respiratory disturbance index (RDI: defined as number of apneas plus hypopneas per
hour of sleep), this association did not hold in a more inclusive model which also included variable of
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SDB, oximetry, sleep and subjective report. The findings could suggest that any relationship between
SDB and cognitive function may be mediated by the effect of SDB on daytime sleepiness. Tworoger et
al125 found no associations with snoring, sleep duration, and difficulty sleeping and cognitive decline over
2 years. Chang et al112 in a retrospective matched-control cohort study estimated and compared the risk
of dementia in Sleep Apnea (SA) and non-SA patients among persons aged 40 and above over a 5-year
follow-up period. Overall findings suggest that SA patients had a 70% greater risk of developing
dementia within 5 years of diagnosis compared to non-SA age- and sex-matched patients, after adjusting
for other risk factors (95% confidence interval (CI) = 1.26-2.31; P < .01).
Yaffe et al128 examined the prospective relationship between sleep disordered breathing (SDB),
and cognitive impairment and investigated potential mechanisms of this association. Using data from 298
women without dementia (mean [SD] age: 82.3 [3.2] years), the authors found that women with SDB had
an 85% increased risk of developing MCI or dementia compared to women without SDB after adjusting
for age, race, body mass index, education, smoking status, presence of diabetes, presence of hypertension,
medication use (antidepressants, benzodiazepines, or non- benzodiazepine anxiolytics) and baseline
cognitive scores (adjusted OR=1.85, 95% CI 1.11-3.08). Measures of disordered breathing i.e., elevated
oxygen desaturation index (≥15 events/hour) and high percentage (>7%) of sleep time in apnea or
hypopnea, were both associated with risk of developing MCI or dementia (adjusted OR=1.71, 95% CI
1.04 − 2.83 and adjusted OR=2.04, 95% CI 1.10 − 3.78, respectively). Sleep fragmentation measures
(arousal index and wake after sleep onset) or sleep duration (total sleep time) were not associated with
risk of cognitive impairment.
C.4 Experimental studies
Shiota et al147 examined the direct effect of intermittent hypoxia (IH) in pathophysiology of AD
in-vivo and in-vitro. In-vivo, 15 male triple transgenic AD mice were exposed to either chronic
intermittent hypoxia (CIH) or normoxia (5% O2 and 21% O2 every 10 min, 8 h/day for 4 weeks). Invitro, human neuroblastoma SH-SY5Y cells stably expressing wild-type amyloid-β protein precursor
were exposed to either IH (8 cycles of 1% O2 for 10 min followed by 21% O2 for 20 min) or normoxia.
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Results showed that CIH significantly increased levels of Aβ42 but not Aβ40 in the brains of mice
without the increase in hypoxia-inducible factor 1, alpha subunit (HIF-1α) expression. Furthermore, CIH
significantly increased intracellular Aβ-42 in the brain cortex. There were no significant changes in
cognitive function. IH significantly increased levels of Aβ42 in the medium of SH-SY5Y cells without
the increase in the HIF-1α expression. CIH directly and selectively increased levels of Aβ42 in the AD
model. Kaushal et al139 hypothesized that acute short-term Intermittent hypoxia (IH) and sleep
fragmentation (SF) (major manifestations of sleep apnea), as well as their combination (IH+SF) may
reveal unique susceptibility in sleep integrity in a murine model of AD. They found that slow wave sleep
(SWS) was significantly decreased, and rapid eye movement (REM) sleep was almost suppressed during
acute exposure to IH alone and IH+SF for 6 h in hApoE4 animals, with milder effects in WT controls.
Reduced delta power during SWS did not show post exposure rebound in hApoE4 unlike WT controls. IH
and IH+SF induced hypothermia was more prominent in hApoE4 than wild type (WT) controls. Mice
subjected to SF also showed sleep deficits but without hypothermia. “hApoE4 mice, unlike WT controls,
exhibited increased sleep propensity, especially following IH and IH+SF, suggesting limited ability for
sleep recovery in hApoE4 mice.” These findings affirm the probable impact of IH and SF in adjusting
sleep architecture and sleep homeostasis including sustenance of body temperature. In addition, the
increased susceptibility and defined recovery capability of hApoE4 mice to sleep apnea suggests that
early identification and treatment of sleep apnea in AD patients may permit interventions to slow AD
progression.
Zhang et al149 investigated the possibility of a direct molecular link between hypoxic insults and
Amyloid Precursor Protein (APP) processing and found that acute hypoxia increased the expression and
the enzymatic activity of β-secretase (BACE1) (Aβ is derived from the β-amyloid precursor protein
(APP) by sequential proteolytic cleavages from β-secretase (BACE1) and presenilin-1 (PS1)/γ-secretase)
by up-regulating the level of BACE1 mRNA, resulting in increases in the APP C-terminal fragment-β
(βCTF) and Aβ. Hypoxia had no effect on the level of PS1, APP, and tumor necrosis factor--converting
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enzyme (TACE, an enzyme known to cleave APP at the α-secretase cleavage site). Sequence analysis,
mutagenesis, and gel shift studies revealed binding of Hypoxia Inducible Factor-1 (HIF-1) to the BACE1
promoter. Overexpression of HIF-1 α increased BACE1 mRNA and protein level, whereas downregulation of HIF-1 α reduced the level of BACE1. Hypoxic treatment failed to further potentiate the
stimulatory effect of HIF-1α overexpression on BACE1 expression, suggesting that hypoxic induction of
BACE1 expression is primarily mediated by HIF-1α. Lastly, the authors observed significant reduction in
BACE1 protein levels in the hippocampus and the cortex of HIF-1α conditional knock-out mice. These
results provide evidence that hypoxia/HIF-1α plays a vital role in balancing the amyloidogenic processing
of APP. It also provides a molecular mechanism to explain increased incidence of AD following cerebral
ischemic and stroke injuries. Following in the same line of thought, Li et al141 investigated molecular
mechanisms underlying hypoxia mediated AD using AD transgenic mice. The authors demonstrated that
repeated hypoxia increased β-amyloid (Aβ) generation and neuritic plaque formation by elevating βcleavage of APP in APPswe + PS1A246E transgenic mice. They also found that hypoxia enhanced the
expression of APH-1a, a component of ɣ-secretase complex, which in turn may lead to increase in ɣcleavage activity. Furthermore, these authors demonstrated that repeated hypoxia treatment can activate
macroautophagy, which may contribute to the increases in Aβ production. Taken together, the results
suggest an important role of hypoxia in modulating the APP processing by facilitating both β- and ɣcleavage which may result in a significant increase of Aβ generation. Sun et al148 constructed a series of
deletion luciferase reporter plasmids containing human BACE1 gene promoter regions to investigate
whether BACE1 is one of the downstream target genes of the hypoxia signaling pathway. In the study,
authors found that hypoxia significantly increased BACE1 gene expression, resulting in increased βsecretase activity and Aβ production. Furthermore, hypoxia treatment markedly increased Aβ deposition
and potentiated the memory deficit in AD transgenic mice. The results demonstrate that hypoxia can
facilitate AD pathogenesis, and they provide a molecular mechanism to link vascular factors to AD.
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C.5 Randomized Controlled Trials
Ancoli-Israel et al130 examined whether treatment of obstructive sleep apnea (OSA) with
continuous positive airway pressure (CPAP) in patients with Alzheimer's disease (AD) would result in
improved cognitive function. Participants were randomized to either therapeutic CPAP for six weeks or
placebo CPAP for three weeks followed by therapeutic CPAP for three weeks. A comparison of subjects
randomized to 3 weeks of therapeutic versus placebo CPAP suggested no significant improvements in
cognition. A comparison of pre- versus post-treatment neuropsychological test scores after 3 weeks of
therapeutic CPAP in both groups showed a significant improvement in cognition. Similarly, Kushida et
al132 determined the neurocognitive effects of continuous positive airway pressure (CPAP) therapy on
patients with obstructive sleep apnea (OSA) in a 6-month, randomized, double-blind, 2-arm, shamcontrolled, multicenter trial. The results showed that CPAP treatment improved both subjectively and
objectively measured sleepiness, especially in individuals with severe OSA (AHI >30). CPAP use also
resulted in mild, transient improvement in the most sensitive measures of executive and frontal-lobe
function for those with severe disease, which suggests the existence of a complex OSA-neurocognitive
relationship.
D. Insomnia and cognitive decline and/or Alzheimer’s disease
Six studies (i.e., 2 cross-sectional87,92 and 4 prospective cohort studies114,115,117,121) examined the
association between insomnia and cognitive decline and/or AD. Table 1.10 presents the results of the
descriptive study characteristics, statistical methods and main findings of the studies.
D.1 Cross-sectional studies
Pistacchi et al92 in their study found that patients with MCI had a frequency of sleep disturbances
of any type equal to that of patients with AD and presented mostly with insomnia. In the study insomnia
occurred more frequently in AD. In their cross-sectional study examining the association between
multiple sleep parameters including insomnia and cognitive impairment in the elderly, Merlino et al87 did
not find an association between insomnia, the most common sleep complaint in their sample, and the
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presence of cognitive decline. These studies assessed the presence of sleep disorders by means of
subjective symptoms and not using objective instruments, such as wrist actigraphy or polysomnography.
Polysomnography is essential for a correct diagnosis of some sleep disturbances. In particular, sleep
disordered breathing can be diagnosed only by means of polysomnographic recordings. Because
assessment of sleep parameters was based on a structured interview, obtaining self-reported description of
sleep characteristics from subjects with significant cognitive impairment becomes challenging and
questionable.
D.2 Cohort studies
Examining whether self-reported symptoms of insomnia independently increase risk of cognitive
decline in older adults, Osorio et al121 and Cricco et al114 found that there is a greater risk of Alzheimer's
disease in adults with self-reported insomnia. Osorio et al121 examined the relationship between insomnia
and AD in 346 cognitively normal older adults evaluated during multiple visits over 7.7 years of followup. Insomnia was collected only during the normal cognition stage and screened using items 4, 5, and 6
from the Hamilton Depression Rating Scale (HAM-D). Participants who reported insomnia had an
increased odds of 2.39 of developing AD when compared to the non-insomnia group. (OR = 2.39, 95%
confidence interval (CI) = 1.03–5.55). Depression did not confound the association, and individuals with
insomnia showed a faster progression to dementia (chi-square = 3.94, P = .047). Cricco et al114 found in
their study sample that self-reported symptoms of insomnia independently predicted incident cognitive
decline in older men, but not in women. Compared to those with no insomnia at the third annual follow
up (FU3) those reporting symptoms of insomnia at both baseline and FU3 had an adjusted odds ratio
(AOR) of 1.49 (95% CI = 1.03–2.14) for cognitive decline among non-depressed men. Men with
insomnia at FU3 only were not at increased risk (OR = 1.16, 95% CI = 0.82–1.65). These relationships
were not found in women. Men and women with depressive symptoms at FU3 were at increased risk for
cognitive decline independent of insomnia. Participants included over 6,000 community-dwelling men
and women age 65 and older from the prospective cohort of the four sites of the Established Populations
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for Epidemiologic Studies of the Elderly (EPESE) in Iceland. The authors noted that sleep complaints
data were only available at 3-year intervals, making misclassification of exposure in some cases more
likely, e.g., some participants classified as experiencing chronic sleep disturbances may have had
transient episodes of sleep difficulty during follow-up but may have had undisturbed sleep over the period
between follow-ups. Likewise, incident cases could have had symptoms for up to 3 years. Thus, the odds
ratios found in this study can be considered conservative estimates of risk.
Using the Maastricht Ageing Study (MAAS) cohort in Netherlands, Jelicic et al117 examined
whether subjective sleep complaints (i.e., extent to which an individual was distressed by difficulties with
falling asleep, waking up too early and by a restless or disturbed sleep) in a population-based sample of
838 middle aged and older adults (≥ 50 years) predicted cognitive decline over a period of 3 years.
Results showed that subjective sleep complaints were negatively associated with cognitive performance at
follow-up (β = -0.05 95% CI: -0.09 to -0.00, p = 0.03). Foley et al115 examined the longitudinal
association between sleep disturbances (insomnia and daytime sleepiness) and incidence of dementia and
cognitive decline in 2346 Japanese-American men aged 71 to 93 in the Honolulu-Asia Aging Study
(HAAS). Sleep disturbances were assessed by a questionnaire that asked whether participants were sleepy
during the day or had insomnia (defined as “usually” having trouble falling asleep or waking up far too
early and not going back to sleep). Individuals were screened for possible dementia using the CASI.
Dementia was diagnosed according to less-restrictive diagnostic criteria developed by Cummings et al.189
for very mild dementia and more-restrictive diagnostic criteria for mild or more severe dementia from the
Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-IIIR).190 Results
from the study showed that participants with excessive daytime sleepiness at baseline (8%) were twice as
likely to be diagnosed with incident dementia than were those not reporting daytime sleepiness [adjusted
odds ratio (OR) = 2.19, 95% confidence interval (CI) = 1.37–3.50] and about 40% more likely to have a 9
or more point drop in their CASI score between examinations [OR = 1.44, 95% CI =1.01–2.08]. Insomnia
was not associated with cognitive decline or incidence of dementia. The authors noted that there was lack
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of information to identify persons with sleep disordered breathing, which has been shown to affect
cognitive performance191,192 and has a 25% prevalence in older persons.193
E. Restless Leg Syndrome and cognitive decline and/or Alzheimer’s disease
Table 1.11 presents the results of the descriptive study characteristics, statistical methods and main
findings of the 3 studies (i.e., 2 cross-sectional84,92 and 1 case-control104) that examined any association
between restless leg syndrome and cognitive decline and/or AD.
E.1 Cross-sectional
Restless legs syndrome (RLS) can inhibit falling asleep or being able to stay asleep. RLS
incidence is higher in women and increases with age.194 Depression, antidepressant drug intake, renal
failure, and peripheral neuropathy, are known risk factors for RLS and also increase with age. Guarnieri
et al84 reported a 6% prevalence of RLS in MCI and Demented (AD/non-AD patients) assessed by the
international RLS study group155,195 questionnaire. However, in cognitively impaired individuals,
assessing RLS by use of a questionnaire might be arduous. Another study196 reported an RLS prevalence
of 24% in 59 demented individuals using specific guidelines of probable RLS that emphasizes behavioral
indicators and supportive features such as dopaminergic responsiveness, patient’s past history, and
presence of periodic limb movements, in cognitively impaired elderly.197 Pistacchi et al92 enrolled 236
patients (78 men and 158 women) with different subtypes of dementia and showed that RLS was one of
the most common symptoms in MCI patients.
E.2 Case-control studies
Given the degree of chronic sleep deprivation that RLS patients’ experience, Pearson et al104
hypothesized that RLS patients would exhibit decreased cognitive performance particularly on the more
pre-frontal cortical functioning (PFC) focused cognitive tasks relative to age matched controls with
relatively less or no impairments on other cognitive tasks. Results showed that RLS patients compared to
controls showed significant (P<0.05) and sizeable (20–40%) deficits on Verbal Fluency tests and the Trail
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Making tests. The authors concluded that RLS patients have statistically significant specific cognitive
deficits and show cognitive deficits similar to those seen with 36 h total sleep deprivation.
DISCUSSION
The purpose of this systematic review was to examine the association of sleep and its related
problems/disorders with Alzheimer’s disease, cognitive decline or dementia and to evaluate the evidence
for a causal association. We systematically and critically synthesized and evaluated data from 72 original
publications. Study quality was assessed using an adaptation from previous systematic reviews73,74 and the
modified version of the Newcastle-Ottawa scale (NOS) for quality assessment of the observational
studies,75,76 with addition of new items relevant to this review. Appropriateness of study design, study
populations, study samples, size of the study sample, exposure and outcome measurement, statistical
analytic design, adjustment of potential sources of confounding, variations in study populations, and
numerous sources of bias were considered. Epidemiological studies can assess risk and contribute to
understanding of possible causation but possess built-in limitations related to their design. Consistency of
results, dose-response relationships and temporality play a crucial role in determining causation; it is
however necessary to consider high quality studies when accepting or rejecting causal associations
between exposure and outcome. Out of the 72 studies reviewed, only 14 studies were assessed to be of
low quality, while 58 studies were of medium to high quality, signifying that the publications reviewed in
this systematic review were mostly satisfactory in their design.
In this comprehensive review of seventy-two studies, there is strong evidence that sleep and its
related abnormalities/disorders are associated with cognitive decline and/or Alzheimer’s disease
independent of other factors. Summarizations of sectional findings already discussed in the sections above
are provided below.
A. Sleep depth and Cognitive decline and/or Alzheimer’s disease
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The vast majority of the cross-sectional studies reviewed demonstrated an association between
sleep depth and cognitive decline and/or AD and/or Dementia. The association between sleep quality and
cognition was not explained by confound factors such as cerebrovascular disease, depression, or
medication usage.88 Objectively measured disturbed sleep was consistently related to poorer cognition,
whereas total sleep time was not. Sleep duration during the 24-h day was positively correlated with the
severity of dementia in nursing home patients,82 however, in a community-dwelling of women 65 years
old or older, there was no significant relationship for total sleep time with poorer cognition. These
findings may suggest that it is disturbance of sleep rather than quantity that affects cognition in demented
patients, while both sleep disturbance and duration affect cognition in the healthy elderly.
It is important to note that one cross-sectional study93 reported no significant differences between
good sleepers (GS) (PSQI <= 5) and poor sleepers (PSQI >= 5) in any of the objective cognitive function
tests except for the Trail Making Test A (TMA-A), processing speed being longer in the PS group (p <
0.001), and as such concluded that in healthy elderly subjects subjective sleep quality and duration was
not associated with subjective and objective cognitive performances, except for attention. However, in
this study, sleep duration and quality were self-reported and the authors had no information on sleep
structure and sleep fragmentation, two factors implicated in self-reported cognitive deficits.
Cross-sectional studies examining the association between sleep depth and AD pathology also
demonstrate an association. Both Spira et al94 and Ju et al85 showed that amyloid deposition in the
preclinical stage of AD appears to be associated with worse sleep quality. Spira et al also demonstrated an
association with sleep duration, however, Ju et al did not. The contrasted findings could possibly be due
to the variations in Aβ42 burden assessment. In Ju et al Aβ42 was measured using the Alzheimer Disease
Research Center (ADRC) Biomarker Core using enzyme linked immunosorbent assay while Spira et al
measured β-amyloid burden, using carbon 11–labeled Pittsburgh compound B positron emission
tomography distribution volume ratios (DVRs).
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Results from reviewed case-control studies examining sleep depth and cognitive decline and/or
AD suggest that sleep disruptions are evident years before diagnosis of AD and that sleep is significantly
impaired in patients with MCI at both the objective and subjective level.98,99 This may have implications
for sleep being used as a surrogate marker of preclinical Alzheimer disease and for early detection of
dementia and/or therapeutic management of sleep complaints in MCI patients.
Case-control studies reviewed show an association between sleep depth and AD pathology
demonstrating that increased plasma Aβ42 levels are significantly associated with fragmented SWS in
amnestic MCI subjects,105 thereby suggesting that sleep disruptions may signal Aβ burden in persons at
increased risk for AD, and that changes in theta rhythm during REM and SWS are a relevant index of
brain impairments in the early stage of AD, and that a deficiency of Ach may result in an increase of
sEMG activity in MCI patients. Since cholinesterase inhibitors are capable of suppressing sEMG activity
in AD patients, it is possible that an increase in sEMG activity is associated with a deficiency of Ach,
which could be an early indicator of dementia
All cohort studies (prospective and retrospective) that evaluated the relationship between sleep
depth parameters and cognitive decline and/or AD reveal that sleep depth parameters increase the risk of
cognitive decline and/or developing AD. Both subjective and objective sleep assessments yield similar
outcomes of a relationship between sleep depth parameters and cognitive decline and/or AD independent
of other factors including depression/depressive symptoms.109,111,122 These findings suggest that sleep
depth parameters such as daytime napping, and night-time sleep duration, may be modifiable behaviors
open to intervention strategies, or, clinical indicators of future decline in older individuals. However, after
adjusting for depressive symptoms, Hahn et al116 could no longer show that self-reported sleep problems
may increase the risk for dementia. However, the authors measured depressive symptoms with only one
self-reported item. They also noted that they did not include longitudinal data on sleep. Research with
longitudinal sleep data is definitely preferable. Also, the relatively small sample size (n=214) may have
biased the results toward a Type II error, particularly in the more refined analyses.
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The only cohort study reviewed,120 examining the relationship between sleep depth parameters
and AD pathology show that better sleep consolidation attenuates the effect of APOE genotype on
incident AD and development of neurofibrillary tangle pathology. Assessment of sleep consolidation may
identify APOE+ individuals at high risk for incident AD, and interventions to enhance sleep consolidation
should be studied as potentially useful means to reduce the risk of AD and development of neurofibrillary
tangles in APOE ε4+ individuals.
Experimental studies and RCTs evaluated the relationship between sleep depth parameters and
AD pathology and all demonstrate that sleep deprivation, or prolonged wakefulness, interferes with a
physiological morning decrease in Aβ42 and that chronic sleep deprivation increases cerebral Aβ42
levels, which elevates the risk of Alzheimer disease. Interestingly, Kang et al138 showed that orexin may
play a role in the pathogenesis of Alzheimer’s disease and Rothman et al146 demonstrated significant
positive correlations between cortical Aβ and p -Tau levels and circulating corticosterone. The latter
finding might suggest a probable role for glucocorticoids in mediating behavioral and biochemical
changes observed after sleep restriction in a mouse model of AD.
B. Circadian Rhythm/sleep-wake abnormalities and cognitive decline and/or Alzheimer’s
disease
All cross-sectional studies that evaluated any association between circadian Rhythm/sleep-wake
abnormalities and cognitive decline and/or Alzheimer’s disease demonstrated that an association between
the rest-activity rhythm and cognitive performance was present in elderly people. They also showed that
with the progression of dementia, excessive daytime sleepiness, the capacity to maintain sleep and the
capacity to maintain wakefulness are impaired, and result in complete fragmentation of sleep/wakefulness
during the night and day.87,89,91 However, it is unlikely that a relationship with a clinically meaningful
correlation exists between the circadian rhythm-associated SNPs and WASO in individuals with AD.95
All case-control studies that examined any association between circadian Rhythm/sleep-wake
abnormalities and cognitive decline and/or Alzheimer’s disease showed that circadian misalignment and
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sleep disruption was evident in patients with MCI, and was consistent with changes observed in
Alzheimer’s disease. Such findings could be a marker for disease trajectory, and may even be implicated
in disease pathogenesis.
Case-control studies that examined any association between circadian rhythm/sleep-wake
abnormalities and AD pathology demonstrated that the hypocretin system was affected in advanced AD,
and that CSF melatonin levels was lower in AD patients than in old control subjects. CSF melatonin
levels from APOE-e3/4 genotype patients were significantly higher than those from the APOE-e4/4
genotype, suggesting a relationship between melatonin levels and signs and symptoms of AD.97,101,107 An
interesting study by Schmidt et al106 reported that cerebrospinal fluid melanin concentrating hormone
(CSF-MCH) correlated with T-tau (p=0.01) and P-tau (p=0.05) in the AD and that CSF-MCH correlated
negatively with MMSE scores in the AD (p=.001). These results add to preclinical studies and may allow
further research on the role of the hypothalamus in pathology and occurrence of behavioral disturbances
in AD. The authors noted that future investigations, including repeated MCH/HCRT-1 level
measurements in combination with sleep-wake-actigraphy and assessment of sleep by questionnaires,
histochemical determinations of MCH in animal and post-mortem tissues are warranted to understand the
hypothalamic impact in AD in greater detail.
All prospective cohort studies in this systematic review that examined the relationship between
circadian rhythm/sleep-wake abnormalities and cognitive decline and/or AD revealed associations
between the two, with older, healthy individuals with decreased circadian activity rhythm amplitude and
robustness, and delayed rhythms demonstrating increased risks of developing dementia and MCI.
Yesavage et al129 also showed that sleep-wake APOE status is associated with the progression of
sleep/wake disturbances in AD
Most experimental studies demonstrated anti-amyloidogenic effects of melatonin either in-vitro
and/or in-vivo in animal studies. These results suggest that melatonin can provide a combination of
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antioxidant and anti-amyloidogenic features that can be explored either as a preventive or therapeutic
treatment for AD or as a model for development of anti-amyloidogenic indole analogs.
It is important to note that Quinn et al145 examined the effect of chronic melatonin therapy
initiated after the appearance of plaques in Tg2576 mice and failed to demonstrate any effect, as chronic
melatonin therapy did not alter amyloid burden or oxidative damage after 4-months of treatment.
Variations in melatonin dose, age of treatment initiation, and species of Aβ measured could possibly have
accounted for the different results. Quinn et al. noted that one of the prior studies used a lower dose and
still found an effect at this dose could not have accounted for the different result. The age at treatment
initiation varied across the studies and might possibly explain the different results. Another study188 using
similar Tg2576 mice initiated treatment at 4 months of age (prior to the appearance of hippocampal and
cortical plaques) also found diminished Aβ and nitrotyrosine at 7–8 months, but no significant difference
in histologically detectable Aβ or brain nitrotyrosine in animals at 15 months of age. The Quinn et al
study initiated treatment at 14 months.
Melatonin administration improved cognitive and non-cognitive functions significantly, and
seemed to be useful for care of the Alzheimer type of dementia patients as shown in the RCT conducted
by Asayama et al.131
C. Hypoxia (Apnea Hypopnea Index) and Cognitive decline and/or Alzheimer’s disease
Cross-sectional studies in our review that examined the association between hypoxemia and
cognitive decline and/or AD all showed that an association exists between SDB/OSA and CSF
Alzheimer’s disease-biomarkers in cognitively normal elderly individuals, thereby suggesting that
existing therapies for SDB such as continuous positive airway pressure could delay the onset to MCI or
dementia in normal elderly individuals. Cross-sectional studies in our review also showed that the APOE
£4 allele was associated with increased risk of SDB/OSAH, particularly in individuals under age 65.83,86
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The only case-control study that evaluated the association between hypoxemia and cognitive
decline and/or AD also demonstrated that nocturnal sleep apnea/hypopnea was associated with lower
memory performance in APOE e4 carriers.103
Most cohort studies (retrospective and prospective) evaluated in our study revealed that
OSA/SDB may be a risk factor for dementia, with some suggesting that this relationship could be genderdependent, age-dependent, and time-dependent.112,128,150 In contrast, Tworoger et al125 in their study
found no associations between snoring or any of the sleep variables examined (average sleep duration,
snoring frequency, and difficulty sleeping over the previous 4 weeks) and cognitive decline over 2 years.
All 5 experimental studies that examined an association between hypoxemia and AD pathology
demonstrated an association between hypoxia and AD biomarkers. Two studies148,149 found that hypoxia
significantly increased BACE1 gene expression, resulting in increased β-secretase activity and Aβ
production. Overexpression of HIF-1 α increased BACE1 mRNA and protein level, whereas downregulation of HIF-1 α reduced the level of BACE1. Hypoxic treatment failed to further potentiate the
stimulatory effect of HIF-1α overexpression on BACE1 expression, suggesting that hypoxic induction of
BACE1 expression is primarily mediated by HIF-1α. Furthermore, hypoxia treatment markedly increased
Aβ deposition and potentiated the memory deficit in AD transgenic mice. These results provide evidence
that hypoxia/HIF-1α plays a vital role in balancing the amyloidogenic processing of APP, that hypoxia
can facilitate AD pathogenesis, and they provide a molecular mechanism to link vascular factors to AD.
Two other studies141,147 demonstrated that repeated hypoxia increased β-amyloid (Aβ) generation
and neuritic plaque formation by elevating β-cleavage of AD transgenic mice. They also found that
hypoxia enhanced the expression of APH-1a, a component of ɣ-secretase complex, which in turn may
lead to increase in ɣ-cleavage activity. Furthermore, these authors demonstrated that repeated hypoxia
treatment can activate macroautophagy, which may contribute to the increases in Aβ production. Taken
together, the results suggest an important role of hypoxia in modulating the APP processing by
facilitating both β- and ɣ-cleavage which may result in a significant increase of Aβ generation
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Both RCTs130,132 that evaluated the cognitive effects of CPAP treatment demonstrated that CPAP
improved both subjectively and objectively measured sleepiness, especially in individuals with severe
OSA (AHI >30). CPAP use resulted in mild, transient improvement in the most sensitive measures of
executive and frontal-lobe function for those with severe disease, which suggests the existence of a
complex OSA-neurocognitive relationship.
D. Insomnia and Cognitive decline and/or Alzheimer’s disease
All the 4 prospective studies reviewed that examined the association between insomnia
parameters and cognitive decline and/or AD revealed that there is a greater risk of cognitive decline
and/or Alzheimer's disease in adults with insomnia and/or insomnia like symptoms. The only study that
did not find an association was cross-sectional and assessment of sleep parameters was based on a
structured interview, obtaining self-reported description of sleep characteristics from subjects with
significant cognitive impairment.
E. Restless Leg Syndrome and Cognitive decline and/or Alzheimer’s disease
All 3 studies (2 cross-sectional and 1 case-control) that evaluated RLS and cognitive decline
and/or AD associations concluded that RLS patients have statistically significant specific cognitive
deficits. Pearson et al104 showed that RLS patients compared to controls showed significant (P<0.05) and
sizeable (20–40%) deficits on Verbal Fluency tests and the Trail Making tests.
Summary of evidence
1. Sleep is associated with cognitive decline and/or AD/AD pathology
Taken together, the cross-sectional studies reviewed in this study generally provide support for an
association of sleep and poor cognitive outcomes, including AD and dementia. They show that
individuals with AD , dementia or MCI are more likely to have several indicators of sleep problems,
including sleep depth problems such poor sleep quality, sleep efficiency, sleep latency and sleep
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deprivation; sleep-wake/circadian rhythm abnormalities, excessive daytime sleepiness and OSA/SDB.
However a significant limitation of cross-sectional studies is that causal inferences cannot be made
because the temporal sequence of sleep and circadian disruption, neurodegeneration, and cognitive
decline cannot be assessed. In addition, depression or its symptoms may be important mediators or
confounders of the association between sleep variables and dementia, and should be considered in these
studies.116 However, not all studies clearly addressed the role of depression with certain studies having a
history of depression as an exclusion criteria without considering current depression which might well be
important when one is examining factors in relation to circadian rhythm. Some studies51,87,93 assessed the
presence of sleep disorders by means of subjective symptoms and not using objective instruments, such as
polysomnography, thereby limiting the credibility of information obtained from subjects with an
important cognitive impairment. Polysomnography is essential for a correct diagnosis of some sleep
disturbances. In particular, sleep disordered breathing can be diagnosed only by means of
polysomnographic recordings. Other studies made use of tools that provided limited information on sleep
maintenance, and no detail of sleep times or other sleep parameters and others had very small sample size.
Furthermore, the association between sleep and Alzheimer’s disease pathology, measured by
Alzheimer’s disease biomarkers such as Aβ and Phosphorylated Tau accumulations, has not been
extensively investigated in humans’ in-vivo. The above study findings linking sleep to AD pathology
definitely complement those linking poor sleep to cognitive decline and dementia, however, because of
the cross-sectional nature of the studies, we cannot establish temporality and consequently causality, as
we are unable to infer whether this pathology might cause or result from poor sleep. As such, Aβ
deposition may be a cause and/or occur as a complication during the progression of AD, and/or sleep
disturbance and Aβ plaques may have a shared cause. It is therefore evident that prospective
observational studies are needed to better understand the temporal order of sleep disturbance and AD
pathogenesis and/or biomarkers. This will aid efforts to better evaluate potential opportunities for targeted
and effective prevention.
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Altogether, it can also be seen that studies suggest that sleep variables interact with the APOE
genotype to affect Alzheimer’s disease-related outcomes. Notably, an association between sleep
disturbance especially Sleep Disordered Breathing (SDB) and CSF Alzheimer’s disease-biomarkers in
cognitively normal elderly individuals is evident. Current treatments for SDB such as continuous positive
airway pressure (CPAP) could interrupt the onset of mild cognitive impairment (MCI) or dementia in
normal elderly individuals.
2. Sleep problems precede the onset of cognitive impairment
Taken together, these prospective studies provide support that sleep problems precede the onset
of cognitive impairment, including AD and dementia. Some of the findings suggest interactions by age,
and/or sex.112,114,126 These findings require replication, and if these associations are causal, prevention
efforts may need to be targeted differently at specific ages or in different populations. It is however
important to note that longitudinal studies of dementia are prone to miss both prevalent and incident cases
because full neurological evaluations are not conducted on all participants, especially when selected
participants refuse further neuropsychological testing and examination or die over the course of followup.198-200 An important limitation of most of the prospective studies is the length of the follow up. Only 4
studies had greater than 5 years follow up. Although longitudinal studies can assess temporality, AD is a
lifelong disease process and preclinical AD is very much present prior to the onset of symptomatic AD,
therefore, reverse causation might have actually been the case in these studies since a <5 year follow-up
period may not be sufficient and thus may not reflect the true prospective nature of AD biomarkers and/or
cognitive decline, as certain participants may already have had the disease but were asymptomatic. Also
self-reported data on sleep duration may be subject to bias, including the existence of a change in the
typical sleep duration anticipating the onset of dementia. On the other hand, objective sleep measures are
particularly useful in studies of sleep, aging, and cognition since self-report sleep measures do not
necessarily correlate with objectively measured sleep, and discrepancies between these modes of
assessment may be more pronounced among older adults with cognitive impairment.108,201
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3. Sleep problems may lead to increased AD pathology or may have their effects on dementia
through other pathways
Altogether, it can be seen that experimental studies provide the most compelling evidence of the
plausibility of causal associations between sleep deprivation and AD pathology and/or AD biomarkers,
but typically are performed in animals. The power of experimental mice models to mirror the extremely
complex physiological and biochemical processes in humans is a matter of dispute because of inherent
translational limitations of these models imposed by variations in size and physiology, as well as
differences in the homology of targets between mice and humans. However, from the above study
findings it is clear that alteration of the sleep-wake cycle and circadian rhythm regulation could be
important players in the onset and development of sporadic AD. Therefore, amending and/or
improvement of sleep-wake cycle abnormalities could be a viable therapeutic strategy for AD at risk
individuals. Both animal experimental studies and RCTs also demonstrate that hypoxemia might
contribute to cognitive dysfunction in severe cases, however, in mildly affected patients,192,202 the
interacting effect of cognitive reserve,203 intelligence level,204 and depression205,206 needs to be
considered. We also see from the above study findings that disrupted melatonin levels could be a
surrogate origin of sleep pathology, as decline in melatonin levels are known to occur with aging and this
decline is enhanced with AD, even in preclinical stages. Studies also show that melatonin’s cognitive
benefits could involve its anti-Aβ aggregation, anti-inflammatory, and/or antioxidant properties. Findings
provide reinforcement for long-term melatonin therapy as a primary or complementary strategy for
abating the progression of Alzheimer disease. Also as a result of the fact that the age at treatment
initiation of melatonin might play a role in its ability to suppress Aβ levels, the implication for human
studies could be that melatonin is probably unlikely to have a role in the treatment of established cerebral
amyloidosis characteristic of AD. If this is found to be true, then clinical trials of melatonin will have to
focus on prevention rather than treatment of established cerebral amyloidosis.
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LIMITATIONS
Several methodological concerns must be considered when interpreting the findings of this
systematic review. First, as with any systematic review, one limitation relates to the potential bias
introduced in the paper selection process. To minimize this bias, we adhered strictly to the guidelines and
recommendations in the Cochrane handbook67 whenever possible. We also ensured that studies were not
restricted by language to guard against language bias. Secondly, the possible bias introduced by the
individual studies that were included is a further limitation. Various study designs were rated low for
assigning the grade of evidence.207 In addition to study design, conclusions made from the poor quality
studies could introduce possible bias. We included both high- and low-quality studies in the
summarization of findings because both mostly came to the same conclusion, therefore possibly
indicating that the study quality might not have influenced the overall conclusion. Thirdly, there was
considerable variation between the studies in the assessment methods used to verify sleep problems and
cognitive decline and/or AD/Dementia, suggesting heterogeneity that could possibly raise some questions
about the comparability of results across studies. Our research question focused on a broad concept of
sleep problems based on having any sleep problem symptoms. Thus, we assumed a common underlying
concept by making general conclusions regarding sleep problems and cognitive decline and/or AD.
Fourthly, as in any systematic review, publication bias may have affected the representativeness of the
included studies by over reporting significant findings. Non assessment of publication bias with a funnel
plot is a limitation. Lastly the possibility of a “file drawer” effect exists because exclusion and inclusion
criteria are always subjective.

CONCLUSION AND FUTURE DIRECTIONS
In summary, there is substantial evidence providing support for sleep and its related abnormalities
as a potential cause of cognitive decline, dementia, and Alzheimer’s disease pathology. Ample evidence
linking sleep impairments and circadian regulating mechanisms directly to clinical symptoms in AD
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patients exist. Future research is needed to make clear the contribution of the different genetic,
neurodegenerative and environmental factors to sleep impairment. There is also growing experimental
and epidemiological evidence for close reciprocal interaction between cognitive decline and sleep
alteration, however, long-term longitudinal studies are required to better understand the relationship
between chronic sleep deprivation, circadian rhythm/sleep-wake abnormalities, sleep-disordered
breathing, sleep disorders like OSAS and cognitive decline. Future studies need to be able to define causal
pathways more definitively so we can be clear for example, whether neurodegeneration is leading to both
sleep changes and memory changes, or whether aging is contributing to OSA and/or sleep architecture
changes that in turn affect memory, and/or whether the effect of aging on sleep architecture predisposes to
both apnea and memory impairment. Thus, further research that examines these basic mechanisms as well
as employing clinical/translational approaches are needed. More research with objective sleep measures,
Alzheimer’s disease biomarkers, and cognitive measures are also needed. There is also significant
evidence from in vitro and animal studies for an important role of both melatonin and hypocretin in
modulating AD pathophysiology. Although the exact underlying mechanisms are unknown as of yet,
future studies examining the role of lack of sleep and circadian rhythm deterioration as causative factors
in the onset of AD, especially human studies, are needed, as their findings can be promising for the
development of new prevention and/or treatment opportunities.
RESEARCH AGENDA AND GAPS IN THE LITEARTURE I INTEND TO ADDRESS
The need for a meta-analysis to quantify the effect of sleep problems/disorders on cognitive
impairment and AD. This would allow for efficient integration of existing information from various
studies enabling us to establish whether the literature is consistent and can be generalized across
populations, settings, and/or whether findings vary significantly by particular subsets.
AIM I: To conduct a meta-analysis to quantify the aggregate effect of sleep problems and/or
disorders on cognitive decline and Alzheimer's disease.
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The need to be able to define causal pathways more definitively so we can be clear for example,
whether neurodegeneration is leading to both sleep changes and memory changes, or whether aging is
contributing to OSA and/or sleep architecture changes that in turn affect memory, and/or whether the
effect of aging on sleep architecture predisposes to both apnea and memory impairment. One way to be
able to do this is to conduct more research examining relationships between OSA (preferably with
objective sleep measures) and Alzheimer’s disease biomarkers, and/or cognitive measures. This led to the
following study aims:
AIM IIa: To examine whether the presence of Obstructive Sleep Disordered Breathing is
associated with CSF P-Tau, Hippocampal atrophy and β-amyloid burden in older adults with
MCI and AD.
AIM IIb: To examine the effect of Obstructive Sleep Apnea on longitudinal changes of
Alzheimer's disease biomarkers in cognitive normal, mild cognitive impairment and Alzheimer's
disease patient
The need for clarity in understanding and appreciating the heterogeneity of OSA and its outcomes
in distinct age groups especially as it relates to cognitive function, subsequent cognitive decline and AD.
One way to do this is to integrate decades of research examining OSA and cognition; OSA and
subsequent cognitive decline; and OSA and AD; with particular focus in appreciating the heterogeneity of
OSA and its outcomes in distinct age groups.
AIM III: To conduct a Review titled "Obstructive Sleep Apnea: A Distinct Physiological
Phenotypic Risk Factor in older adults with Cognitive decline and Alzheimer’s disease"
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Table 1.1 Literature Search Terms for the Systematic Review of Sleep and Alzheimer’s disease
Sleep Related

Alzheimer's Disease Related

Alzheimer's disease pathology related

Study Types

Sleep (MeSH)

Alzheimer's disease Dementia

Amyloid beta

Cross sectional

Sleep loss

Cognitive Decline

Amyloid beta deposition/generation

Prevalence studies

Sleep deprivation

Cognitive Impairment

Alzheimer's disease pathogenesis

Experimental studies

Sleep disruption

Mild Cognitive Impairment (MeSH)

Amyloid Precursor Protein

Randomized Control Trials

Sleep apnea

MCI

Amyloid cascade hypothesis

Incidence studies

Obstructive sleep apnea

aMCI

Inflammation

Epidemiologic studies

Sleep Disordered Breathing

Cognition

P-Tau

Case control

Excessive Daytime sleepiness

Alzheimer (MeSH)

Phosphorylated Tau

Prospective Cohort

Sleep Disorders (MeSH)

Hippocampal atrophy

Retrospective cohort

Rapid Eye Movement Behavioral Disorder

Apolipoprotein E

Historical cohort

NREM Slow wave sleep

APOE4

Closed cohort

Hypoxia

Case-Comparison

Sleep Dependent Memory

Nested case control

Sleep quality

Case-Referent Study

Sleep function

Matched case control

Wakefulness

Cochrane database of systematic reviews

Circadian Rhythm (MeSH)

Meta-analysis

Melatonin

Synthesis

Hypocretin

Research integration

78

Table 1.2: Scoring system for quality of paper of the Systematic Review of Sleep and
Alzheimer's disease
·

Hypotheses (maximum possible=1 star)
o The hypothesis/research question of the study not clearly described
o The hypothesis/research question of the study clearly described ¨

·

Sampling (maximum possible= 2 stars)a
o Sample source and size
Ø Routine data=0
Ø Sample size: less than 50 per comparison groups
Ø Sample size: more than 50 per comparison groups ¨
o Type of sampling
Ø Consecutive patients or opportunistic
Ø Random representative of populations studied ¨

·

Type of Study (maximum possible=3 stars)
o Ecological Study
o Case-control/Cross-sectional ¨
o Retrospective/Prospective Cohort ¨¨
o Randomized Control Trial/Experimental ¨¨¨

·

Selection (Cohort studies) (maximum possible=4 stars)
o Representativeness of the exposed cohort

Ø Truly representative of the average distribution of sleep problems in the community ¨
Ø Somewhat representative of the average distribution of sleep problems in the community ¨
Ø Selected group of users e.g., nurses, volunteers
Ø No description of the derivation of the cohort
o Selection of the non-exposed cohort
Ø Drawn from the same community as the exposed cohort ¨
Ø Drawn from a different source
Ø No description of the derivation of the non-exposed cohort
o Length of follow up of cohorts to determine outcome
Ø Follow up period greater than 5 years ¨
Ø Follow up period less than 5 years
o Adequacy of follow up of cohorts (Likelihood to introduce bias)
Ø Complete follow up- all subjects accounted for ¨
Ø Follow up rate ≥ 50% and description of loss to follow up subjects
Ø Follow up rate < 50% and no description of loss to follow up subjects
Ø Follow up rate not mentioned
Table continues
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Table 1.2 continued
·

Selection (Case-control studies) (maximum possible=4 stars)
o Is the case definition adequate?
Ø Yes, with independent validation ¨
Ø Yes, e.g., record linkage or based on self-reports ¨
Ø No description
o Representativeness of the cases

Ø Consecutive or obviously representative series of cases ¨
Ø Potential for selection biases or not stated
o Selection of controls
Ø Community controls ¨
Ø Hospital controls
Ø No description of source
o Non response rate
Ø Same rate for both groups ¨
Ø Non respondents described
Ø Rate different and no designation
·

Selection (Experimental studies) (maximum possible=4 stars)
o Appropriate description of experimental mice/population
Ø Yes, with transgenic status described ¨
Ø No description
o Appropriate description of experimental procedures

Ø Yes, with application of standard protocols ¨
Ø Standardized protocols not adhered to.
o Controls or comparison group
Ø Comparison group present ¨
Ø No controls used
o Comparability of experimental conditions
Ø Mice/population in both groups exposed to similar experimental conditions except for exposure/intervention ¨
Ø Experimental conditions not described
Ø Conditions different and no designation
Table continues
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Table 1.2 continued
·

Methodology (maximum possible=5 stars)
o Definition/ Operationalization of Alzheimer's Disease/Dementia/Cognitive Decline(2)b
Ø No standardized measures (e.g. self-reported diagnosis)
Ø Standardized Operationalized criteria (e.g. ICD-9, ICD-10, DSM-IV)* ¨
Ø Objective measures (e.g., PET scan, MRI) * ¨¨
o Definition/Operationalization of Sleep and its related abnormalities/disorders
Ø No standardized measures (e.g. self-reported diagnosis) =0

Ø Standardized Operationalized criteria/questionnaire (e.g. ICD-9, ICD-10, DSM-IV, PSQI, ESS)^ ¨
Ø Objective measures (e.g., Actigraph, Polysomnography)^ ¨¨
o Study Population (Not applicable to Animal Experimental studies)
Ø No appropriate description of study population
Ø In-patient non-population based
Ø Study population is population based ¨
·

Statistical analyses and results (maximum possible=5 stars)
o Statistical analysis
Ø Statistical methods not described =0
Ø Statistical methods clearly described ¨
o Statistical outcomes
Ø Statistical outcome not clearly reported
Ø Statistical outcomes clearly reported (e.g. OR, RR, CIs) ¨
o Other explanatory variables in the analysis (e.g. confounders) (4)c
Ø No explanatory variables involved
Ø Age and/or gender controlled for ¨
Ø Age, gender, SES and risk factors (sleep related and AD related covariates) ¨¨
o Results
Ø Research questions/hypotheses not clearly answered/tested
Ø Research questions/hypotheses clearly answered/tested ¨

a: Sample size values. The sample size value of 50 participants per group has been chosen as these permits reasonable estimates of rates of
CF. Not Applicable to Animal Experimental studies
b: ICD-9/10 International Classification of Disease version 9/10; DSM-IV Diagnostic Statistical Manual-IV; PQSI Pittsburg Sleep Quality
Index; ESS Epworth Sleepiness Scale
c: Adjustment for confounding variables. From an overview of studies on sleep and Alzheimer's Disease; Age, years of education, marital
status, forced expiratory volume in one second based on spirometry, self-reported history of physician’s diagnosis of asthma, number of hours
of sleep and napping, and use of benzodiazepines. Chronic obstructive pulmonary disease, Nonfatal coronary heart disease including
myocardial infarction, Stroke, The ankle-brachial index calculated as the mean of the posterior tibial pressure on each side divided by the
mean of the two right brachial pressures. Apolipoprotein E genotype, BMI and Depression were all-important covariates to adjust for. Not
Applicable to Animal Experimental studies
* Must be independent blind assessment or made use of record linkage to receive a star
^ Must be use of secure record (eg surgical records) or made use of structured interview where blind to case/control status to receive a star
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Table 1.3 : Quality Assessment of Cross-sectional studies
First Author, Country, Year Published
(Reference)

Hypotheses
(maximum
possible=1 star)

Sampling
(maximum
possible=2 stars)

Type of Study
(maximum
possible=3
stars)

Methodology
(maximum
possible=5 stars)

Statistical
Analysis
(maximum
possible=5 stars)

Total (maximum
possible=16
stars)

Quality Rating

Blackwell, United States, 2006 ()

♦

♦♦

♦

♦♦♦♦

♦♦♦♦♦

13

High

Nebes, United States, 2009 ()

♦

♦

♦

♦♦♦

♦♦♦♦

10

Medium

Saint Martin, France, 2012 ()

♦

♦♦

♦

♦♦♦

♦♦♦♦

10

Medium

Guarnieri, Italy, 2012 ()

♦

♦

♦

♦♦

♦♦♦♦

9

Medium

Moran, Ireland, 2005 ()

♦

♦

♦

♦♦

♦♦♦♦

9

Medium

Pistacchi, Italy, 2014 ()

♦

♦

♦

♦♦

♦♦♦

8

Low

Fetveit, Norway, 2006 ()

♦

♦

♦♦♦

♦♦

7

Low

Ju, United States, 2013 ()

♦

♦

♦♦♦♦

♦♦♦

9

Medium

Spira, United States, 2013 ()

♦

♦

♦♦♦

♦♦♦♦♦

10

Medium

Craig, Northern Ireland, UK, 2006 ()

♦

♦

♦♦♦

♦♦

8

Low

Oosterman, Netherlands, 2009 ()

♦

♦

♦♦♦

♦♦♦♦

9

Medium

Merlino, Italy, 2010 ()

♦

♦

♦♦

♦♦♦

8

Low

Pat-Horenczyk, United States, 1998 ()

♦

♦

♦♦♦

♦♦

7

Low

Yesavage, United States & France, 2011 ()

♦

♦

♦

♦♦♦

♦♦

8

Low

Gottlieb, United States, 2004 ()

♦

♦♦

♦

♦♦♦♦♦

♦♦♦♦

13

High

Kadotani, United States, 2001 ()

♦

♦♦

♦

♦♦♦♦

♦♦♦♦

12

High

Osorio, United States, 2014 ()

♦

♦

♦♦♦♦

♦♦♦♦

10

Medium

Djonlagic, United States, 2014 ()

♦

♦

♦♦♦

♦♦♦

8

Low

♦

♦
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Table 1.4: Quality Assessment Scores of Case-control studies
First Author, Country, Year
Published (Reference)

Hypotheses
(maximum
possible=1 star)

Sampling
(maximum
possible=2 stars)

Type of Study
(maximum
possible=3
stars)

Selection (Casecontrol study)
(maximum
possible=4 stars)

Methodology
(maximum
possible=5
stars)

Statistical
Analysis
(maximum
possible=5
stars)

Total
(maximum
possible=20
stars)

Quality Rating

Chen, Taiwan, 2011 ()

♦

♦

♦♦♦

♦♦♦

♦♦

10

Low

Hita-Yañez, Spain, 2013 ()

♦

♦

♦♦♦

♦♦♦

♦♦♦

11

Medium

Hita-Yañez, Spain, 2012 ()

♦

♦

♦♦♦

♦♦♦♦

♦♦♦

12

Medium

Hot, France, 2011 ()

♦

♦

♦♦

♦♦♦

♦♦

9

Low

Sanchez-Espinosa, Spain, 2014 ()

♦

♦

♦♦♦♦

♦♦♦♦

♦♦♦

13

Medium

Naismith, Australia, 2014 ()

♦

♦

♦♦♦

♦♦♦

♦♦

10

Low

Fronczek, Netherland, 2012 ()

♦

♦

♦♦♦

♦♦♦♦

♦♦

11

Medium

Slats, Netherlands, 2012 ()

♦

♦

♦♦

♦♦♦♦

♦♦♦♦

12

Medium

Schmidt, Germany, 2013 ()

♦

♦

♦♦

♦♦♦♦

♦♦♦

11

Medium

Liu, Netherlands and China, 1999 ()

♦

♦

♦♦

♦♦♦♦

♦♦♦

12

Medium

O’Hara, United States, 2005 ()

♦

♦

♦♦

♦♦♦♦

♦♦

10

Low

Pearson, United States, 2006 ()

♦

♦

♦♦

♦♦♦

♦♦♦

10

Low

♦
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Table 1.5: Quality Assessment Scores of Cohort studies/Randomized Clinical Trials

Hypotheses
(maximum
possible=1 star)

Sampling
(maximum
possible=2
stars)

Type of
Study
(maximum
possible=3
stars)

Selection
(Cohort studies)
(maximum
possible=4 stars)

Methodology
(maximum
possible=5 stars)

Keage, Australia, & United Kingdom
2012 ()

♦

♦♦

♦♦

♦♦♦♦

♦♦♦

♦♦♦♦

16

High

Tworoger, United States, 2006 ()

♦

♦♦

♦♦

♦♦

♦♦♦

♦♦♦♦

14

Medium

Virta, Finland, 2013 ()

♦

♦♦

♦♦

♦♦♦♦

♦♦♦

♦♦♦

15

High

Song, United States, 2014 ()

♦

♦♦

♦♦

♦♦♦

♦♦♦

♦♦♦♦

15

High

Blackwell, United States, 2014 ()

♦

♦♦

♦♦

♦♦♦

♦♦♦

♦♦♦♦♦

16

High

Sterniczuk, Canada, 2013 ()

♦

♦♦

♦♦

♦♦♦

♦♦

♦♦♦♦

14

Medium

Benito-León, Spain, 2014 ()

♦

♦♦

♦♦

♦♦♦♦

♦♦

♦♦♦♦♦

16

High

Hahn, United States, 2013 ()

♦

♦

♦♦

♦♦♦♦

♦♦

♦♦♦♦♦

15

High

Bidzan, Poland, 2011 ()

♦

♦♦

♦♦

♦♦

♦♦

9

Low

Lim, Canada, 2013 ()

♦

♦

♦♦

♦♦♦

♦♦♦

♦♦♦

13

Medium

Ooms, Netherlands, 2014 ()

♦

♦

♦♦♦

♦♦

♦♦♦♦

♦♦♦♦

15

High

Walsh, United States 2014 ()

♦

♦♦

♦♦

♦♦♦

♦♦♦

♦♦♦♦

15

High

Anderson, United Kingdom, 2014 ()

♦

♦♦

♦♦

♦♦

♦♦♦

♦♦♦

13

Medium

Tranah, United States, 2011 ()

♦

♦♦

♦♦

♦♦♦

♦♦♦

♦♦♦♦♦

16

High

Lim, United States, 2013 ()

♦

♦♦

♦♦

♦♦

♦♦♦

♦♦♦♦♦

15

High

Yesavage, United States, 2004 ()

♦

♦♦

♦♦

♦♦♦♦

♦♦

11

Medium

Asayama, Japan, 2003 ()

♦

♦♦♦

♦♦

♦♦♦

♦♦♦♦

14

Medium

Cohen-Zion, United States, 2001 ()

♦

♦♦

♦♦

♦♦♦

♦♦♦

10

Low

Chang, Taiwan, 2013 ()

♦

♦♦

♦♦♦

♦♦♦

♦♦♦♦

15

High

First Author, Country, Year
Published (Reference)

♦

♦♦
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Statistical
Analysis
(maximum
possible=5
stars)

Total
(maximum
possible=20
stars)

Quality
Rating

Yaffe, United States, 2011 ()

♦

♦

♦♦

♦♦

♦♦♦♦

♦♦♦♦♦

15

High

Kushida, United States, 2012 ()

♦

♦

♦♦♦

♦♦

♦♦♦♦

♦♦♦♦

15

High

Ancoli-Israel, United States, 2008 ()

♦

♦

♦♦♦

♦♦

♦♦♦♦

♦♦♦♦

15

High

Cricco, Iceland, 2001 ()

♦

♦♦

♦♦

♦♦

♦♦♦

♦♦♦♦♦

15

High

Jelicic, The Netherlands, 2002 ()

♦

♦♦

♦♦

♦♦

♦♦♦

♦♦♦

13

Medium

Foley, United States, 2001 ()

♦

♦♦

♦♦

♦♦

♦♦♦

♦♦♦♦♦

15

High

Osorio, United States, 2011 ()

♦

♦♦

♦♦

♦♦♦

♦♦♦

♦♦♦♦

15

High

Table 1.6: Quality Assessment Scores of Experimental studies
First Author, Country, Year Published
(Reference)

Hypotheses
(maximum
possible=1
star)

Type of Study
(maximum
possible=3 stars)

Selection
(Experimental
studies)
(maximum
possible=4 stars)

Methodology
(maximum
possible=4
stars)

Statistical
Analysis
(maximum
possible=3
stars)

Total
(maximum
possible=15
stars)

Quality Rating

Rothman, United States, 2013 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Di Meco, United States, 2014 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Kang, United States, 2009 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Mander, United States, 2013

♦

♦♦♦

♦♦♦

♦♦♦♦

♦♦

13

High

Craig, Canada, 2008 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Jyoti, Scotland, UK, 2010 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Quin, United States, 2005 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

DENG. China, 2005 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Papolla, United States, 1998 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Olcese, United States, 2009 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Lahiri, United States, 2004 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High
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Shiota, Japan, 2013 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Kaushal, United States, 2012 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Sun, Canada, China, United States, 2006
()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Li, China, 2009 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Zhang, China, 2007 ()

♦

♦♦♦

♦♦♦♦

♦♦♦♦

♦

13

High

Table 1.7. Sleep Depth and Cognitive/Alzheimer's Disease Measures: Descriptive Study Characteristics, and Main Findings
First Author,
Country, Year
Published (Reference)

Blackwell, United
States, 2006 ()

Nebes, United States,
2009 ()

Study Design

Cross sectional

Cross-sectional

Sample size N

N=2,242

N=157

Study Population

Community-dwelling women
65 years old or older

Participants were 65–80 years
old community volunteers

86

Sleep Depth
Assessment

Cognitive/AD Measures
Assessment

Actigraphy

Mini-Mental State
Examination (MMSE) and
the Trail Making B Test
(Trails B)

Objectively measured
disturbed sleep was
consistently related to
poorer cognition, whereas
total sleep time was not.

Pittsburgh Sleep
Quality Index
[PSQI]

Repeatable Battery for the
Assessment of
Neuropsychological Status
(RBANS). Test of
Nonverbal Intelligence
(TONI))

Sleep problems may
contribute to performance
variability between
elderly individuals but
only in certain cognitive
domains.

Conclusion

Guarnieri, Italy, 2012 ()

Pistacchi, Italy, 2014 ()

Fetveit, Norway, 2006
()

Cross-sectional

Cross-sectional

Cross-sectional

N= 431

Participants were patients
enrolled consecutively in 10
Italian neurological centers:
204 had Alzheimer’s disease
(AD), 138 mild cognitive
impairment (MCI), 43 vascular
dementia (VaD), 25
frontotemporal dementia and
21 Lewy body dementia
(LBD) or Parkinson’s disease
dementia (PDD).

N= 236

236 patients (78 men and 158
women) were enrolled with
different subtypes of dementia:
(AD), (VaD), mixed dementia
(MCI), dementia with Lewy
bodies (DLB), (PDD), and
frontotemporal lobar
degeneration (FTLD)

N=23

Nursing home residents with
varying degree of dementia

87

PSQI, Berlin
questionnaire and
the International
Restless Leg
Syndrome (RLS)
Study Group
questionnaire

DSM-IV-TR criteria. AD
and Vascular Dementia
(VaD) were diagnosed
respectively according to
NINCS-ARDRA and
NINDS-AIREN criteria.
LBD and PDD,
frontotemporal dementia
(FTD) and MCI were
diagnosed according to
specific consensus
guidelines

A careful clinical
evaluation of sleep
disorders should be
performed routinely in the
clinical setting of persons
with cognitive decline.
Instrumental supports
should be used only in
selected patients

PSQI, Berlin
questionnaire and
the International
Restless Leg
Syndrome (RLS)
Study Group
questionnaire

DSM-IV-TR criteria . AD
and VaD were diagnosed
respectively according to
NINCS-ARDRA and
NINDS-AIREN criteria .
LBD and PDD,
frontotemporal dementia
(FTD) and MCI were
diagnosed according to
specific consensus
guidelines .

Findings demonstrate that
sleep disturbance was
related to dementia

Actigraphy

Grades of dementia were
assessed by Mini-Mental
Status Examination Score
(MMSE) and Clinical
Dementia Rating (CDR).

Sleep duration during the
24-h day was positively
correlated with the
severity of dementia in
nursing home patients.

Ju, United States, 2013
()

Spira, United States,
2013 ()

Craig, Northern
Ireland, UK, 2006 ()

Cross-sectional

Cross-sectional

Cross-sectional

N=142

N= 70

N=426

Longitudinal studies of
memory and aging at the
Washington University Knight
Alzheimer Disease Research
Center (ADRC). The Adult
Children Study, in which all
were age 45-75 years at
baseline and 50% have a
parental history of sAD.

Actigraphy

Participants were adults (mean
age, 76 [range, 53-91] years)
from the neuroimaging substudy of the Baltimore
Longitudinal Study of Aging,
a normative aging study.

Subjects were identified from
outpatient memory-clinic
records based at the Belfast
City Hospital Trust, Mater
Infirmorum, and Holywell
Hospital. Patients fulfilled the
criteria for probable AD.

88

Aβ42 was measured by the
Alzheimer's Disease
Research Center (ADRC)
Biomarker Core using
enzyme linked
immunosorbant assay
(INNOTEST; Innogenetics,
Ghent, Belgium).

Amyloid deposition in the
preclinical stage of AD
appears to be associated
with worse sleep quality,
but not with changes in
sleep quantity.

Self-reported sleep
variables: The 5item Women’s
Health Initiative
Insomnia Rating
Scale (WHIIRS)

β-Amyloid burden,
measured by carbon 11–
labeled Pittsburgh
compound B positron
emission tomography
distribution volume ratios
(DVRs).

Among communitydwelling older adults,
reports of shorter sleep
duration and poorer sleep
quality are associated with
greater Aβ burden.

A validated
neuropsychological
assessment tool,
the
Neuropsychiatric
Inventory with
Caregiver Distress
(NPI-D), was
employed to record
sleep disturbances
during the course
of the dementing
illness.

Outpatient memory-clinic
records. DNA extracted
from peripheral blood
leukocytes was analyzed
for the APOE and MAO-A
30 bp VNTR
polymorphisms

Sleep disturbance in AD
is common and distressing
and is associated with
genetic variation at MAOA.

Hita-Yañez, Spain,
2012 ()

Chen, Taiwan, 2011 ()

Hita-Yañez, Spain,
2013 ()

Case-control

Case-control

Case-control

N=50

Twenty-five MCI patients (7
females, mean age: 70.5 ± 6.8
yr) and 25 healthy old (HO)
volunteers (13 females, mean
age: 67.1 ± 5.3 yr)

Polysomnography
(PSG)

ApoE genotype was
determined by conventional
PCR (polymerase chain
reaction) methods. The
diagnosis of MCI was
based on consensus criteria.
Global cognitive status was
assessed with the Mini
Mental State Examination
(MMSE).

N=21

Authors recruited 9 controls
without dementia, 6 patients
with mild cognitive
impairment (MCI), and 6
patients with mild Alzheimer's
disease (AD). None of the
participants had sleep
complaints, and all AD
patients were receiving
cholinesterase inhibitors.

Polysomnography
(PSG)

MMSE. NINCDSADRDA. All patients with
AD were taking acetyl
cholinesterase inhibitors
(AChEI)

A deficiency of Ach may
result in an increase of
sEMG activity in MCI
patients.

Overnight PSG
recordings and
self-reported sleep
measures were
obtained

The diagnosis of MCI was
based on consensus criteria.
Global cognitive status was
assessed with the Mini
Mental State Examination
(MMSE).

Sleep is significantly
impaired in patients with
mild cognitive
impairment at both the
objective and subjective
level, which may be used
as a surrogate marker of
preclinical Alzheimer
disease.

N=50

Twenty-five patients with MCI
(7 females, mean age: 70.5 ±
6.8 y) and 25 HE subjects (13
females, mean age: 67.1 ± 5.3
y) were enrolled in the study,
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Sleep disruptions are
evident years before
diagnosis of AD, which
may have implications for
early detection of
dementia and/or
therapeutic management
of sleep complaints in
MCI patients.

Hot, France, 2011 ()

Sanchez-Espinosa,
Spain, 2014 ()

Keage, Australia, &
United Kingdom 2012
()

Case-control

Case-control

Prospective cohort

N=28

N=21

N= 2012

Fourteen un-medicated AD
patients (seven men and seven
women; mean age (±SD): 76.7
± 3.8 years) participated in this
study

Participants were primarily
recruited from older people's
associations, normal
community health screening,
and hospital outpatient
services.

The Medical Research
Council Cognitive Function
and Ageing Study (CFAS), a
longitudinal multi-center
population-based study of
ageing and dementia
(www.cfas.ac.uk). . Follow-up
time: 10-years

90

Polysomnography
(PSG)

Polysomnography
(PSG)

Self-reported
measures .

Episodic memory was
assessed with an original
task derived from Grober
and Buschke’s procedure
(1987).This task consisted
in learning 15 words,
presented by series of three
on separate cards

Changes in theta rhythm
during REM and SWS are
a relevant index of brain
impairments in the early
stage of AD, and are
related to episodic
memory performance.

Neuropsychological
testing; diagnostic criteria
of aMCI proposed by
Petersen et al. Plasma Aβ
levels. Cerebral MRI
acquisition, image
preprocessing and cortical
thickness estimation was
done for each participant

Increased plasma Aβ42
levels are significantly
associated with
fragmented SWS in aMCI
subjects, suggesting that
sleep disruptions may
signal Aβ burden in
persons at increased risk
for AD. Reduced REM
sleep and plasma Aβ
levels in aMCI subjects
were significantly related
to thinning of cortical
regions targeted by AD
neuropathology.

MMSE

Daytime napping, nighttime sleep duration, and
excessive daytime
sleepiness may be
modifiable behaviors
open to intervention
strategies, or, clinical
indicators of future
decline in older
individuals.

Tworoger, United
States, 2006 ()

Virta, Finland, 2013 ()

Song, United States,
2014 ()

Blackwell, United
States, 2014 ()

Prospective cohort

Prospective cohort

Prospective cohort

Prospective Cohort

Self-reported
measures .

Women completed six tests
of cognitive function
encompassing general
cognition, verbal memory,
category fluency, and
attention. Tests were
repeated 2 years later.

Diminished cognition is a
risk factor for dementia.
However, the lack of an
association with
prospective cognitive
decline warrants further
investigation

This is the first study
indicating that midlife
sleep length, sleep quality,
and use of hypnotics are
associated with late life
cognitive function. .

N= 1844

Participants (all women) were
members of the Nurses’
Health Study cohort aged 70
to 81 years at initial cognitive
interview in 2000. Follow-up
period: 2years

N= 2,336

The subjects of the current
study were members of the
older Finnish Twin Cohort,
consisting of same-sex twin
pairs born in Finland prior to
1958 with both co-twins alive
in 1967. Follow-up time: 1826years

Self-reported
measures .

Between 1999 and 2007,
participants were assigned
a linear cognitive score
with a maximum score of
51 based on a telephone
interview (mean score 38.3,
Standard Deviation (SD)
6.1).

N = 2,601

The Osteoporotic Fractures
in Men Study (MrOS).
Participants were age 65 and
older and free of probable
dementia at sleep visit.
Follow-up averaged 3.4 years

Sleep stages were
identified by inhome
polysomnography
at the initial sleep
visit (2003-2005).

Cognitive outcomes were
assessed with the Trail
Making Test Part B and
Modified Mini-Mental
State Examination (3MS) at
sleep visit and two followup

Increased time in Stage
N1 and less time in Stage
R are associated with
worsening cognitive
performance in older men
over time

Actigraphy

Clinically significant
cognitive decline: fivepoint decline on the
Modified Mini-Mental
State examination (3MS),
change score for the Trails
B test time in the worse
decile.

Among older communitydwelling men, reduced
sleep efficiency, greater
nighttime wakefulness,
greater number of long
wake episodes, and poor
self-reported sleep quality
were associated with
subsequent cognitive
decline.

N=2822

The Osteoporotic Fractures
in Men Study (MrOS).
Participants were age 65 and
older (mean age 76.0 ± 5.3
y)and free of probable
dementia at sleep visit.
Follow-up averaged 3.4 ± 0.5
y.
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Sterniczuk, Canada,
2013 ()

Benito-León, Spain,
2014 ()

Hahn, United States,
2013 ()

Bidzan, Poland, 2011 ()

Retrospective
Cohort

Prospective cohort

Prospective cohort

Prospective cohort

Self-reported sleep
measures

Alzheimer’s
disease/Dementia was
reported by the participants
themselves and/or by a
proxy respondent
.Cognition was assessed
using performance-based
cognitive tests

These findings indicate
that sleep disturbance may
exist prior to the
manifestation of other
typical symptoms
observed in AD (e.g.,
memory loss).

Self-reported long sleep
duration was associated
with 58% increased risk
of dementia-specific
mortality in this cohort of
elders without dementia.

N= 28,697

The Survey of Health,
Ageing and Retirement in
Europe (SHARE) (N =
30,038). Follow-up period:
4.3years

N= 3,857

Neurological Disorders in
Central Spain (NEDICES)
Study, a longitudinal,
population-based survey
followed for a median of 12.5
years

Self-reported sleep
measures

ICD-9 codes for deaths that
occurred before 1999 and
ICD-10 codes for deaths
occurring thereafter.

N= 214

The population-based
Kungsholmen Project, a
longitudinal study of aging and
dementia among adults aged
75 years and older residing in
Kungsholmen district,
Stockholm, Sweden. Followup time: Up to 9-years

Comprehensive
Psychopathological
Rating Scale
(CPRS)

DSM-III-Revised and AD
diagnosis was made using
the NINCDS-ADRDA
criteria

Self-reported sleep
problems may increase
the risk for dementia, and
depressive symptoms may
explain this relationship.

Care centers residents age 55
and older, who had had the
presence of dementia excluded
(n = 2910).. Follow-up time:
7-years

The
Neuropsychiatric
Inventory-Nursing
Home (NPI-NH)
scale and the
Association for
Methodology and
Documentation in
Psychiatry
(AMDP) scale.

Alzheimer’s disease
Assessment Scale
Cognitive (ADAS-cog)
scale. Dementia in the
Alzheimer’s disease was
diagnosed based on the
NINCDS-ADRDA criteria.

The patients in the
preclinical period of
dementia experienced
sleep disturbances more
frequently and with
greater intensity, which in
combination with other
factors may have some
prognostic value.

N=150
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Lim, Canada, 2013 ()

Rothman, United
States, 2013 ()

Di Meco, United States,
2014 ()

Prospective cohort

Experimental

Experimental

N= 698

Participants were communitydwelling older adults without
dementia (mean age, 81.7
years; 77% women) in the
Rush Memory and Aging
Project. follow-up period of
up to 6 years.

Not Applicable

Male 3xTgAD mice were
subjected to sleep
restriction(SR) for 6h/day for 6
weeks using the modified
multiple platform technique,
and behavioral(Morris water
maze, fear conditioning, open
field)

Not Applicable

A total of 18 mice were kept in
a pathogen-free environment,
on a 12-hour light and/or dark
cycle and had access to food
and water ad libitum. Starting
at the age of 8 months, mice
were randomized to 2 groups,
one underwent a 20/ 4-hour
light and/or dark cycle for 2
months (4 males and 5
females), the other was kept on
a normal light and/or dark
cycle, as controls (5 males and
4 females).
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Actigraphy

Mice were tested
in the Morris water
maze (MWM)

The locomotor
cage test was used
to record the sleepwake cycle of the
animals. The fear
conditioning tests.
The Morris watermaze test

Neuropsychometric tests.
NINCDS-ADRDA criteria.
Autopsies were performed
on 201 participants who
died, and β-amyloid (Aβ)
and neurofibrillary tangles
were identified by
immunohistochemistry and
quantified. Peripheral blood
lymphocytes were used for
DNA extraction, and
APOE genotype was
determined

Better sleep consolidation
attenuates the effect of
APOE genotype on
incident AD and
development of
neurofibrillary tangle
pathology.

Hippocampal and cortical
Aβ and P-Tau
concentrations were
obtained

Significant positive
correlations between
cortical Aβ and p -Tau
levels and circulating
corticosterone indicate a
potential role for GCs in
mediating behavioral and
biochemical changes
observed after sleep
restriction in a mouse
model of AD

Mouse brain homogenates
were extracted in radioimmuno-precipitation assay
(RIPA) buffer and were
prepared for
immunohistochemistry.
Cd-5 kinase (Cdk-5)
activity was carried out.

Authors conclude that
alteration of the sleepwake cycle and circadian
rhythm regulation could
be important players in
the onset and
development of sporadic
AD. Correction of sleepwake cycle aberrations
could be a viable
therapeutic strategy for
individuals bearing this
risk factor.

Kang, United States,
2009 ()

Mander, United States,
2013

Ooms, Netherlands,
2014 ()

Experimental

Experimental

Randomized
Controlled Trial

Mice were forced
into wakefulness
for 6 hours at the
beginning of the
second 12-hour
light period when
they would
naturally be asleep.

Authors monitored
hippocampal Aβ levels
using in vivo micro dialysis
in both wild-type mice and
human APP transgenic
(Tg2576) mice, which
express a mutated form of
human amyloid precursor
protein (APP). ISF Aβ was
assessed in Tg2576 mice at
3 months of age, several
months earlier than Aβ
deposition begins.

Sleep-wake cycle and
orexin may play a role in
the pathogenesis of
Alzheimer’s disease.

N=33

A group of cognitively normal
older adults (n=18 mean age
20.4 ± 2.1) and a group of
healthy young adults (n=15
mean age 72.1 ± 6.6)

Measured with
Polysomnogram
(PSG), starting at
their habitual bed
time to minimize
the influence of
age-related
circadian
differences.

Approximately 2 h postawakening, participants
performed an event-related
fMRI scanning session
while performing a longdelay (10 h) recognition
test

Together, these data
support a model in which
age-related mPFC atrophy
diminishes SWA, the
functional consequence of
which is impaired longterm memory.

N=26

The Alzheimer,
Wakefulness, and Amyloid
Kinetics (AWAKE) study at
the Radboud Alzheimer
Center, a randomized clinical
trial that took place between
June 1, 2012, and October 1,
2012.

Sleep was
monitored using
continuous
polysomnographic
recording from 3
PM until 10 AM.

Cerebrospinal fluid, Aβ42,
P-tau, and T-tau were
deter-mined using the
xMAP-based Innobia assay
(Innogenetics) and CSF
Aβ40 was measured using
an enzyme-linked immunosorbent assay

Sleep deprivation, or
prolonged wakefulness,
interferes with a
physiological morning
decrease in Aβ42.
Chronic sleep deprivation
increases cerebral Aβ42
levels, which elevates the
risk of Alzheimer disease.

Not Applicable

Both wild-type mice and
human APP transgenic
(Tg2576) mice
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Table 1.8. Sleep-wake cycle abnormalities and Cognitive/Alzheimer's Disease Measures: Descriptive Study Characteristics, and Main
Findings
First Author,
Country, Year
Published
(Reference)

Oosterman,
Netherlands, 2009
()

Merlino, Italy,
2010 ()

Pat-Horenczyk,
United States, 1998
()

Yesavage, United
States & France,
2011 ()

Study Design

Cross-sectional
(Correlational)

Cross-sectional

Cross-sectional

Cross-sectional

Sample
size N

Study Population

N= 144

Study was part of a larger study on the
eﬀects of cardiovascular risk factors, and
participants (90 males and 54 females,
aged 69.5 ± 8.5 years (mean ± SD), range
50–91) were recruited among people
visiting the outpatient clinic (of
cardiology, internal medicine, or
neurology) of the Saint Lucas Andreas
Hospital in Amsterdam, the Netherlands.

N=750

N= 67

N=300

Subjects aged 65 years or older, living
independently or in an institution, who
resided in the seventh district of Udine,
Italy were recruited.

Sleep-wake cycle
Assessment

Cognitive/AD Measures
Assessment

Wrist Actigraphy

Mental speed: Stroop test
(Stroop, 1935). The Word (W)
and Color (C) cards of the
Stroop test Memory: 15-words
test. The Dutch version (Saan
and Deelman, 1986) of the
Auditory Verbal Learning Test
(Rey, 1964) .Digit span
forward (Wechsler, 1987).

An association between the restactivity rhythm and cognitive
performance is present in elderly
people.

Sleep disorders were
investigated with a
battery of standardized
questions and
questionnaires

The diagnosis of dementia was
made according to the DSMIV-TR criteria . AD and VaD
were diagnosed respectively
according to NINCS-ARDRA
and NINDS-AIREN criteria .
LBD and PDD, frontotemporal
dementia (FTD) and MCI were
diagnosed according to specific
consensus guidelines .

Excessive daytime sleepiness
was significantly related to
dementia. Insomnia, was not
associated with the presence of
cognitive decline.

Conclusion

Nursing home residents (mean age = 85.7
years). There were 46 severely demented
patients, and 21 mild-moderately
demented patients

Actigraphy

Levels of dementia were
assessed by Mini-Mental State
Examination (MMSE)

With the progression of
dementia, both the capacity to
maintain sleep and the capacity
to maintain wakefulness are
impaired, and result in complete
fragmentation of
sleep/wakefulness during the
night and day.

Two cohorts of AD participants. Cohort 1
(n=124): individuals with probable AD
recruited from the Stanford/Veterans
Affairs NIA Alzheimer’s Disease Core
Center (n=81) and the Memory Disorders
Clinic at the University of Nice School of
Medicine (n=43). Cohort 2 (n=176):
individuals with probable AD derived
from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) data set.

Wrist actigraphy data for
seven days in Cohort 1
and by the
Neuropsychiatric
Inventory (NPI-Q) for
Cohort 2.

Diagnosis of probable AD by
NINCDS-ADRDA criteria
based on relevant neurological,
medical, neuroimaging, and
neuropsychological
assessments.

It is unlikely that a relationship
with a clinically meaningful
correlation exists between the
circadian rhythm-associated
SNPs and WASO in individuals
with AD.
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Naismith,
Australia, 2014 ()

Fronczek,
Netherland, 2012 ()

Slats, Netherlands,
2012 ()

Schmidt, Germany,
2013 ()

Case-control

Case-control

Case-control

Case-control

N=58

Participants (30 patients with MCI and 28
age-matched controls) were recruited from
a specialist ‘Healthy Brain Ageing’ Clinic,
at the Brain & Mind Research Institute,
Sydney, Australia.

Actigraphy.
Polysomnographic (PSG)
assessments, on separate
nights. Salivary
melatonin was assessed
to determine dim light
melatonin onset (DLMO)

A clinical diagnosis of MCI
was obtained using Petersen’s
criteria

Circadian misalignment and
sleep disruption is evident in
patients with MCI, and is
consistent with changes observed
in Alzheimer’s disease. Such
findings could be a marker for
disease trajectory, and may even
be implicated in disease
pathogenesis.

N=49

Ten patients with AD (Braak 5 or 6) and
10 non-demented controls (Braak 0 or 1)
were matched for sex, age, postmortem
delay (PMD), and fixation time
(hypothalamus group).

Hypocretin-1
immunocytochemistry
and neuron quantification
and measurement in
ventricular CSF was
done.

Clinical diagnosis and
Neuropathological examination
according to van de Nes et al.
1993 and Braak et al. 1998

Hypocretin system is affected in
advanced AD. This is reflected in
a 40% decreased cell number,
and 14% lower CSF hypocretin-1
levels.

CSF hypocretin-1 was
measured using a
commercially available
RIA kit (Phoenix
Pharmaceuticals,
Belmont, CA).

CSF Aβ42 was determined
using the xMAP-based Innobia
assay (Innogenetics NV, Ghent,
Belgium) CSF Aβ40 using
ELISA (the Genetics Company,
Schlieren, Switzerland).Total
protein level in CSF was
analyzed using the Lowry
method.

Mean Aβ42 levels and mean
hypocretin-1 levels and
amplitude may suggest a
relationship between AD
pathology and hypocretin
disturbance, which could hold
possibilities for treatment of AD
related sleep disorders.

Melanin-concentrating
hormone (MCH) and
hypocretin-1 (HCRT-1,
orexin-A) were measured
using a fluorescence
immunoassay (FIA)

Consortium to Establish a
Registry for Alzheimer’s
Disease (CERAD), Wechsler
Memory Scale-Revision
(WMS-R), clock drawing test,
and Trail Making Test (TMT),
a MRI head-scan, genotyping
of ApoE4 and determination of
Ab42, T-tau and P-tau in the
CSF.

This report on MCH in patients
with AD adds to preclinical
studies and may allow further
research on the role of the
hypothalamus in pathology and
occurrence of behavioral
disturbances in AD.

N=12

N=66

Six patients with AD (59-85 yrs, MMSE
16-26) and six healthy volunteers (64-77
yrs).

33 patients with mild to severe AD and 33
subjects without any psychiatric or
neurological disorder (HS) that were
consecutively recruited to participate in
the study.
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Liu, Netherlands
and China, 1999 ()

Walsh, United
States 2014 ()

Keage, Australia, &
United Kingdom
2012 ()

Anderson, United
Kingdom, 2014 ()

Case-control

Prospective
Cohort

Prospective
cohort

Prospective
Cohort

Melatonin in postmortem
CSF was measured by a
direct RIA

ApoE genotyping. The
genotype of each extracted
DNA sample was determined
by polymerase chain reaction
(PCR)

CSF melatonin levels fromApoE€3/4 genotype patients were
significantly higher thanthose
from the ApoE-€4/4 genotype,
suggesting a relationship between
melatonin levels and signs and
symptoms of AD. CSF melatonin
levels was lower in AD patients
than in old control subjects.

Actigraphy

Modified Mini-Mental Status
Examination (3MS), California
Verbal Learning Task (CVLT),
digit span, Trail Making Test B
(Trails B), categorical fluency,
and letter fluency.

Weaker Circadian Activity
Rhythm patterns are associated
with worse cognitive function,
especially executive function, in
older women without dementia.

N=167

Autopsies were performed within the
framework of The Netherlands Brain
Bank. Ventricular postmortem CSF was
obtained at autopsy, 1–12 h after death,
from 85 patients with AD (mean age, 75 ±
1.1 yr) and 82 age-matched controls
(mean age, 76 ± 1.4 yr) without a primary
neurological or psychiatric disease.

N=1287

1,287 community-dwelling older women
(82.8 ± 3.1 y) participating in an ongoing
prospective study who were free of
dementia at the baseline visit. Follow-up
time: 5 years

N= 2012

The Medical Research Council
Cognitive Function and Ageing Study
(CFAS), a longitudinal multi-center
population-based study of ageing and
dementia (www.cfas.ac.uk). Follow-up
time: 10-years

Self-reported sleep
measures

MMSE

Excessive daytime sleepiness
may be modifiable behaviors
open to intervention strategies,
or, clinical indicators of future
decline in older individuals.

N= 421

The study was nested in the Newcastle
85+ Study, a population-based
longitudinal study of health and ageing in
the very old. Follow-up time: 2 years

Pittsburgh Sleep
Questionnaire Inventory
(PSQI) and the Epworth
Sleepiness Score (ESS)
as subjective measures of
sleep and wake.

Cognition assessed by the
Mini-Mental State Examination
(MMSE)

Abnormal sleep–wake patterns
are associated with cognitive
impairment
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Tranah, United
States, 2011 ()

Lim, United States,
2013 ()

Yesavage, United
States, 2004 ()

Craig, Canada,
2008 ()

Prospective
Cohort

Prospective
Cohort

Prospective
Cohort

Experimental

N=1282

Women were participants of the Study of
Osteoporotic Fractures (SOF), a
longitudinal epidemiologic study of
10,366 community-dwelling women age
65 years or older. Follow-up time: 4.9
years

Circadian activity
rhythms were measured
with the Sleep-Watch-O
(Sleep-Watch-OVR,
Ambulatory Monitoring,
Inc., Ardsley, NY)
actigraph.

Modified Mini-Mental State
Examination (3MS);
California Verbal Learning
Test (CVLT) delayed recall;
Informant Questionnaire on
Cognitive Decline in the
Elderly (IQCODE); selfreported previous dementia
diagnosis

Older, healthy women with
decreased circadian activity
rhythm amplitude and
robustness, and delayed rhythms
have increased odds of
developing dementia and MCI

Actigraphy

Battery of Neuropsychological
Tests

Sleep fragmentation in older
adults is associated with incident
AD and the rate of cognitive
decline.

APOE status is associated with
the progression of sleep/wake
disturbances in AD

Authors propose that chronic
circadian disruption may play a
role in the development of agerelated cognitive deficits and
dementia in the elderly

N=737

Rush Memory and Aging Project
(MAP)which is an ongoing communitybased cohort study of aging which began
in 1997. Follow-up period was up to 6
years (mean 3.3 years).

N=44

To be included in the current analysis, the
patient must have been assessed during at
least 2 stages of cognitive impairment,
defined as a decline from one stage of AD
to another.

Actigraphy

APOE genotypes were then
determined. Diagnosis of
probable AD by NINCDSADRDA criteria and a score of
15 or higher at entry on the
Mini-Mental State Exam
(MMSE). .

Not
Applicable

Twenty-four male Long Evans hooded
rats (300–400 g) obtained from Charles
River (Saint-Constant, PQ) were used for
all studies. They were divided into three
groups: acutely phase shifted rats (acute; n
= 8), chronically phase shifted rats
(chronic; n = 8), control rats for water
maze testing (control; n=7) and control
rats for fear conditioning (control; n = 14).

In order to create a state
of circadian disruption a
two-stage phase shifting
session which lasted 16
days was used.

Rats underwent Behavioral
Testing on a 6 day version of
the water maze task, followed
by 3 days of testing on a fear
conditioning task. They then
underwent a Rapid Acquisition
Task training in three stages.
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Jyoti, Scotland,
UK, 2010 ()

Quinn, United
States, 2005 ()

DENG. China,
2005 ()

Experimental

Experimental

Experimental

Not
Applicable

APP/PSEN1 and PSEN1 Transgenic
mice. Transgenic mice were singly housed
and assigned to the following groups,
depending upon age (5 or 20 months) and
genotype: 1) APP/PSEN1 [5 months: n =
8; 20 months: n = 6]; 2) PSEN1 [5
months: n = 8; 20 months: n = 11]; 3) WT
[5 months: n = 9; 20 months: n = 8].

Not
Applicable

Transgenic mice that were bred from a
breeding pair of Tg2576 mice

Not
Applicable

N2a cells were grown and differentiated in
96-well culture plates at density of
1.5×105 cells in 100 μL. Cells were
exposed to various concentrations of
wortmannin for 2 h at 37 ºC in the
presence or absence of a 12-hpreincubation with melatonin 25, 50, and
100 μmol/L or Vitamin E (VE).
Dimethylsulfoxide (Me2SO, 0.01%), in
which wortmannin, melatonin and VE
were dissolved, served as a vehicle
control.
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Circadian activity was
recorded in PhenoTyper
home cages (Noldus, The
Netherlands) through
video observation
techniques and XY
coordinates recorded over
7 consecutive days.

Authors characterized sleep,
electroencephalogram (EEG)
disturbances i.e.,
endophenotypes of Alzheimer’s
disease (AD) patients alongside
cognitive dysfunction in
transgenic mice carrying
transgenes for amyloid-protein
precursor (APPswe) and
presenilin 1 (PSEN1A246E) at
5 (pre-plaque) and 20 months,
relative to PSEN1 and wildtype (WT) mice, using a novel
wireless microchip device.

APP/PSEN1 mice exhibit
abnormalities in activity and
sleep architecture preceding
amyloid plaque deposition as
well as age-related changes in
cortical EEG power.

Plasma melatonin

Soluble and formic acid
extractable beta amyloid
determination was done and Aβ
burden in hippocampus and
cerebral cortex was quantified
with NIH image.

Melatonin failed to produce antiamyloid or antioxidant effects
when initiated after the age of
amyloid plaque deposition. These
findings diminish the possibility
that melatonin will be useful for
the treatment of established
Alzheimer’s disease.

Western blot, P-labeling
and the detection of
malondialdehyde level
and superoxide dismutase
activity

MTT (3-[4,5-dimethylthiazol2-yl]-2,5-diphenyl-tetrazolium
bromide), crystal violet assay,
phase-contrast, dead end
colorimetric apoptosis
detection system (TUNEL) and
electron microscopy were used
to detect cell viability,
morphology and apoptosis

Wortmannin is an effective tool
for reproducing Alzheimer-like
tau hyperphosphorylation cell
model and melatonin/vitamin E
can effectively protect the cells
from wortmannin-induced
impairments

Papolla, United
States, 1998 ()

Olcese, United
States, 2009 ()

Lahiri, United
States, 2004 ()

Asayama, Japan,
2003 ()

Experimental

Experimental

Experimental

Randomized
Controlled Trial

Aliquots of Aβ1–40 and Aβ1–42 at a
concentration of 250 μm in 5 mm TrisHC1, pH 7.4, were incubated at room
temperature

Melatonin or the
melatonin analog 5hydroxy-N-acetyltryptamine (NAT)
(Sigma) orN-t-butyl-αphenylnitrone (PBN)
(Sigma),

Peptides Aβ1–40 and Aβ1–42
were synthesized in the W. M.
Keck Foundation (Yale
University, CT), and their
purity was evaluated by amino
acid sequence and laser
desorption mass spectrometry.

Melatonin can provide a
combination of antioxidant and
anti-amyloidogenic features that
can be explored either as a
preventive or therapeutic
treatment for AD or as a model
for development of antiamyloidogenic indole analogs.

Not
Applicable

APP + PS1 double transgenic (Tg) mice

Authors administered
melatonin (100 mg/L
drinking water) to
APP + PS1 double
transgenic (Tg) mice
from 2–2.5 months of age
to their killing at age
7.5 months.

Mice were initially genotyped
at the time of weaning and then
had confirmatory genotyping
within several months
thereafter, with further
confirmation via plasma Ab40
expression.

Results are consistent with a
melatonin-facilitated removal of
Aβ from the brain. Inflammatory
cytokines such as tumor necrosis
factor (TNF)-α were decreased in
hippocampus (but not plasma) of
Tg+ melatonin mice.

Not
Applicable

Male B6C3F1 mice, a hybrid between
C57BL/6 and C3H from Harlan Labs
(Indianapolis, IN, USA), aged 6 months
(young group), 12 months (middle-aged
group) and 27 months (old group), were
housed two or three per cage and were
maintained on a 12 hr light/dark cycle in a
temperature controlled (22 ± 1°C) room.

An ELISA procedure was
used for the quantitative
measurement of
melatonin in serum

A sensitive enzyme-linked
immunosorbent assay (ELISA)
test for measuring levels of Aβ40 was performed in the
murine brain homogenates.
ELISA test was also performed
using the IBL assay reagents
for the quantitative
determination of Aβ-42 in the
murine brain homogenates.

Melatonin supplementation may
retard neurodegenerative changes
associated with brain aging.
Depletion of melatonin in the
brain of aging mice may in part
account for this adverse change.

Actigraph data from 18
patients (PLA8, MLT10)

Diagnosis of AD via CT or
MRI and a clinical diagnosis
based on DSM IV criteria and
the NINCDS-ADRDA criteria,
Dementia severity was assessed
by the Clinical Dementia
Rating Scale (CDR), Cognitive
funcion was assessed by the
Alzheimer's Disease
Assessment Scale (ADAS) the
MMSE

Melatonin administration
improved sleep time and night
activity significantly, but no
significant effect with regard to
improving daytime naps and
activity. Melatonin
administration improved
cognitive and non-cognitive
functions significantly.

Not
Applicable

N=20

The subjects were 9 persons given a
placebo (PLA), and 11 given melatonin (3
mg)(MLT). The drugs were given at 20:
30 each day for 4 weeks.
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Table 1.9. Sleep Disordered Breathing/Sleep Apnea and Cognitive/Alzheimer's Disease Measures: Descriptive Study
Characteristics, Statistical Methods and Main Findings
First Author, Country, Year
Published (Reference)

Gottlieb, United States, 2004
()

Kadotani, United States, 2001
()

Osorio, United States, 2014 ()

Djonlagic, United States,
2014 ()

Study Design

Cross sectional

Cross-sectional

Cross-sectional

Cross-sectional

Sample
size N

Study Population

Hypoxia Assessment

Cognitive/AD Measures
Assessment

Conclusion

N=1,775 .

Participants were aged 40 to
100 years from the Sleep
Heart Health Study (SHHS)
a longitudinal cohort study of
the relation of sleepdisordered breathing to CVD.

Obstructive Sleep
Apnea/Hypopnea (OSAH)
was defined as an Apnea
Hypopnea Index (AHI) ≥
15.

APOE was genotyped

The APOE £4 allele is
associated with increased
risk of OSAH,
particularly in individuals
under age 65.

N=791

Probability based sampling of
791 middle-aged adults, mean
age of 49 and age range 32-68

Nocturnal Polysomnography
with Sleep Disordered
Breathing defined as AHI ≥
15

APOE was genotyped

A significant proportion
of Sleep Disordered
Breathing is associated
with APOE £4 allele in
the general population

N=95

Ninety-ﬁve cognitively normal
elderly participants were
recruited at NYU Center for
Brain Health ongoing
between 2009 and 2013.

Among the 95 participants,
25 were considered free of
SDB (AHI4% < 5) and were
included as normal controls,
51 had mild SDB (AHI4%
5-14.99), and 19 had
moderate to severe SDB
(AHI4% > 15).

CSF measures of
phosphorylated-tau (ptau), total-tau (t-tau), and
amyloid beta 42 (Ab-42),
as well as ApoE allele
status

There is an association
between SDB and CSF
Alzheimer’s diseasebiomarkers in cognitively
normal elderly
individuals..

N=44

Participants (19–68 years)
who had been referred by a
physician for a baseline
polysomnography (PSG)
evaluation.

Based on their PSG, patients
were assigned either to the
OSA group (AHI>5/h), or
control (Non-OSA) group
(AHI<5/h).

Psychomotor Vigilance
Task (PVT) and the Motor
Sequence Learning Task
(MST)

The presence of untreated
obstructive sleep apnea is
associated with an agingrelated cognitive deficit,
otherwise not present in
individuals without OSA.
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O’Hara, United States, 2005
()

Cohen-Zion, United States,
2001 ()

Tworoger, United States,
2006 ()

Case-control

Prospective
cohort

Prospective
cohort

N=36

Twelve men and 24 women
participated. All were over age
60, with a mean age of 70.6
(SD = 8.1), a mean of 16.1
(SD = 2.4) years of education,
and a mean Mini-Mental State
Examination (MMSE) of 28.7
(SD = 1.2; range 27 to 30).
Eighteen had an APOE €4
allele, and 18 were noncarriers

The apnea-hypopnea index
(AHI), i.e., the average
number of apneas or
hypopneas per hour of
estimated sleep measured
OSAH severity in each
subject.

N=46

Community-dwelling people
age 65 and older with high risk
for SDB were originally
studied from 1981 through
1985 and then followed every
2 years. Follow-up period:
2years

Subjects’ sleep was recorded
using the Modified
Respitrace/Medilog system,
which measured thoracic
and abdominal respiration,
tibialis electromyogram
(EMG), and wrist activity
(to discriminate sleep/wake
states).

N = 1844

Participants were women
aged 70 to 81 years at initial
cognitive interview in 2000
and members of the Nurses’
Health Study cohort. Followup period: 2years
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Authors collected
information about average
sleep duration and snoring
frequency on questionnaires
in 1986 and 2000;

APOE genotyping.
MMSE; the Rey Auditory
Verbal Learning Test of
immediate verbal recall
(RAVLT1); short-term
free recall (RAVLT6) and
30-minute delayed freerecall (RAVLT Delayed);
the Stroop Color and
Word (SCW) measure of
attention and cognitive
flexibility; and the
Symbol-Digit Modalities
Test (SDMT) of
information processing
speed.

Nocturnal sleep
apnea/hypopnea is
associated with lower
memory performance in
APOE €4 carriers

MMSE

The results of this study
could theoretically
suggest that any
relationship between
SDB and cognitive
function may be mediated
by the effect of SDB on
daytime sleepiness.

Women completed six
tests of cognitive function
encompassing general
cognition, verbal memory,
category fluency, and
attention. Tests were
repeated 2 years later.

Associations between
sleep patterns and initial
cognitive function may be
clinically relevant given
that diminished cognition
is a risk factor for
dementia. However, the
lack of an association
with prospective
cognitive decline was
seen

Chang, Taiwan, 2013 ()

Yaffe, United States, 2011 ()

Shiota, Japan, 2013 ()

Kaushal, United States, 2012
()

Retrospective
cohort

Prospective
cohort

Experimental

Experimental

Diagnoses of SA [ICD-9Codes 327.23, 780.51,
780.53, 780.57] between
January 2003 and December
2005. Clinically assessed
including only cases in
which patients obtained ≥2
SA diagnoses in outpatient
visits or ≥1 inpatient service.

ICD-9 code

SA may be a genderdependent, agedependent, and timedependent risk factor for
dementia

N=298

Study of Osteoporotic
Fractures. Follow-up
period: 2.3 years

Sleep disordered breathing
was defined as an apneahypopnea index of 15 or
more events per hour of
sleep.

Diagnostic and Statistical
Manual of Mental
Disorders (Fourth Edition)
criteria. MCI was
diagnosed using the
modified criteria by
Peterson et al

Among older women,
those with sleep
disordered breathing,
compared with those
without SDB, were
associated with an
increased risk of
developing cognitive
impairment

Not
Applicable

In vivo, 15 male triple
transgenic AD mice were
exposed to either Chronic
Intermittent Hypoxia (CIH) or
normoxia (5% O2 and 21%
O2 every 10 min, 8 h/day for 4
weeks). In vitro, human
neuroblastoma SH-SY5Y cells
stably expressing wild-type
amyloid-β protein precursor
were exposed to either IH (8
cycles of 1% O2 for 10 min
followed by 21% O2 for 20
min) or normoxia

CIH was applied (n = 9) by
exposing to alternating 5%
O2 and 21% O2 every 10
min for 8 h per day during
daytime for 8 weeks in a
chamber (370×260×250
mm, 26 L, Sibata Scientific
Technology Ltd, Tokyo,
Japan). Control mice (n = 6)
were kept under normoxia
and touched by human
hands once a day to balance
out their stress through
direct human contact.

Amyloid-β (Aβ) profile,
cognitive brain function,
and brain pathology were
evaluated.

Results suggest that
Obstructive Sleep Apnea
(OSA) would aggravate
AD. Early detection and
intervention of OSA in
AD may help to alleviate
the progression of the
disease.

SLEEP INTEGRITY
MEASURE
Polysomnography

The increased
susceptibility and limited
recovery ability of
hApoE4 mice to sleep
apnea suggests that early
recognition and treatment
of the latter in AD
patients may restrict the
progression and clinical
manifestations of this
frequent
neurodegenerative
disorder

N=8484

Not
Applicable

Longitudinal Health
Insurance Database 2005
(LHID2005) in Taiwan, 1414
patients with Sleep Apnea
(SA) aged 40 years Followup period: 5years

Adult male human ApoE4targeted replacement mice
[B6.129P2Apoetm3(APOE*4)MaeN8]
(hApoE4) and C57BL/6NTac
(wild-type, WT) mice,
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HYPOXIA MEASURE
O2 concentration was
continuously measured by
an O2 analyzer and was
changed from 1:00 PM until
7:00 PM by a computerized
system controlling the gas
valve outlets.

Sun, Canada, China, United
States, 2006 ()

Li, China, 2009 ()

Zhang, China, 2007 ()

Kushida, United States, 2012
()

Experimental

Experimental

Experimental

Randomized
Controlled Trial

Not
Applicable

Not
Applicable

Not
Applicable

N=1,098

APP23 Transgenic mice

APP23 mice (8 months of
age, n = 20, 50% female)
were assigned randomly to
hypoxia and control groups.
The hypoxia group was
treated in a hypoxia
chamber at 8% O2 for 16
h/day for 1 month.

Transgenic mice (The Jackson
Lab, No. 003378, APPSwe +
PS1A246E)

Mouse neuroblastoma N2a
cells stably expressing human
APP695 (N2a-APP) were
maintained in cell culture
medium containing 50% DME
high glucose medium

The Apnea Positive Pressure
Long-term Efficacy Study
(APPLES) was a 6-month,
randomized, double-blind, 2arm, sham-controlled,
multicenter trial conducted at
5 U.S. University, hospital, or
private practices.
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The water maze test.
Neuritic Plaque Staining
was done.

The results demonstrate
that hypoxia can facilitate
AD pathogenesis, and
they provide a molecular
mechanism to link
vascular factors to AD

The mice were treated with
hypoxia once a day and
repeated for 60 days. Mice
were assigned randomly to
hypoxia and control groups
(9 months old female, 10
mice in each group).

Neuritic plaques staining
was performed.

Taken together, the
results suggest an
important role of hypoxia
in modulating the APP
processing by facilitating
both β- and ɣ-cleavage
which may result in a
significant increase of Aβ
generation.

Cell culture, Transfection
and Hypoxic treatment was
done.

Immunoblotting and
Antibodies, Aβ ELISA
Assay, In Vitro βSecretase Activity Assay,
Pulse-chase experiments,
Quantitative Real-time
Polymerase Chain
Reaction (RT-PCR), HIF1α RNA Interference,
Tissue Isolation from HIF1α Conditional Knock-out
Mice were also carried out
on the mice models

The results demonstrate
an important role for
hypoxia/HIF-1α in
modulating the
amyloidogenic processing
of APP and provide a
molecular mechanism for
increased incidence of
AD following cerebral
ischemic and stroke
injuries

Diagnosis of Obstructive
Sleep Apnea (OSA) with an
apnea-hypopnea index
(AHI) ≥ 10 and age ≥ 18
years

Three neurocognitive
variables, each
representing a
neurocognitive domain:
Pathfinder Number TestTotal Time (attention and
psychomotor function
[A/P]), Buschke Selective
Reminding Test-Sum
Recall (learning and
memory [L/M]), and
Sustained Working
Memory Test-Overall
Mid-Day Score (executive
and frontal-lobe function
[E/F])

CPAP treatment
improved both
subjectively and
objectively measured
sleepiness, especially in
individuals with severe
OSA (AHI >30).

Ancoli-Israel, United States,
2008 ()

Randomized
Controlled Trial

N=52

Participants were men and
women with mild-moderate
AD and OSA recruited from
the University of California
San Diego (UCSD)
Alzheimer's Disease Research
Center.

Diagnosis of Obstructive
Sleep Apnea (OSA) with an
apnea-hypopnea index
(AHI) ≥ 10.CPAP unit
pressure was set at 8 cm
H2O pressure while the
system mask's pressure
varied from 0.5 cm H2O at
end-expiration to 0.0 cm
H2O during inspiration

NINCS-ARDRA and a CT
or MRI of the brain
consistent with AD done
within 24 months Mini
Mental Status
Examination (MMSE)
score greater than 17.

OSA may aggravate
cognitive dysfunction in
dementia and thus may be
a reversible cause of
cognitive loss in AD
patients.

Table 1.10. Insomnia and Cognitive/Alzheimer's Disease Measures: Descriptive Study Characteristics, and Main Findings
First Author,
Country, Year
Published
(Reference)

Merlino, Italy, 2010
()

Cricco, Iceland, 2001
()

Jelicic, The
Netherlands, 2002 ()

Study Design

Cross-sectional

Prospective cohort

Prospective
Cohort

Sample size
N

Study Population

N=750

Subjects aged 65 years or
older, living independently
or in an institution, who
resided in the seventh
district of Udine, Italy were
recruited.

Insomnia and other sleep
abnormalities were
investigated with a battery
of standardized questions
and questionnaires

DSM-IV-TR criteria . AD and VaD were
diagnosed respectively according to
NINCS-ARDRA and NINDS-AIREN
criteria . LBD and PDD, frontotemporal
dementia (FTD) and MCI were diagnosed
according to specific consensus guidelines
.

Insomnia was not associated
with the presence of cognitive
decline. As opposed to
insomnia, excessive daytime
sleepiness was significantly
related to dementia.

N=6444

The four sites of the
Established Populations
for Epidemiologic Studies
of the Elderly (EPESE).
Follow-up period: 3 years

Insomnia was defined as
self-report of trouble falling
asleep or waking up too
early most of the time.

Cognitive decline was defined as two or
more errors on the Short Portable Mental
Status Questionnaire (SPMSQ) at FU3.

Chronic insomnia
independently predicts incident
cognitive decline in older men.

N=838

Maastricht Ageing Study
(MAAS), a prospective
cohort study of cognitive
ageing based in the
Netherlands. Follow-up
period: 3 years

Self-reported sleep
measures

Cognitive performance at follow-up,
measured with the Mini Mental Status
Examination (MMSE)

Subjective sleep complaints
predict cognitive decline in
middle aged and older adults

Insomnia Assessment
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Cognitive/AD Measures Assessment

Conclusion

Foley, United States,
2001 ()

Osorio, United
States, 2011 ()

Prospective
Cohort

Prospective
Cohort

N=2346

N=346

Japanese-American men
age 71 to 93 of The
Honolulu-Asia Aging
Study (HAAS)

Sleep disturbances were
assessed by questionnaire.

Brain aging studies at
New York University’s
Alzheimer’s Disease
Research Center. Followup period: over 7.7 years.

Insomnia was collected only
during the normal cognition
stage and screened using
items 4, 5, and 6 from the
Hamilton Depression Rating
Scale (HAM-D)

Dementia was diagnosed according to
less-restrictive diagnostic criteria
developed by Cummings et al. for very
mild dementia and more-restrictive
diagnostic criteria for mild or more severe
dementia from the Diagnostic and
Statistical Manual of Mental Disorders,
Third Edition, Re-vised (DSM-IIIR).

Mini-Mental State examination

Daytime sleepiness in older
adults may be an early indicator
of decline in cognitive
functioning and onset of
dementia.

There is a greater risk of
Alzheimer's disease in adults
with Insomnia

Table 1.11 Restless Less Syndrome (RLS) and Cognitive/Alzheimer's Disease Measures: Descriptive Study Characteristics, and Main
Findings
First Author,
Country, Year
Published
(Reference)

Pearson, United
States, 2006 ()

Study Design

Case-control

Sample size
N

N=31

Study Population

Sixteen patients off RLS
treatment for at least 2
weeks and 15 age- and
gender-matched control
subjects

RLS Assessment

Cognitive/AD Measures Assessment

RLS patients were required
to have daily symptoms and
to have periodic leg
movements in sleep (PLMS)
of greater than 20/h on a
screening nocturnal
Polysomnogram (PSG).

Cognitive Tests consisted of the
following: the Stroop color-word test,
Trail Making Test (A and B), the Porteus
Maze Test (Vineland Revision), the
Colored Progressive Matrices Test, and
two verbal fluency tests (words beginning
with a fixed first letter and words in
categories).
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Conclusion

RLS patients have statistically
significant specific cognitive
deficits and show cognitive
deficits similar to those seen
with 36 h total sleep
deprivation.

Figure 1.1 Flow Diagram of Systematic Review of Sleep and Alzheimer’s disease

Studies identified through database searching (n = 2341)
(PubMed=904, Embase=1026, Web of Science=305, Cochrane library=106)

Duplicates removed
(n = 1120)
Studies after duplicates removed
(n = 1221)

Studies screened for titles
(n = 1221)

Studies excluded
(n = 180)

Studies screened for abstracts

Studies excluded
(n = 840)

(n = 1041)

Full-text articles assessed
for eligibility
(n = 201)
Article identified from
reference search
(n = 1)

Full-text articles excluded,
with reasons (n = 130)
-

Studies included in
systematic review
(n = 72)
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-

Review article (n = 7)
No risk estimate (n =
17)
Sleep not assessed (n =
18)
Relationship not
studied (n = 53)
Not peer reviewed (n =
10)
Alzheimer not
examined (n = 25)
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ABSTRACT
Study Objectives: Mounting evidence implicates disturbed sleep or lack of sleep as one of the risk
factors for Alzheimer’s disease (AD) but the extent of the risk is uncertain. We conducted a broad
systematic review and meta-analysis to quantify the effect of sleep problems/disorders on cognitive
impairment and AD.
Methods: Original published literature assessing any association of sleep problems or disorders with
cognitive impairment or AD was identified by searching PubMed, Embase, Web of Science, and the
Cochrane library. Effect estimates of individual studies were pooled and relative risks (RR) and 95%
confidence intervals (CI) were calculated using random effects models. We also estimated the population
attributable risk (PAR).
Results: Twenty-seven observational studies (n = 69,216 participants) that provided 52 RR estimates
were included in the meta-analysis. Individuals with sleep problems had a 1.55 (95% CI: 1.25-1.93), 1.65
(95% CI: 1.45-1.86) and 3.78 (95% CI: 2.27-6.30) times higher risk for AD, cognitive impairment and
preclinical AD than individuals without sleep problems respectively. The overall meta-analysis revealed
that individuals with sleep problems had a 1.68 (95% CI: 1.51-1.87) times higher risk for the combined
outcome of cognitive impairment and/or AD. Approximately 15% of AD in the population may be
attributed to sleep problems.
Conclusion: This meta-analysis confirmed the association between sleep and cognitive impairment or
AD and, for the first time, consolidated the evidence to provide an “average” magnitude of effect. As
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sleep problems are of a growing concern in the population, these findings are of interest for potential
prevention of AD.
Statement of Significance: This study systematically and efficiently integrated existing information from
various studies, and for the first time, consolidated the evidence of the association between sleep and
Alzheimer’s disease (AD) and/or cognitive impairment by providing an “average” magnitude of the
effect. Subgroup meta-analysis of various aspects of sleep problems examined in this analysis each
significantly increased the risk for AD. The public health relevance of these findings is buttressed by the
population attributable risk percent, suggesting that approximately 15% of AD may be prevented should
interventions be implemented to reduce sleep problems and disorders. These novel findings are of
pertinent interest to further understand the etiology of AD and are likely to be of interest to researchers,
clinicians’ and public health policy makers.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder afflicting approximately five million
older Americans, with a projected annual incidence of one million cases in the United States by 2050.1, 2
AD and other dementias are associated with significant morbidity and mortality, with worldwide costs
estimated at US$604 billion in 2010.3 Preventive and/or therapeutic measures targeted at delaying or
curing AD are therefore imperative to mitigate this societal burden.
Mounting evidence implicates disturbed sleep or lack of sleep as a risk factor for AD. Demented
older adults exhibit significant sleep disturbance and unhealthy sleep patterns, including shorter sleep
duration and fragmented sleep,4-7 altered circadian rest/activity patterns,5 and elevated rates of sleep
disordered breathing (SDB).8, 9 It is estimated that about 45% of AD patients have sleep disturbances.10, 11
However, the ultimate etiologic role of sleep in AD pathogenesis remains unknown. Sources of sleep
disturbances in AD are thought to include degeneration of neural pathways that regulate sleep-wake
patterns and sleep architecture.10, 12 Sleep disorders also may exacerbate cognitive symptoms through
impairment of sleep-dependent memory consolidation processes.13, 14 It is possible that circadian rhythms
and sleep disorders have a causal role in the pathophysiology of AD. If this is true, they could be critical
to the goal of preventing this disease, because effective interventions exist to improve sleep.15 Narrative
review articles examining this association16-19 reflect the opinion and consensus among specialists that
there is growing experimental and epidemiologic evidence for a close reciprocal association of cognitive
impairment and AD with sleep problems and disorders. However, to date, no review has quantified the
effect of having sleep problems and disorders on cognitive impairment and AD. In this context, we
conducted a broad systematic review and meta-analysis to quantify the effect between sleep problems and
disorders on cognitive impairment and AD.
METHODS
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We conducted this review in accordance with the step-by-step guide for systematic reviews and
meta-analysis by Pai et al.,20 and adhered to the preferred reporting items for systematic reviews and
meta-analyses (PRISMA) statement by Moher et al.,21 and the Cochrane handbook.22
Identification of eligible studies
Electronic search
A broad search strategy was employed to identify all eligible published articles in scientific
(medical, psychological and epidemiological) journals up to November 2014. This strategy combined
terms characterizing clinical AD or AD pathology as the outcome variable, sleep, as the exposure
variable, and a third set of terms specifying specific study types including cross-sectional, case control,
cohort (retrospective and prospective), Randomized Clinical Trials (RCTs), literature reviews, systematic
reviews, and ecological studies. All terms within each set were combined with the Boolean operator OR,
and the three sets were combined using AND. Articles were identified by searching four bibliographic
databases on November 21, 2014:
•

Medline (through PubMed; all years 1946 - present)

•

Embase (through www.embase.com by Elsevier B.V. 2011; all years from 1947 - present)

•

Web of ScienceTM (Thomson Reuters 2014; all years from 1900 – present)

•

Cochrane library (i.e., the Cochrane Central Register of Controlled Trials; all years from 1900 present).

Articles written in other languages other than English were also considered and screened with the help of
Google translator. The PubMed search (see supplemental Table 2A in appendix) was adapted to
searching the other databases.
Searching other sources
To locate additional relevant studies, the reference lists of articles identified through database
searches and the bibliographies of narrative review articles were examined. We also hand-searched the
previous year’s issues (November 2013 to November 2014) of high ranking journals that published more
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than one relevant identified article during the initial search, for example Sleep Medicine Reviews,
Neurology, JAMA (journal of American medical association), Sleep Medicine, Sleep, Journal of Sleep
Research and Journal of Clinical Sleep Medicine.
Selection criteria
Type of studies
Original articles from observational studies (cross-sectional, case-control and
retrospective/prospective cohort) and randomized controlled trials (RCT) were included in this review.
Eligible studies for the meta-analysis were required to: i) have reported a primary or secondary data
analysis using any of the above mentioned study design of any association of sleep problems or disorders
with cognitive impairment or AD; ii) have an explicit measure of cognitive impairment or AD (e.g.
performance on individual cognitive tests, international classification of disease-9 (ICD -9), diagnostic
statistical manual-IV text revision (DSM-IV TR)) or objective measures of Alzheimer pathology (e.g.,
positron emission tomography (PET) scan); iii) have an explicit or obvious measure of sleep problems or
disorders (e.g., Pittsburgh sleep quality index (PQSI)), Epworth sleepiness scale (ESS)) or objective
measures (e.g., wrist actigraphy or polysomnography (PSG)); iv) study a comparison group without sleep
problems or disorders in cohort studies; and v) provide sufficient data to quantify the measure of
association of sleep problems or disorders with cognitive impairment or AD. The following studies were
excluded: i) case series, case reports, narrative reviews, abstracts or editorials, and ii) any RCT that did
not examine the cognitive effects of treating sleep and its related problems or disorders in AD.
Sleep problems and/or disorders
Sleep problems and/or disorders were considered as the risk factor of interest in this systematic
review. All sleep disorders described in the international classification of sleep disorders (ICSD-2)23 were
considered. Previous studies24, 25 employed various concepts to define sleep problems in order to fit their
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study design. Accordingly, for sub-group analysis, we grouped eligible studies in this review measuring
sleep using parameters such as quality, efficiency and/or disturbance as sleep quality.
Alzheimer’s disease/cognitive impairment
The outcomes of interest in this review were cognitive impairment or AD. AD is the most
common form of dementia accounting for up to 50-80% of dementia cases.2 Studies that solely looked at
specific forms of dementia other than AD, e.g., vascular, Lewy body, or frontotemporal dementia, were
excluded.
Participants and setting
Participants of the included studies were middle aged and elderly adults of both sexes with age
ranging from 40 – 91 years. Studies were considered from multiple continents and no geographic
restrictions were imposed.
Data Extraction
An independent assessment of all titles and abstracts of eligible studies identified by the search
strategy was performed by two authors (OB, OU) using EndNote X6. Potential articles for the study were
retrieved and examined for possible inclusion by the same two authors. Discordant decisions regarding
inclusion were resolved by two other authors (YS and YW). Data extraction was performed by two
authors (OB, OU). Extracted fields included study design, study population, exposure and outcome
assessment, statistical methods and tests used, covariates, and the main results of the study. Differences in
the information extracted were resolved by two other authors (YS and YW). Reviewers were not blinded
to the funding, authors, or institutions.
Assessment of study quality
Study quality was assessed using an adaptation from previous systematic reviews26, 27 and the
modified version of the Newcastle-Ottawa scale (NOS) for quality assessment of the observational
studies,28, 29 with addition of new items relevant to this review. Parameters used for the quality assessment
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included well-specified hypothesis, study design type, appropriately described sample, sample size,
definition of sleep and its related abnormalities, definition of cognitive impairment or AD, statistical
analytic methods, and inclusion of or approach used to adjust for potential confounders. For each
assessment category, a star rating system was used with specific maximum number of stars awarded (see
supplemental table 2). Studies were divided into three categories: low quality (< 50% of the maximum
number of stars), medium quality (≈ 55-70% of the maximum number of stars), and high quality (70% or
more of the maximum number of stars).
Statistical analysis
This systematic review consisted of both binary and continuous outcomes. Effect sizes from the
reviewed studies included odds ratios (OR), hazard ratios (HR), Pearson’s correlation coefficient (r), beta
estimates (β) and standardized mean differences (d). To proceed with the meta-analysis, we converted the
different indices to a common index: odds ratios (meta-analyses were computed using log (OR) but were
converted back to odds for presentation) (see Table 2B in supplemental material). Conversions
included converting from d to the log(OR) (Log(OR) = d
(approximately 3.14159)), converting from r to d (d = d

π

√

√

, where π is the mathematical constant
), and converting from β to OR (exp(β) (see

Table 2C in supplemental material).30 The question of whether or not it is appropriate to combine effect
sizes from studies using varying metrics is under debate. We considered the fact that studies included in
the review and subsequent analyses had to meet certain inclusion and exclusion criteria and were judged
to be comparable in relevant ways. Since our aim was to compute a summary effect size of the impact of
sleep problems on AD, we accounted for multiple outcome measures on the same subjects by computing
the mean of the effect sizes for each study and used the average effect size as the unit of analysis (see
Table 2D in supplemental material). For example, we pooled the effect estimates in a single study that
had separate outcome measures using the mini mental state examination (MMSE) and the trail making B
test (Trails B) on the same subjects.31 This influenced the calculation of the variance of the sum and mean
effects of the correlated variables (see Table 2D in supplemental material). For our analysis, we worked
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with a plausible range of correlations ranging from 0.5-1.0 and performed sensitivity analyses to find the
most appropriate standard error range. Our method could only have overestimated the variance and
underestimated the precision of our summary effect. Individual studies that examined the effect of sleep
on AD on different populations were treated as independent.32-38 Re-analyses of reported effect estimates
was conducted where appropriate in order to maintain consistency of definitions. For example, effect
estimates for sleep duration of ≤ 5 h, 6 h, and for <= 6.5 h were pooled to a single estimate for sleep
duration of <= 6.5 h.32, 38, 39 Furthermore, we converted the risk estimate for better sleep consolidation to a
risk estimate for poor sleep consolidation.40 Participants in the reviewed studies were between the ages of
40 -91. Because the prevalence of AD in this population and in the general population is just under 5%,2
no relevant artificial bias was introduced by pooling effects from cohort studies with effects from casecontrol and cross-sectional studies. Therefore, we will refer to the pooled effect estimates as relative
risks, understanding that these are estimated in some studies. Effect estimates of all individual studies
were pooled and relative risks (RR) and 95% confidence intervals (CI) were calculated using random
effects models. Heterogeneity of results across studies was assessed using chi-square test and quantified
using I-square statistics.41 Subgroup analyses were conducted to explore potential causes of heterogeneity.
We anticipated heterogeneity and as such restricted subgroup analyses to situations where four or more
studies were available per subgroup, because heterogeneity is better assessed with multiple studies.41
Multivariate meta-regression analysis was also performed to examine the effect of possible influential
factors (i.e., sex, mean age, sample size and study quality). We assessed for publication bias using a
funnel plot asymmetry test and trim-and-fill. Additionally, the population attributable risk percent (PAR
%), which estimates the percentage of the outcome (AD) that would be prevented in the population if the
exposure (sleep problems or disorders) was eliminated, was calculated. All statistical analysis were
conducted using metaphor in R42 and SAS® 9.4.43
RESULTS
Study Selection
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Figure 1 shows the study retrieval and selection process for the effects of sleep on cognitive
impairment and/or AD. Of the 2,341 publications identified initially from the literature search, 27 studies
were included in the meta-analysis (Figure 1). A total of 1,120 duplicates were removed. The remaining
1,221 publications were screened for titles resulting in the exclusion of 180 publications. After this
exclusion, 1,041 publications were screened using published abstracts, resulting in the exclusion of 840
publications that were either case series/reports, literature reviews, abstracts or editorials. Two hundred
and one full text articles were assessed for eligibility and 130 publications (105 observational studies and
25 RCTs) were further excluded because they were either review articles, did not provide any measure of
association, were not peer reviewed or because sleep and AD were not assessed. One study was included
from a search of the reference lists of articles identified through database searches. The remaining 72
studies were selected for the systematic review. For the meta-analysis, 45 publications were further
excluded because they lacked sufficient information needed for a meta-analysis, were duplicate studies
presenting similar or exact information from same study population or had an experimental study design,
leaving 27 studies with 52 effect estimates.
Study characteristics
Design and Quality
Among the 27 studies identified for the meta-analysis, there were eight cross-sectional31, 37, 44-49
one case-control.50 two retrospective cohort33, 51 and sixteen prospective cohort,32, 34, 36, 38-40, 52-61 (Table 1).
Of these, 15 were considered to be of high quality, ten were of medium quality and two were of low
quality. Selection bias related to sampling, measurements of sleep and/or AD solely based on self-report,
and insufficient adjustment for core confounders were the main limitations. All of the included articles in
the meta-analysis were written in English and published in peer-reviewed journals.
Participants and setting
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The 27 studies included in the meta-analysis were published between 2001 and 2014 and included
a total of 69,216 participants from four continents (Table 1). Pooled relative risks included 25 estimates
from studies conducted in North America, 14 estimates from Europe, one from Australia, and four from
Asia (Table 2). Twenty-one studies included both sexes, of which three had separate analysis for men and
women, five were limited to women, and one was limited to men (Table 1).
Sleep problems/disorders
Sleep problems were based on a physician diagnosis (e.g. ICD-9 codes and apnea hypopnea index
(AHI) scores for sleep apnea), or were assessed using self-reported questionnaires or interviews (Table
1). There was considerable variability in the methods used to define and validate sleep problems. Nine
studies utilized objective measures (e.g., wrist actigraphy or PSG), while seven studies utilized
standardized questionnaires such as the PQSI or ESS. Five studies utilized self-constructed questionnaires
and one study made use of fluorescence immune-assay (FIA) to determine melatonin/hypocretin
concentrations.50 Most studies reported risk estimates for individual symptoms. Multiple symptoms were
also assessed in some studies. Sleep parameters assessed included (but were not limited to) sleep
duration, sleep quality, daytime sleepiness, sleep latency, sleep efficiency, wake after sleep onset, sleep
fragmentation, circadian rhythm abnormalities, obstructive sleep apnea, and insomnia. The interval over
which sleep problems was assessed extended from about a week to a median of 12.5 years.32
Cognitive impairment and/or Alzheimer’s disease
There also was significant variability in the methods used to diagnose cognitive impairment or
AD. Most studies used self-reported diagnoses with information collected to determine whether they
likely met standardized criteria (e.g. (DSM-IV TR) (Table 2.1). Cognitive function was assessed by
various global cognitive function and neuropsychological tests. Individuals were regarded as cognitively
normal with Mini-Mental State Examination (MMSE) scores between 27 and 30, and a Clinical Dementia
Rating of 0. For "Mild Cognitive Impairment," MMSE scores ranged from 22-27 according to a DSM-III-
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R definition (ICD-10: 23-28). Studies utilizing objective measures of Alzheimer pathology (e.g., PET
scan for amyloid load (Aβ)) to examine associations between sleep and preclinical AD were also
considered because we intended to also describe possible potential mechanisms showing that sleep is
possibly associated with changes in AD biomarkers predictive of individuals who develop AD in
subsequent sub-group analyses..
Meta-analysis
Overall meta-analysis based on risk estimates for the effect of sleep on cognitive impairment and
Alzheimer’s disease
Sleep problems including short and long sleep duration, poor sleep quality, circadian rhythm
abnormality, insomnia and obstructive sleep apnea, were associated with a significantly increased relative
risk (RR) for the combined outcome of cognitive impairment and AD of 1.68 (95% CI: 1.51-1.87) (Fig.
2.2). The relative risks ranged from 1.0734 to 4.2549 with two low outliers; 0.56,61 and 0.76,32 and five
high outliers 5.10,50 5.13, and 5.85,59 6.08,33 and 8.17.37 Removing these 7 outliers from the analysis had
no significant effect on the pooled RR (RR: 1.62, 95% CI: 1.47-1.79). There was signiﬁcant heterogeneity
among the effect sizes (I-square 64.50%, p < 0.001). The random-effects variance component was .05
(95% CI: .023-.195). A prediction interval that considers both sampling error and random-effects
variance showed relative risk values ranging from 1.05 to 2.50. Removal of the 7 outliers reduced
heterogeneity but it remained statistically signiﬁcant (I-square 54.36%, p < 0.001), indicating that these
outliers were not the sole source of heterogeneity.
Sub-group meta-analysis based on risk estimates for the effect of sleep on cognitive impairment, Preclinical and ICD9/DSMIV Diagnoses of Alzheimer’s disease
Separate analyses of the studies in terms of the outcome measures were also conducted. Our
outcome measures included the use of cognitive tests by studies examining sleep and the risks of
cognitive impairment; the use of AD biomarkers or abnormal proteins by studies examining sleep and the
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risk of preclinical AD; and the use of ICD9/DSMIV diagnoses of AD by studies examining the risk of
sleep and symptomatic AD respectively. Sleep problems including short and long sleep duration, poor
sleep quality, circadian rhythm abnormality, insomnia and obstructive sleep apnea, were associated with
significantly increased relative risks of cognitive impairment (RR: 1.64, 95% CI: 1.45-1.87) ), preclinical
AD (RR: 3.78, 95% CI: 2.27-6.30) and ICD9/DSMIV diagnoses of AD (RR: 1.55, 95% CI: 1.25-1.93)
respectively (Fig. 2.3) These results highlight potential mechanistic relationships suggesting that sleep is
not only associated with cognitive impairment, or symptomatic AD but is also associated with changes in
AD biomarkers predictive of persons that ultimately develop AD.
Funnel Plot Asymmetry Test and Trim and Fill Analysis Assessment of Publication Bias
Regarding possible publication bias, a funnel plot asymmetry test was significant (z = 5.5109, p <
.0001),62 indicating that some form of publication bias exist. Furthermore, a trim-and-fill analysis63
(which aims both to identify and correct for funnel plot asymmetry arising from publication bias by
essentially ‘trimming’ or removing the smaller studies causing funnel plot asymmetry, and then using the
trimmed funnel plot to estimate the true ‘center’ of the funnel, while replacing the omitted studies and
their missing ‘counterparts’ around the center (filling)) imputed 17 unpublished studies and conﬁrmed
that in smaller studies, weaker effects were less often published (Fig. 2.4). The trim and fill method does
not require any assumptions regarding mechanisms leading to bias in publication, rather it provides an
estimate of the number of missing studies, and calculates an estimated effect ‘adjusted’ for the publication
bias (based on the filled studies).
Sub-group meta-analysis based on risk estimates for the effect of different sleep problems and
disorders on cognitive impairment and Alzheimer’s disease
Analyzing various sleep problems and disorders (Fig. 2.5), the highest relative risk for AD and/or
cognitive impairment was noted for obstructive sleep apnea (OSA) (RR: 2.37, 95% CI: 1.82-3.08). The
relative risk for cognitive impairment and/or AD associated with sleep quantity was 1.86 (95% CI: 1.34-
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2.57), while sleep quality was 1.62 (95% CI: 1.34-1.97). Insomnia (RR: 1.38 95% CI: 1.13-1.67) and
circadian rhythm abnormalities (RR: 1.38, 95% CI: 1.18-1.61) were associated with the lowest relative
risks. After excluding the outliers, the relative risk for cognitive impairment or AD associated with OSA,
sleep quantity and sleep quality remained statistically significant (RR: 2.30, 95% CI: 1.59-2.41; RR:
1.72, 95% CI: 1.24-2.61 and RR: 1.51, 95% CI: 1.244-1.81 respectively).
Subgroup analyses (Table 2.2) investigating various sleep parameters revealed that poor sleep
efficiency was associated with the highest risk for cognitive impairment or AD, followed by sleep latency
and wake after sleep onset (WASO). Nighttime problems were associated with the strongest measure of
effect for cognitive impairment or AD, with smaller effects seen for night- and daytime problems. When
examined separately, men and women with sleep problems including short and long sleep duration, poor
sleep quality, circadian rhythm abnormality, insomnia and obstructive sleep apnea, each had similar
relative risks. The risk for cognitive impairment or AD due to sleep duration was higher in long sleepers
(> 8 h/day) when compared to normal sleepers (7 – 8 h/day), than in short sleepers (≤ 7 h/day). Studies
with ≥ 5 years of follow-up reported higher relative risks due to sleep problems including short and long
sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia and obstructive sleep apnea,
than those with < 5 years of follow-up. Studies from North America and Europe reported similar relative
risks due to sleep problems. Prospective studies showed slightly lower relative risks than non-prospective
studies, perhaps indicating a problem with temporality. Finally, the estimated risk for cognitive
impairment or AD due to sleep problems was lower in the high-quality studies than in the low-quality
studies.
Sub-group meta-analysis based on risk estimates for the effect of self-report and actigraphic data of
poor sleep on cognitive impairment and/or Alzheimer’s disease
Furthermore, we analyzed studies that generated data on total sleep times (measured
actigraphically) and examined these effects separately in relation to cognition from more generally
defined poor sleep or self-reported sleep durations (Fig. 2.5). The relative risk for cognitive impairment
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or AD associated with self-reported poor sleep was 1.49 (95% CI: 1.26-1.76), while actigraphic report
was 1.80 (95% CI: 1.56-2.09). These findings somewhat corroborate effects of self-reported sleep
durations in relation to cognition examined in terms of actigraphic data.
Exploring Potential Causes of Heterogeneity
The overall meta-analysis included a wide array of studies including different measures with
varying neurobiological substrates (breathing control in sleep, circadian rhythmicity, sleep durations,
perceived sleep depth) as well as varying outcome measures of AD, including ICD9/DSM diagnoses,
cognitive tests and abnormal proteins; and this could possibly be a potential source of heterogeneity.
Therefore, we explored this and other potential causes for heterogeneity and conducted several subgroup
meta-analyses (Figures 2.4-2.6 and Table 2.2) (also see Figures 2A-2C in supplemental material). The
differences seen across the subgroups failed to account for significant amounts of heterogeneity except for
the varying outcome measures of AD and sample size. However, tendencies could be observed. As
sample size increased, the effect size decreased. This agreed with the funnel plot. The varying outcome
measures of AD accounted for 12.78% heterogeneity. Several of the other subgroup analyses were close
to being statistically significant; however, there were only 52 effect sizes in the analysis, so power may
have been an issue for some sub-analyses.
Sensitivity Analyses
Sensitivity analysis incorporating only studies that examined the relationship between sleep and
cognitive impairment and/or symptomatic AD for the overall meta-analysis yielded a RR of 1.62 (95%
CI: 1.45-1.80), suggesting that exclusion of studies that examined sleep associations with preclinical AD
could reduce the overall effect size, however, the change in effect size was not statistically significant.
Similarly, removing effect estimates of outliers from the analysis had no significant effect on the pooled
RR (RR: 1.62, 95% CI: 1.47-1.79). Furthermore, exclusion of studies examining sleep associations with
preclinical AD for the sub-group meta-analysis based on risk estimates for the effect of different sleep
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problems and disorders on cognitive impairment and Alzheimer’s disease produced similar relative risks
for the relationships between OSA, sleep quantity, sleep quality, insomnia and cognitive impairment
and/or AD.
Sensitivity analyses incorporating the 17 studies imputed by trim-and-fill showed an estimated
relative risk of 1.42 (95% CI: 1.28-1.58), suggesting that bias could reduce the size of the effect, but is
unlikely to explain it entirely. It should also be noted that the small sample, large effect size studies were
mostly based on results of studies in which correlations were converted to odds ratios, so there may be a
methodological explanation of funnel asymmetry other than bias. Altogether, the results support an
association between sleep problems and cognitive impairment or AD. Despite possible publication bias
and evidence of heterogeneity in the effect sizes, the overall association between sleep problems and
cognitive impairment or AD remained positive in all sensitivity analyses.
Furthermore, we clearly understand that testing for heterogeneity may not explain the variability
in the data because its basis may not simply be empirical but more fundamentally conceptual, therefore
we conducted several sensitivity analyses on both our exposure and outcome. Sensitivity analyses
examining the effect of omitting one study revealed no effect as the estimated relative risk remained
stable (See Fig. 2D in supplemental material). Sensitivity analyses were also conducted to see if all of
the subcategories of exposure can be combined into one exposure. We examined the effect of the
exposure on cognitive impairment and AD initially combined as presented in the overall meta-analysis
(Fig. 2.2) and while excluding each subcategory (Sleep Quality, Sleep Quantity, Obstructive Sleep
Apnea, Circadian Rhythm Abnormalities and Insomnia) from the exposure one at a time. No significant
change in the effect size was seen. We also conducted separate analyses of studies in terms of the
outcome measure since different outcome measures of cognitive impairment and AD was used. We
conducted analyses with the combined outcome of cognitive impairment and AD and examined the
change in the estimate while excluding each subcategory (cognitive tests, ICD-9/DSM IV and abnormal
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proteins). No statistically significant difference was observed in the change in effect estimate. (Type I
error rate (α=0.05)).
Meta-regression analysis
A multivariate meta-regression analysis (Table 2.3) was conducted to examine the potential
inﬂuence of different factors on the natural logarithm of the odds ratio of sleep problems with cognitive
impairment or AD. None of the studied factors was statistically signiﬁcant except for sample size (p =
.01), with larger samples showing smaller effects.
Population attributable risk percent
The PAR% suggested that approximately 15% of AD may be attributed to sleep problems, using
a conservative estimate of 30% as the prevalence of sleep problems in the populations of the included
studies and the pooled relative risk (RR: 1.55). By comparison, the prevalence of sleep problems in AD
ranges between 25% – 50%.11
DISCUSSION
Summary of the main results
In the present meta-analysis comprising 27 studies, individuals with sleep problems including
short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia and obstructive
sleep apnea, had a 1.68 times higher risk for the combined outcome of cognitive decline and AD
compared to individuals without sleep problems. Individuals with sleep problems including short and
long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia and obstructive sleep
apnea, had a 1.55, 1.65 and 3.78 times higher risk for AD, cognitive impairment and preclinical AD than
individuals without sleep problems respectively. A subgroup meta-analysis of classified sleep disorders
revealed a relative risk of 2.37 for obstructive sleep apnea, 1.86 for sleep duration problems, 1.62 for
sleep quality problems, and 1.38 for both insomnia and circadian rhythm abnormalities. Various aspects
of sleep problems examined in this analysis each significantly increased the risk for cognitive impairment
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or AD. Approximately 15% of cognitive impairment or AD may be attributed to sleep problems including
short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia and obstructive
sleep apnea.
Effect of sleep problems on cognitive impairment or Alzheimer’s disease (meta-analysis)
Altogether, sleep problems including short and long sleep duration, poor sleep quality, circadian
rhythm abnormality, insomnia and obstructive sleep apnea, signiﬁcantly increased cognitive impairment
or AD risk. Our findings show a RR increase seemingly inverse to diagnostic confidence (e.g., 1.55, 1.65
and 3.78 for AD, MCI and preclinical AD). These findings may reflect the use of more objective
investigative or diagnostic measures to identify individuals with preclinical AD in our study, however it
highlights potential mechanistic relationships suggesting that sleep is not only associated with cognitive
impairment, or symptomatic AD but is also associated with changes in AD biomarkers predictive of
persons that ultimately develop AD. Although there was heterogeneity in effect sizes, the variables
included in the meta-analysis failed to explain significant amounts of this variability. OSA appeared to be
a strong risk factor for AD. This may be explained by the fact that hypoxia plays a vital role and may
contribute to increases in Aβ production64, 65 thereby facilitating AD pathogenesis.66 Insomnia and
circadian rhythm abnormalities were each associated with an intermediate risk for cognitive impairment
or AD. Sleep quantity and quality seemed more important than insomnia and circadian activity rhythm as
a risk factor for cognitive impairment or AD. This could be because individuals with insomnia and/or
circadian rhythm abnormalities tend to have poor sleep quantity and quality, and as such the effect seen
could possibly reflect other underlying sleep problems such that individuals in the sleep quantity or
quality groups may also have associated insomnia and/or circadian rhythm abnormalities. Both long sleep
(> 8 h/day) and short sleep duration (< 7 h/day) increased the risk for cognitive impairment or AD when
compared to normal sleepers (7 – 8 h/day), with a higher risk seen in long sleepers. Although certain
prospective studies have shown associations between long sleep and cognitive impairment,67, 68 it is highly
plausible that this association is as a result of a general decline with old age and maybe reflective of other
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disease conditions such as depression or other neurological disorders. AD patients, like in Parkinson’s
disease, may also exhibit a more bimodal distribution of sleep patterns (i.e. short or long) possibly
reflective of some pre-existing genetic predisposition that develops at disease inception.
Potentially inﬂuencing factors (meta-regression analysis)
The heterogeneity seen across studies could not be explained by our subgroup meta-analyses,
except for sample size and the different AD measures. It is likely that much of the heterogeneity can be
explained by the conceptual differences in exposure and/or outcome assessment. We explored this further
by conducting several sensitivity analyses on both our exposure and outcome, each initially combined as
presented in the overall meta-analysis and also with exclusion of each subcategory one at a time. No
significant change in the effect size was seen. Sensitivity analyses examining the effect of omitting one
study revealed no effect as the estimated relative risk remained stable. Several of the subgroup analyses
were close to being statistically significant. However, since there were only 52 effect sizes in the analysis,
power may have been an issue. Pooled relative risks from sub-group meta-analyses for the effect of sleep
problems on cognitive impairment or AD revealed consistent moderate to strong relative risks and these
relationships could possibly contribute to a causal interpretation of the ﬁndings. No RCT was included,
suggesting that additional work examining the effect of sleep therapy on cognitive impairment or AD
would be useful.
Among the factors tested only sample size signiﬁcantly inﬂuenced the effect size between sleep
problems and AD such that larger sample size studies tended to result in smaller risk estimates for
cognitive impairment or AD while smaller sample size studies tended to result in larger risk estimates for
cognitive impairment or AD (Table 3). Overall, the results indicate that the meta-analyzed estimate
reﬂects an appropriate estimate of the general association. The need for proper multivariate modeling
approaches is underscored by the fact that the heterogeneity due to adjustment was close to statistical
signiﬁcance in some instances, although power was limited.
Study results in comparison with other reviews on the topic
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The results of this systematic review and meta-analysis are largely consistent with previous
reviews. Our study is the ﬁrst systematic review and meta-analysis to quantify an “average” magnitude of
the association between sleep problems and cognitive impairment or AD. Previous narrative review
articles that have examined this association did so with a focus on different aspects of sleep
disturbances/disorders16-19. Palma et al.,16 focusing on sleep deprivation, reviewed how sleep loss
constitutes a risk factor for various neurologic diseases including AD. Slats et al.,18 focusing on the role of
hypocretin and melatonin, concluded that there is substantial evidence for impairments in both sleep and
circadian regulating mechanisms resulting from AD pathology, which may be linked to clinical
symptoms. Peter-Derex et al.,17 performed a thorough clinical review of sleep and AD, observing that
micro-architectural sleep alterations, nocturnal sleep fragmentation, decreased sleep duration, diurnal
napping and inversion of the sleep-wake cycle are the main disorders observed in patients with AD. Spira
et al.,19 concluded that poor sleep is a risk factor for cognitive impairment and AD and that healthy sleep
appears to play an important role in maintaining brain health with age, and could play a key role in AD
prevention. Various reviews69, 70 on the effect of OSA on AD agree on a bidirectional relationship
between these entities.
Strengths and Limitations of the study
Our systematic review allows for a systematic, scientific, constructive and yet replicable review
of the association between sleep and AD with a pre-specified hypothesis and specific inclusion and
exclusion criteria. We were able to systematically and efficiently integrate existing information from
various studies enabling us to establish whether the literature is consistent and can be generalized across
populations, settings, and/or whether findings vary significantly by particular subsets. The meta-analyses
in particular increased the power and precision of estimates of the risk of cognitive impairment or AD
from sleep problems. The explicit methods employed in our meta-analysis limit bias and, hopefully,
improved reliability and accuracy of our conclusions. Lastly, the generalizability of our findings can be
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established as this review included a diversity of studies across various continents, providing an
interpretive context not available in any one study.
Several methodological concerns must be considered when interpreting the findings of this metaanalysis. First, one potential limitation relates to the possible bias introduced in the paper selection
process. To minimize this bias, we adhered strictly to the guidelines and recommendations in the
Cochrane handbook 22 whenever possible. We also ensured that studies were not restricted by language to
guard against language bias. Second, the possible bias introduced by the individual studies that were
included is a further limitation. Various study designs were rated low for assigning the grade of
evidence71. With a scarcity of controlled studies, this analysis relied mostly on observational studies.
However, the subgroup meta-analysis revealed no significant difference between the prospective and nonprospective studies, suggesting that our average estimate adequately reflects the general effect. In addition
to study design, conclusions made from the poor quality studies could introduce possible bias. We
included high, medium and low-quality studies in the summarization of findings. Our meta-regression
analysis indicated that study quality might not have influenced the overall conclusion. Third, there was
considerable variability between the studies in the assessment methods used to verify sleep problems and
AD or cognitive impairment, revealing moderate heterogeneity that could possibly raise questions about
the comparability of results across studies. Our research question focused on a broad concept of sleep
problems based on having any symptoms. Thus, we assumed a common underlying concept by making
general conclusions regarding sleep problems and cognitive impairment or AD. We based our assumption
on findings from reviews that consistently found associations of various sleep problems or disorders such
as sleep deprivation/loss,16, 19 sleep-wake abnormalities,17, 18 or sleep apnea,69, 70 with cognitive
impairment or AD. Moreover, our sensitivity analyses on the exposure and outcome measures which
involved examining the effect of sleep problems on cognitive impairment and AD with the exposure or
outcome measures combined and separated into subcategories did not reveal any statistical significant
change in the estimate. The persistence of heterogeneity in the subgroup meta-analysis of sleep
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parameters and various sleep problems and disorders suggests within-study variation, possibly due to lack
of objective assessment, standardization or success in controlling for psychiatric and somatic comorbidities. However, the prediction interval that considered both sampling error and study heterogeneity
suggested that although the association may vary across studies, it appears to be positive in at least 97.5
percent of them. Finally, although funnel plot asymmetry was consistent with publication bias, trim-andfill results were also positive; suggesting that our overall result might be an overestimate, but that the
association does not appear to be explained by biased reporting of studies.
Future directions
Existing reviews note growing experimental and epidemiologic evidence for close reciprocal
associations between cognitive impairment and sleep alteration. However, longer-term longitudinal
studies are required to better understand whether sleep problems precede the onset of cognitive
impairment or AD by many years. Future studies need to be able to define causal pathways more
definitively so we can test whether neurodegeneration is leading to both sleep changes and memory
changes, or whether aging is contributing to OSA and/or sleep architecture changes that in turn affect
memory, or whether the effect of aging on sleep architecture predisposes to both apnea and memory
impairment. More research with objective sleep measures, AD biomarkers, and cognitive measures also
are needed. To facilitate appropriate comparisons among studies, it would be expedient to have greater
standardization of sleep and measures of cognitive impairment or AD. Future research is needed to make
clear the contribution of different genetic, neurodegenerative and environmental factors to sleep
impairment, as their findings can be promising for the development of new prevention and/or treatment
opportunities.
Conclusion
This meta-analysis confirmed the association between sleep and cognitive impairmentor AD and,
for the first time, consolidated the evidence by providing an “average” magnitude of the effect (RR=1.55,
95% CI: 1.25-1.93). The public health relevance of this finding is buttressed by the PAR%, suggesting
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that approximately 15% of cognitive impairment or AD might be prevented if effective interventions
could be implemented to reduce sleep disorders.
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Table 2.1. Characteristics of included studies. Meta-analysis of sleep, cognitive decline and Alzheimer's disease/cognitive decline
Authors, year

Study design

Sample N

Study population, mean age/age

(study quality)

(location)

range in years (follow-up time,

Sleep assessment

Cognitive/AD

Impact of sleep problems/disorders

measures

on AD

years)
Benito-León et al.

Prospective cohort

3,857

Community-dwelling elderly, 65

Daily total sleep duration

Death

Long sleepers (≥ 9h), aHR=1.63 [1.04-

201432

(high)

(Spain)

(median,12.5)

(self-reported)

certificates,

2.56]* Short sleepers (≤ 5h), aHR=0.76

ICD-9

[0.33-1.74]
aOR=1.48 [1.44–1.52]*ˠ

Blackwell et al.

Cross sectional

2,242

Community-dwelling women, 83.5

Poor sleep (wrist

MMSE, Trails

200631

(high)

(U.S.)

(N/A)

actigraphy)

B

Blackwell et al.

Prospective cohort

2822

Community-dwelling men, 76, (3.4 ±

Sleep quality (wrist

MMSE, Trails

201451

(high)

(U.S.)

0.5 y)

actigraphy, PSQI, ESS).

B

Chang et al.

Retrospective cohort

8484

Sleep apnea patients. 40+ (5)

Sleep apnea (ICD-9)

ICD-9

201333

(high)

(Taiwan)

aOR=1.44 [1.38, 1.51]*ˠ

aHR=1.70 [1.26-2.31]*;
Females, aHR=2.38 [1.51–3.74]*;
Males, 50-59 years, aHR=6.08 [3.1511.70]*; 2.5 to 5 y of follow-up,
aHR=2.31 [2.07-2.58]*ˠ

Cohen-Zion et al.

Prospective cohort

46

200152

(Low)

(U.S.)

Cricco et al.

Prospective cohort

6,444

200134

(high)

(Iceland)

Community-dwelling, 80

(2)

Wrist actigraphy

MMSE

EDS, aOR=2.26 [1.21-4.20]*;
SA, aOR=4.04 [2.40-6.68]*

Community-dwelling elderly, 72 (3)

Insomnia (self-reported)

SPMSQ

Male non-depressed, aOR=1.33 [1.251.42]*; Male depressed, aOR=1.89
[1.60-2.23]*; Female non-depressed,
aOR=1.07 [1.03-1.11]*;
Female depressed, aOR=1.23 [1.161.31]*
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Foley et al.

Prospective cohort

2,346

Community-dwelling Japanese-

Sleep disturbance (self-

CASI, DSM-

200153

(high)

(U.S.)

American men, 76.6 (3)

reported)

IIIR.

Hahn et al.

Prospective cohort

214

Community-dwelling elderly, 83.4

Poor sleep (CPRS)

DSM-IIIR

201354

(high)

(U.S.)

(9)

aOR=1.44 [1.34-1.54]*

aOR=1.78 [1.50-2.11]*ˠ

NINCDSADRDA

Jelicic et al.

Prospective cohort

838

Community-dwelling elderly, 63.3 (3)

Poor sleep (self-reported)

MMSE

aOR=1.46 [1.38-1.54]*

200255

(medium)

(Netherlands)

Keage et al.

Prospective cohort

2,012

Community-dwelling elderly, 64-94

EDS (self-report)

MMSE

aOR=2.09 [1.75-2.50]*ˠ

201239

(high)

(Australia,

(10)

Sleep consolidation

NINCDS-

aHR=1.49 [1.39-1.60]*

(actigraphy)

ADRDA

Sleep fragmentation

Cognitive

aHR =1.22 [1.03-1.44]*;

(actigraphy)

performance

Male, aHR=1.33 [0.90-1.96]*;

U.K.)
Lim et al.

Prospective cohort

698

2013a40

(medium)

(Canada)

Lim et al.

Prospective cohort

737

(high)

(Canada)

2013b

36

Community-dwelling elderly, 83.3 (6)

Community-dwelling elderly, 81.6 (6)

Female, aHR=1.29 [0.99-1.69]*
Merlino et al.

Cross-sectional

750

Institutionalized and community-

201044

(low)

(Italy)

dwelling elderly, 76.7 (NA)

Insomnia (self-report)

DSM-IV-TR,

cOR=1.76 [1.02–3.11]*

NINCSARDRA,
NINDSAIREN

Nebes et al.

Cross-sectional

157

200945

(medium)

(U.S.)

Community volunteers, 72.2 (NA)

Sleep quality (PSQI)

RBANS
TONI
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aOR=2.21 [1.88-2.59]*

Ooms et al.

Randomized controlled

26

201461

trial (high)

(Netherlands)

Middle-aged men, 49.9 (1 night)

Sleep deprivation (PSG)

CSF Aβ42,

aOR=5.06 [1.48-17.28]*

Aβ40, P-tau,
T-tau

Oosterman et al.

Cross-sectional
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Cardiology/internal medicine

Sleep fragmentation

Cognitive

200946

(medium)

(Netherlands)

outpatients, 69.5 (NA)

(actigraphy)

performance

Osorio et al.

Prospective cohort

346

Brain aging study participants, 24-96

Insomnia (HAM-D)

MMSE

201156

(high)

(U.S.)

(7.7)

aOR=1.84 [1.60-2.12]*

Insomnia, aOR=2.39 [1.03–5.55]*;
Insomnia w/o depression, aOR=3.32
[1.33–8.28]*

Osorio et al.

Cross-sectional

95

Brain aging study participants, 67.7

201437

(medium)

(U.S.)

(NA)

Saint Martin et al.

Cross-sectional

272

Community-dwelling elderly, 74.8

201247

(medium)

(France)

(NA)

SDB (AHI ≥ 15).

CSF P-tau, T-

aOR=4.46 [2.35-8.48]*

tau, Aβ42

Sleep quality (PSQI)

MMSE,

aOR=1.65 [1.46-1.86]*

GBSRT,
BVRT, Trail
A & B,
WAIS-III,
Stroop test,
AFCFT

Schmidt et al.

Case-control

66

Consecutive AD patients and controls,

Melanin-concentrating

CERAD,

201349

(medium)

(Germany)

62.9 (NA)

hormone (MCH) and

WMS-R, Trail

hypocretin-1 (HCRT-1,

B, MRI, CSF
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aOR=5.1 [1.98-13.12]*

Spira et al.

Cross-sectional

70

Normative aging study participants,

201348

(medium)

(U.S.)

76.4 (NA)

orexin-A) (fluorescence

Aβ42, Aβ40,

immunoassay (FIA))

P-tau, T-tau

WHIIRS

β-amyloid

Lower sleep quality, aOR=3.38 [2.05–
5.58]*; Insomnia, aOR=1.87 [1.19–
2.94]*

Sterniczuk et al.

Retrospective cohort

28,697

Community-dwelling middle-aged

Sleep disturbance Index

AD (self-

201350

(medium)

(Canada)

and elderly, 64.6 (4.3)

(SDI) (self-report)

reported),

Tranah et al.

Prospective cohort

1,282

Community-dwelling women, 82.7

CAR (actigraphy).

Modified

201157

(high)

(U.S.)

(4.9)

aOR=1.18 [1.17-1.19]*

aOR=1.66 [1.55-1.77]*

MMSE CVLT
IQCODE,
dementia
(self-reported)

Tworoger et al.

Prospective cohort

1,844

200638

(medium)

(U.S.)

Community-dwelling women, 74.2 (2)

Sleep duration (self-

Cognitive

reported)

performance

≤ 6 h sleep, aOR=2.35 [1.90-2.91]*;
Difficulty initiating sleep, aOR=2.21
[1.84-2.65]*;
≥ 8 h sleep, a0R=1.31 [0.76-2.29]

Virta et al.
2013

58

Prospective cohort

2,336

(high)

(Finland)

Elderly twins, 65+ (18-26)

Poor sleep (self-reported)

Linear

≤ 7 h sleep, aOR=4.15 [3.12–5.54]*;

cognitive

Hypnotic use, aOR=1.23 [0.73–2.08]

score (selfreport)
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Walsh et al.

Prospective cohort

287

201459

(high)

(U.S.)

Community-dwelling women, 82.8 (5)

CAR (actigraphy)

Modified

aOR=3.43 [1.74–6.75]*

MMSE
CVLT, Trails
B

Yaffe et al.

Prospective cohort

298

Community-dwelling women, 82.3

201160

(high)

(U. S.)

(2.3)

SDB (AHI ≥ 15).

DSM-IV

Sleep-wake problems, aOR=1.09
[0.90–1.32]ˠ; SDB , aOR=1.87 [1.61–
2.18]*ˠ;

Sleep

duration, aOR=0.56 [0.46-0.67]*ˠ
*: significant, ˠ: multiple outcome measure on same subject, so mean of the outcome computed. Abbreviations; a: adjusted, Aβ40/42: amyloid beta-40/42, AD: Alzheimer's disease, AFCFT: alphabetic fluency and category fluency
tasks, AHI ≥ 15: apnea hypopnea index of 15 or more events per hour of sleep, APOE: apolipoprotein epsilon4, BVRT: Benton visual retention test, c: crude, CAR: circadian activity rhythms, CASI: cognitive abilities screening
instrument, CERAD: consortium to establish a registry for Alzheimer’s disease, CPRS: comprehensive psychopathological rating scale, CSF: cerebrospinal fluid, CVLT: California verbal learning test , DSM-IIIR/IV-TR:
diagnostic and statistical manual of mental disorders, third edition/fourth edition, text revised, EDS: Excessive daytime sleepiness, ESS: Epworth sleepiness scale, GBSRT: Grober and Buschké selective reminding test, HAM-D:
Hamilton Depression Rating Scale , HR: hazard ratio, ICD-9/10: international classification of diseases ninth/tenth edition AD criteria, IQCODE: informant questionnaire on cognitive decline in the elderly, , MMSE: mini mental
state examination, MRI: magnetic resonance imaging, N: number of participants, NA: not applicable, N/A: not available, NINCDS-ADRDA: national institute of neurological and communicative disorders and stroke and the
Alzheimer's disease and related disorders association, NINDS-AIREN: national institute of neurological disorders and stroke and association internationale pour la recherché et l'enseignement en neurosciences vascular dementia
criteria, OR: odds ratio, PSG: polysomnography, PSQI: Pittsburgh sleep quality index, P-tau: phosphorylated tau, RBANS: repeatable battery for the assessment of neuropsychological status, RR: relative risk, SDB: sleep
disordered breathing, SPMSQ: short portable mental status questionnaire , TONI: test of nonverbal intelligence, Trails B: trail making b test, T-tau: total-tau, WAIS-III: Wechsler adult intelligence scale third version, WHIIRS:
women’s health initiative insomnia rating scale, WMS-R: Wechsler memory scale-revision

141

Table 2.2: Pooled relative risks from sub-group meta-analysis for the effect of sleep on Alzheimer's
disease/cognitive decline
Subgroup

N

Relative risk

(95% CI)

Sleep Efficiency

7

1.98

(1.11, 3.52)

Sleep Latency

4

1.33

(1.13, 1.57)

Wake After Sleep Onset

7

1.26

(1.19, 1.33)

Daytime Sleepiness

7

1.49

(1.17, 1.90)

Nighttime problems

31

1.7

(1.48, 1.94)

Night & Daytime problems

6

1.45

(1.17, 1.78)

Female

7

1.56

(1.24, 1.96)

Male

13

1.49

(1.23, 1.79)

Both male & female

24

1.74

(1.49, 2.03)

Long sleepers > 8 hrs/day

6

2.05

(1.24, 3.38)

Short sleepers ≤ 7 hrs/day

6

1.63

(1.13, 2.34)

< 5 years

18

1.4

(1.23, 1.59)

≥ 5 years

18

1.76

1.46, 2.112

Insomnia

11

1.5

(1.25, 1.80)

Obstructive Sleep Apnea Syndrome

11

1.96

(1.59, 2.41)

Circadian-Rhythm Sleep Disorders

8

1.38

(1.09, 1.75)

Sleep parameter

Daytime vs. nighttime sleepiness

Gender

Sleep duration

Follow-up time

Classified sleep disorders
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Sleep Depth (Not classified)

18

1.62

(1.38, 1.91)

North America

25

1.53

(1.35, 1.74)

Europe

14

1.54

(1.27, 1.86)

Australia

1

2.09

(1.16, 3.78)

Asia

4

2.23

(1.60, 3.11)

Prospective studies

36

1.57

(1.41, 1.77)

Non-prospective studies

8

1.70

(1.44, 2.02)

High quality

31

1.58

(1.40, 1.79)

Medium quality

10

1.67

(1.32, 2.10)

Low quality

3

2.17

(1.38, 3.41)

Continent

Temporality

Study quality

Abbreviations N: Number of relative risk estimates, CI: confidence interval
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Table 2.3: Results of meta-regression analysis examining potential effects of different factors on the natural logarithm of the odds ratio between
sleep and Alzheimer's disease/cognitive decline
Risk for Alzheimer's disease
Meta-regression variables

Univariable analysis

Multivariable analysis

Coef.

p-Value

Coef.

p-Value

Proportion of females (in %)

-0.0004

0.8647

0.0007

0.7224

Mean age (in years)

-0.0022

0.7898

-0.0147

0.2287

Sample size (in number of people)

-0.000

0.0413

-0.000

0.0175

Quality rating (in %)

0.1043

0.3046

0.0198

0.8721
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Figure 2.1: Study retrieval and selection for effects of sleep on Alzheimer’s disease/cognitive decline
meta-analysis.
Studies identified through database searching (n = 2341)
(PubMed=904, Embase=1026, Web of Science=305, Cochrane library=106)

Duplicates removed
(n = 1120)
Studies after duplicates removed
(n = 1221)

Studies

screened for titles
(n = 1221)

Studies excluded
(n = 180)

Studies screened for abstracts

Studies excluded
(n = 840)

(n = 1041)

Full-text articles excluded, with
reasons (n = 130)
Full-text articles assessed for
eligibility
(n = 201)
Article identified from reference
search
(n = 1)

-

Studies included in systematic
review
(n = 72)

Review article (n = 7)
No risk estimate (n = 17)
Sleep not assessed (n = 18)
Relationship not studied (n =
53)
Not peer reviewed (n = 10)
Alzheimer not examined (n
= 25)

Studies excluded from analysis, with
reasons (n = 45)
-

Studies included in metaanalysis
(n = 27)
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-

Study design (n = 16)
Duplicate studies (n =
12)
Insufficient
information for a metaanalysis (n = 17)

Figure 2.2 Study retrieval and selection for effects of sleep on cognitive decline and/or Alzheimer’s
disease meta-analysis

Abbreviations: EDS, excessive daytime sleepiness; RR, relative risk; SA, sleep apnea; SDB, sleep disordered breathing; TST, total sleep time;
WASO, wake after sleep onset; w/D, with depression; w/o D, without depression; w/o, without
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Figure 2.3: Forest plot presenting sub-group meta-analysis based on risk estimates for the effect
of sleep on Cognitive decline, Pre-clinical and Symptomatic Alzheimer’s disease

Abbreviations: EDS, excessive daytime sleepiness; RR, relative risk; SA, sleep apnea; SDB, sleep disordered breathing; TST, total sleep time;
WASO, wake after sleep onset; w/D, with depression; w/o D, without depression; w/o, without
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0.396
0.594
0.792

Standard Error

0.198

0.000

Figure 2.4*: Trim and fill funnel plot for effects of sleep on Alzheimer’s disease/cognitive decline metaanalysis

-1.00

0.00

1.00

2.00

Observed Outcome

*Filled dots represent published studies. Empty dots represent unpublished and/or imputed studies
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Figure 2.5 Forest plot presenting sub-group meta-analysis based on risk estimates for the effect
of different sleep problems and disorders on cognitive decline and/or Alzheimer’s disease

Abbreviations: EDS, excessive daytime sleepiness; RR, relative risk; SA, sleep apnea; SDB, sleep disordered breathing; TST, total sleep time;
WASO, wake after sleep onset; w/D, with depression; w/o D, without depression; w/o, without
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Figure 2.6: Forest plot presenting sub-group meta-analysis based on risk estimates for the effect
of self-report versus actigraphic data of poor sleep on cognitive decline and/or Alzheimer’s disease

Abbreviations: EDS, excessive daytime sleepiness; RR, relative risk; SA, sleep apnea; SDB, sleep disordered breathing; TST, total sleep time;
WASO, wake after sleep onset; w/D, with depression; w/o D, without depression; w/o, without
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APPENDIX A
SUPPLEMENTAL TABLES AND FIGURES: SLEEP AND AD META-ANALYSIS

Table 1A: Main findings from included studies and comments regarding computed conversions of the different indices to a common index: odds ratios and regarding
computing a summary effect size of the impact of sleep problems on AD
Authors, year, reference
number, (country)

Study Main Findings

Benito-León et al. 2014,32
(Spain)

Long sleepers (≥ 9h)
Short sleepers (≤ 5h)

aHR=1.63 [1.04-2.56]
aHR=0.76 [0.33-1.74]

Sleep efficiency (MMSE)
Sleep efficiency (Trails B)
Sleep latency (MMSE)
Sleep latency (Trails B)
WASO (MMSE)
Sleep latency (Trails B)
Napping (MMSE)
Napping (Trails B)

aOR=1.61 [1.20–2.16],
aOR=1.96 [1.43–2.67],
aOR=1.23 [1.13–1.33];
aOR=1.13 [1.04–1.24],
aOR=1.15 [1.06–1.23];
aOR=1.24 [1.15–1.34].
aOR=1.42 [1.05–1.93];
aOR=1.74 [1.26–2.40].

Blackwell et al. 2014,51
(United States)

Sleep efficiency (Trails B)
WASO
LWEP
3MS:LWEP

aOR=1.53 [1.07, 2.18];
aOR=1.47 [1.09, 1.98];
aOR=1.38 [1.02, 1.86].
aOR=1.36 [1.09, 1.71]

Chang et al. 2013,33
Taiwan

SA
Females
Males 50-59 years
Females ≥ 70 years
First 2.5 years of follow-up
5 years of follow-up

Blackwell et al.
(United States)

2006,31

aHR=1.70 [1.26-2.31]
aHR=2.38 [1.51–3.74]
aHR= 6.08 [1.96-18.90],
aHR=3.20 [1.71–6.00].
aHR: =2.04 [1.35-3.07].
aHR=1.70 [1.26-2.31]
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Comments for conversion

Impact of sleep problems/disorders on
Alzheimer's disease

No conversions and/or mean computation
done

Long sleepers (≥ 9h), aHR=1.63 [1.04-2.56]*
Short sleepers (≤ 5h), aHR=0.76 [0.33-1.74]

We accounted for multiple outcome
measures on the same subjects by
computing the mean of the effect sizes
for each study and used the average effect
size as the unit of analysis

aOR=1.44 [1.07–1.94]*ˠ

We accounted for multiple exposure
measures on the same subjects by
computing the mean of the effect sizes
for each study and used the average effect
size as the unit of analysis
No conversions and/or mean computation
done for separate populations and
measures. Follow-up time measures were
on the same subjects as such we
computed the mean of the effect sizes and
used the average effect size as the unit of
analysis

aOR=1.48 [1.17, 1.88]*ˠ;

aHR=1.70 [1.25-2.31]*;
Females, aHR=2.38 [1.51–3.74]*;
Males, 50-59 years, aHR=6.08 [1.96-18.90]*;
2.5 to 5 y of follow-up, aHR=2.31 [1.45-3.69]*ˠ

Cohen-Zion et al. 2001,52
United States

Cricco et al. 2001,34
Iceland

Foley et al.
States

Hahn et al.
States

2001,53

2013,54

United

United

Jelicic et al. 2002,55 The
Netherlands

Increased RDI (t=-2.17, 42 df, r=-0.32, P=.036)
Increased EDS (t=-3.32, 42 df, r=-0.46, P=.002)
EDS (t39 = -2.45, r=-0.37, P= .019)-Adjusted model
RDI (t39=- 0.66, r=-0.11, P=.515)-Adjusted model
Non-depressed men chronic insomnia
aOR=1.49
[1.03–2.14]
Non-depressed men incident insomnia
aOR=1.16
[0.82–1.65]
Depressed men incident insomnia
aOR=1.60
[0.87-2.95]
Depressed men chronic insomnia
aOR=2.18
[1.30-3.67]
Non-depressed women chronic insomnia aOR=1.18
[0.92–1.52]
Non-depressed women incident insomnia aOR=0.95
[0.71–1.26]
Depressed women incident insomnia
aOR=1.10
[0.75-1.61]
Depressed women chronic insomnia
aOR=1.36
[1.01-1.84]
Excessive daytime sleepiness DSM-IIIR aOR=2.19
[1.37–3.50]
Excessive daytime sleepiness
CASI
aOR=1.44 [1.01–2.08].
Insomnia DSM-IIIR
aOR=0.99 [0.70-1.41]
Insomnia CASI
aOR=1.14 [0.91-1.43]
Reduced sleep (Dementia)a
Reduced sleep (AD)a
Reduced sleep (Dementia)b
Reduced sleep (AD)b
Reduced sleep (Dementia)c
Reduced sleep (AD)c
Reduced sleep (Dementia)d
Reduced sleep (AD)d

aHR=1.75 [1.04-2.93]
aHR=2.01 [1.12-3.61]
aHR=1.50 [0.87-2.59]
aHR=1.69 [0.91-3.14]
aHR=1.73 [1.02-2.91]
aHR=2.02 [1.11-3.65]
aHR=1.68 [0.98-2.86]
aHR=1.86 [1.00-3.70]

Overall sleep problems continuous scores β=-0.05 (0.09,-0.00)
Overall sleep problems dichotomized scores β=-0.38 (0.71,-0.05)
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Converted from r to d (d = d2r/√(1-r^2 ) )
and from d to the log(OR) (Log(OR) =
dp/√3 and mean computation done for
separate populations

SA, aOR=2.26 [0.75-6.80];
EDS, aOR=4.04 [1.48-11.06]*

We accounted for multiple exposure
measures on the same subjects by
computing the mean of the effect sizes
for each study and used the average effect
size as the unit of analysis for each
population

Male non-depressed, aOR=1.33 [0.93-1.90]ˠ;
Male depressed, aOR=1.89 [1.07-3.34]*ˠ;
Female non-depressed, aOR=1.07 [1.03-1.11]*ˠ;
Female depressed, aOR=1.23 [0.87-1.73]ˠ;

We accounted for multiple exposure
measures on the same subjects by
computing the mean of the effect sizes
for each exposure category and used the
average effect size as the unit of analysis

EDS: aOR=1.82 [1.19-2.79]*
Insomnia: aOR=1.07 [0.81-1.42]

We accounted for multiple outcome
measures on the same subjects by
computing the mean of the effect sizes
for each study and used the average effect
size as the unit of analysis

aOR=1.78 [0.86-3.70]ˠ

Converted from β to OR

aOR=1.46 [1.05-2.03]*

Ju et al. 2013, United
States

Sleep efficiency

No conversions and/or mean computation
done

OR=5.60 [0.97- 32.5]

Keage et al. 2012,39
Australia, & United
Kingdom

Napping (2years)
aOR=0.38 [0.22–0.67].
Napping (10years)
aOR=0.48 [0.29–0.78].
Sleep duration (<= 6.5 h 10years) aOR=2.02 [1.17–
3.48]
Sleep duration (>= 9 h 10years) aOR=1.27 [0.64-2.48]
Daytime sleepiness (10 years) aOR=2.43 [1.24–4.75].

We accounted for multiple exposure
measures on the same subjects by
computing the mean of the effect sizes
for each exposure category and used the
average effect size as the unit of analysis

Sleep Quality: aOR=1.10 [0.58-2.07]ˠ
<= 6.5h sleep: aOR=2.02 [1.17-3.48]*ˠ;
>= 9h sleep: aOR=1.27 [0.65-2.48]ˠ;

Lim et al. 2013a,40 Canada

Better Sleep consolidation

We converted the risk estimate for better
sleep consolidation to a risk estimate for
poor sleep consolidation

aHR=1.49 [1.02-2.17]*

Lim et al. 2013b,36 Canada

Sleep fragmentation
Male
Female

aHR =1.22 [1.03-1.44]
aHR=1.33 [0.90-1.96]
aHR=1.29 [0.99-1.69]

No conversions and/or mean computation
done

aHR =1.22 [1.03-1.44]*;
Male, aHR=1.33 [0.90-1.96];
Female, aHR=1.29 [0.98-1.69]

Merlino et al. 2010,44 Italy

Excessive daytime sleepiness OR=1.76 (1.02–3.11)

No conversions and/or mean computation
done

cOR=1.76 [1.02–3.11]*

Nebes et al. 2009,45 United
States

Sleep latency correlated the RBANS (r = −.241, p =
.002)
Sleep latency correlated the TONI (r = −.258,
p = .001).
Sleep efficiency correlated with the
RBANS (r = .185, p = .020), Sleep efficiency correlated
with the TONI (r = .197, p = .013), Sleep efficiency
correlated with the N-Back (r = .211, p = .008).

Converted from r to d (d = d2r/√(1-r^2 ) )
and from d to the log(OR) (Log(OR) =
dp/√3 and computed the mean of the
effect sizes for each study and used the
average effect size as the unit of analysis

aOR=2.21 [1.26-3.87]*

Fragmentation of the sleep-wake rhythm (Mental: r =0.16, Memory: - 0.19, andExecutive: - 0.16 respectively)

Converted from r to d (d = d2r/√(1-r^2 ) )
and from d to the log(OR) (Log(OR) =
dp/√3 and computed the mean of the
effect sizes for each study and used the
average effect size as the unit of analysis

aOR=1.84 [1.09-3.11]*

Insomnia
Insomnia without depression

No conversions and/or mean computation
done

Insomnia, aOR=2.39 [1.03–5.55]*;
Insomnia w/o depression, aOR=3.32 [1.33–
8.28]*

Oosterman et al.
Netherlands

2009,46

Osorio et al. 2011,56
United States

OR=5.60 [0.97- 32.5]

aHR 0.67 [0.46-0.97]

aOR=2.39 [1.03–5.55].
aOR=3.32 [1.33–8.28].
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Osorio et al. 2014,37
United States

In ApoE3+ subjects, significant differences were found
between sleep groups for p-tau (F[df2] = 4.3, p =0.017),
and t-tau (F[df2] = 3.3, p = 0.043). Additionally, among
ApoE3+ subjects, the apnea and/or hypopnea with 4%
O2-desaturation index was positively correlated with ptau (r = 0.30, p = 0.023), t-tau (r = 0.31, p = 0.021), and
Aβ-42 (r = 0.31, p = 0.021). In ApoE2+ subjects, the
apnea and/or hypopnea with 4% O2-desaturation index
was correlated with lower levels of CSF Aβ-42
(r = −0.71, p = 0.004), similarly to ApoE4+ subjects
where there was also a trend toward lower CSF Aβ-42
levels.

Converted from r to d (d = d2r/√(1-r^2 ) )
and from d to the log(OR) (Log(OR) =
dp/√3 and computed the mean of the
effect sizes for each study population and
used the average effect size as the unit of
analysis

ApoE3+ subjects: aOR=3.20 [1.18-8.66]*
ApoE2+ subjects: aOR= 8.17 [1.96-34.07]*

Saint Martin et al. 2012,47
France

PSQI correlated with the MMSE (r = -0.14, p = .03)
Sleep Quality correlated with Delayed free recall (r = 0.14, p < .05)

Converted from r to d (d = d2r/√(1-r^2 ) )
and from d to the log(OR) (Log(OR) =
dp/√3 and computed the mean of the
effect sizes for each study and used the
average effect size as the unit of analysis

aOR=1.65 [1.02-2.68]*

Schmidt et al. 2013,49
Germany

A significant main effect of diagnosis (F(1,62) = 8.490,
p<0.01) on MCH levels was found between AD (93.76 ±
13.47 pg/mL) and HS (84.65 ± 11.40 pg/mL). MCH
correlated with T-tau (r = 0.47; p<0.01) and P-tau (r =
0.404; p,0.05) in the AD but not in the HS. CSF-MCH
correlated negatively with MMSE scores in the AD (r = 0.362, p<0.05) and was increased in more severely
affected patients (MMSE ≤ 20) compared to HS
(p<0.001) and Behavioral and Psychological Symptoms
of Dementia (BPSD) positive patients compared to HS
(p<0.05). In CSF-HCRT- 1, a significant main effect of
sex (F(1,31) = 4.400, p<0.05) with elevated levels in
females (90.93 ± 17.37 pg/mL vs. 82.73 ± 15.39 pg/mL)
was found whereas diagnosis and the sex*diagnosis
interaction were not significant.

Converted from r to d (d = d2r/√(1-r^2 ) )
and from d to the log(OR) (Log(OR) =
dp/√3 and computed the mean of the
effect sizes for each study and used the
average effect size as the unit of analysis

aOR=5.1 [1.31-19.89]*

Spira et al. 2013,48 United
States

Shorter sleep duration
Mean cortical DVR (B = 0.08 [95% CI, 0.03-0.14]; r
=.38; P = .005) Mean precuneus DVR (B = 0.11 [0.030.18]; r =.36; P = .007).
Lower sleep quality
Mean cortical DVR (B = 0.04 [95% CI, -0.01-0.09]; r
=.19; P = .13) Mean Precuneus DVR (B = 0.08 [0.010.15]; r=.29; P = .03). WHIIRS, Women’s Health
Initiative Insomnia Rating Scale
Mean cortical
DVR (B = 0.01 [95% CI, -0.004-0.02]; r =.16; P=.23)
Mean Precuneus DVR(B = 0.01 [95% CI, -0.004-0.02]
r=.18; P=.16).

Converted from β to OR Converted from
r to d (d = d2r/√(1-r^2 ) ) and from d to
the log(OR) (Log(OR) = dp/√3 and
accounted for multiple exposure
measures on the same subjects by
computing the mean of the effect sizes
for each study and used the average effect
size as the unit of analysis

Sleep duration, aOR= 4.25 [1.52-11.88]*ˠ;
Lower sleep quality, aOR=2.51 [0.96–6.56]ˠ;
Insomnia, aOR=1.87 [0.73–4.80]ˠ
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We accounted for multiple outcome
measures on the same subjects by
computing the mean of the effect sizes
for each study and used the average effect
size as the unit of analysis
We accounted for multiple outcome
measures on the same subjects by
computing the mean of the effect sizes
for each study and used the average effect
size as the unit of analysis

Sterniczuk et al. 2013,50
Canada

SDI
SDI

Tranah et al. 2011,57
United States

Decreased activity rhythms
Rhythm robustness
Peak Activity timing

Tworoger et al 2006,38
United States

<=5hrs of sleep aOR=2.19 (1.10-4.39)
6hrs of sleep aOR=1.01 (0.61-1.67)
8hrs of sleep aOR=1.16 (0.74-1.82)
>=9hrs of sleep aOR=1.46 (0.77-2.76)
TICS aOR=2.51 (1.38, 4.54) Women who regularly had
difficulty falling or staying asleep
TICS (aOR: 1.85, 95% CI: 1.04, 3.30) global score
(aOR: 2.57, 95% CI: 1.39, 4.74) TICS (Telephone
Interview of Cognitive Status)

We accounted for multiple exposure
measures on the same subjects by
computing the mean of the effect sizes
for each exposure category and used the
average effect size as the unit of analysis

≤ 6 h sleep, aOR=1.68 [0.92-3.08]ˠ;
Difficulty initiating sleep, aOR=2.21 [1.224.01]*ˠ;
≥ 8 h sleep, a0R=1.30 [0.71-2.39]ˠ;

Sleep Length (N=2328)
Sleep Length (< 7 h/day) (β = -0.84 (-1.51,-0.17), P =
0.014
Sleep Length (< 7 h/day) (β = -0.79 (-1.44,-0.14), P =
0.019 and Sleep Length (> 8 h/day) (β = -1.66 (-2.37,0.95) P < 0.001
Sleep Length (> 8 h/day) (β = -1.61 (-2.33,-0.91) P <
0.001.
Poor sleep quality (β = -1.00 (-1.77,-0.23) P = 0.011.
Poor sleep quality (β = -0.89 (-1.69,-0.09) P = 0.028
The use of hypnotics ≥ 60 days per year (β = -1.92 (3.11,-0.73), P = 0.002). The use of hypnotics ≥ 60 days
per year (β = -1.58 (-2.75,-0.41), P = 0.008).
Model 1 adjusted for age, sex, education, ApoE status,
and follow-up.
Model 2 adjusted for life satisfaction, obesity,
hypertension, physical inactivity, heavy drinking, and
binge drinking in addition to the factors adjusted for in
Model 1

We accounted for multiple exposure
measures on the same subjects by
computing the mean of the effect sizes
for each exposure category and used the
average effect size as the unit of analysis

≤ 7 h sleep, aOR=2.26 [1.17–4.38]*ˠ;
>=8 h sleep, aOR=5.13 [2.51-10.49]*ˠ;
Sleep quality, aOR=3.72 [2.45-5.65]*ˠ;
Hypnotic use, aOR=5.85 [1.80–19.03]*ˠ

Virta et al

2013,58

Finland,

aOR=1.23 [1.11-1.36]
aOR=1.12 [1.00-1.25]

aOR=1.57 [1.09–2.25]
aOR=1.57 [1.10–2.26]
aOR=1.83 [1.29–2.61]
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aOR=1.18 [1.06-1.31]*ˠ;

aOR=1.66 [1.16-1.31]*ˠ;

Walsh et al 2014,59 United
States

Yaffe et al.
States

2011,60

United

Women lowest vs. highest quartile
CAR amplitude (group difference (d) = 30.42 sec, d = 1.01 words respectively, P < 0.05).
Categorical fluency mesor (d = -0.86 words, P < 0.05).
Women Categorical fluency later acrophase categorical
fluency (d = -0.69 words, P < 0.05).
Controlling for baseline Mini-Mental State Examination
and sleep factors had negligible effects on the results.

Converted from d to the log(OR)

aOR=3.43 [1.08–10.85]*

SDB (Women)
aOR=1.85 [1.11-3.08].
AHI (≥15 events/hour) aOR=1.71 [1.04 − 2.83]
>7% of sleep time in apnea/hypopnea aOR=2.04 [1.10
− 3.78] respectively).
Sleep Fragmentation Mild aOR=0.54 [0.29-0.98]
Sleep Fragmentation High aOR=0.58 [0.32-1.07]
WASO
Mild
aOR=1.17 [0.63-2.19]
WASO
High
aOR=1.79 [0.97-3.29]
Sleep Duration Mild
aOR=0.58 [0.31-1.09]
Sleep Duration High
aOR=0.83 [0.46-1.51]

We accounted for multiple exposure
measures on the same subjects by
computing the mean of the effect sizes
for each exposure category and used the
average effect size as the unit of analysis

Sleep Fragmentation, aOR=0.56 [0.31-1.02]ˠ
WASO, aOR=1.48 [0.80–2.74]ˠ;
SDB , aOR=1.87 [1.08–23.23]*ˠ;
TST, aOR=0.71 [0.37-1.35]ˠ

*: significant, ˠ: multiple exposure/outcome measure on same subject, so mean of the outcome computed. Abbreviations; a: adjusted, AD: Alzheimer's disease, APOE: apolipoprotein epsilon4, c: crude,
CAR: circadian activity rhythms, CASI: cognitive abilities screening instrument, MMSE: mini mental state examination, OR: odds ratio, PSG: polysomnography, PSQI: Pittsburgh sleep quality index,
RR: relative risk, SDB: sleep disordered breathing, Trails B: trail making b test, TST: total sleep time, WASO: wake after sleep onset,
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Table 2A: Formula used for converting among effect sizes and for calculating the variance of the
effect sizes

Converting Among Effect
Sizes*
Converting from d to the log
odds ratio

Converting from r to d

Converting from d to r

Formula

Variance Formula**
π

Log(OR) = d , where π is
√
the mathematical constant
(approximately 3.14159)

(

d=d

)

=

π

3
The variance of d computed
in this way (converted from r)
is

√

4
(1 −
)
The variance of r computed in
this way (converted from d) is
=

, where a is a
r=√
correction factor for cases
where n1 ≠ n2,
a=

(

=

)

The correction factor (a)
depends on the ratio of n1 to
n2, rather than the absolute
values of these numbers.
Therefore, if n1 and n2 are
not known precisely, use n1=
n2, which will yield a=4.
Converting from the log odds
ratio to d
converting from β to OR

The variance of
Log(OR) would then be

d = Log(OR)*

√

π

exp(β)

=

N/A

(

+ )

(

)

∗

√

π

*Effect sizes from the reviewed studies included odds ratios (OR), hazard ratios (HR), Pearson’s correlation coefficient (r), beta
estimates (β) and standardized mean differences (d). To proceed with the meta-analysis, we converted the different indices to a
common index: odds ratios (meta-analyses were computed using Log(OR) but were converted back to OR for presentation).
** Reference #30 in manuscript: Borenstein Michael HLV, Higgins J. P. T., Rothstein H.R. Introduction to Meta-Analysis. : John
Wiley & Sons, Ltd.; © 2009
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Table 3A: Formula used for computing the variance of a composite or a difference

Computing the variance of a composite or
a difference*
The variance of the sum of two correlated
variables

The variance of the mean of two correlated
variables

Formula**
If we know that the variance of Y1 is V1 and
the variance of Y2 is V2, then
+
+2 # #
Var (! + ! ) =
Where r is the correlation coefficient that
describes the extent to which Y1 and Y2 covary. If Y1 and Y2 are inextricably linked (so
that a change in one determines completely
the change in the other), then r =1, and the
variance of the sum is roughly twice the sum
of the variances. At the other extreme, if Y1
and Y2 are unrelated, then r=0 and the
variance is just the sum of the individual
variances.
Var $ (! + ! )% = & ' Var (! + ! ) =
(

)

+

+2 # #

*

The variance of the mean of several correlated
+
var&+ ∑+
-. !- '= &+' var)∑-. !- *=
variables
The variance of the difference between two
correlated variables

&+' /∑+
-.

-

+ ∑- 30 /

-0

1

-

# 0 22

If we know that the variance of Y1 is V1 and
the variance of Y2 is V2, then
Var (! − ! ) =
+
−2 # #

*Since our aim was to compute a summary effect size of the impact of sleep problems on cognitive decline and Alzheimer’s
disease, we accounted for multiple exposure or outcome measures on the same subjects by computing the mean of the effect sizes
for each study and used the average effect size as the unit of analysis. This influenced the calculation of the variance of the sum
and mean effects of the correlated variables. For our analysis, we worked with a plausible range of correlations ranging from 0.51.0 and performed sensitivity analyses to find the most appropriate standard error range.
** Reference #30 in manuscript: Borenstein Michael HLV, Higgins J. P. T., Rothstein H.R. Introduction to Meta-Analysis. : John
Wiley & Sons, Ltd.; © 2009
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Figure 1A Forest plot presenting sub-group meta-analysis based on continent in which study
was published for the effect of sleep problems and disorders on cognitive decline and/or Alzheimer’s
disease

159

Figure 2A: Forest plot presenting sub-group meta-analysis based on day versus night time
sleepiness for the effect of sleep problems and disorders on cognitive decline and/or Alzheimer’s disease
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Figure 3A Forest plot presenting sub-group meta-analysis based on study temporality for the
effect of sleep problems and disorders on cognitive decline and/or Alzheimer Disease
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Figure 4A Forest plot presenting meta-analysis risk estimates based on omitting one study for
the effect of sleep problems and disorders on cognitive decline and/or Alzheimer Disease
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SECTION 3
OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH LONGITUDINAL INCREASES IN BRAIN
FLORBETAPIR PET IMAGING, CSF TAU, PTAU, AND DECREASE IN CSF AΒ42 BURDEN, IN
ELDERLY COGNITIVE NORMAL AND MCI INDIVIDUALS.

KEY POINTS
Question: Does Obstructive Sleep Apnea (OSA) affect longitudinal changes in brain amyloid deposition
and cerebrospinal fluid (CSF) Aβ42, t-tau and p-tau181 in cognitive normal (NL), mild cognitive
impairment (MCI) and Alzheimer’s Disease (AD) older adults.
Findings: OSA accelerates increases in brain amyloid deposition, CSF TAU and PTAU and decreases in
CSF biomarkers burden, over time, both in elderly NL and MCI individuals.
Meaning: Clinical interventions aimed at OSA, such as treatment with CPAP or dental appliances, in NL
and MCI patients, could possibly slow the progression of cognitive impairment to AD.
ABSTRACT
Importance: Recent studies demonstrate that OSA is associated with AD biomarkers. To evaluate
evidence for a causal association between OSA and AD, demonstrating AD-specific neuropathology
changes resulting from increased disease burden in OSA patients is vital.
Objective: To determine the effect of OSA on longitudinal changes in brain amyloid deposition and CSF
Aβ42, t-tau and p-tau181 in NL, MCI and AD older adults.
Design: Longitudinal study. Mean follow up time was 2.52 ±0.51 years.
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Setting: Data used for this study were obtained from the Alzheimer’s disease Neuroimaging Initiative
(ADNI) database (adni.loni.usc.edu) on December 7, 2016.
Participants: 516 NL, 798 MCI and 325 AD subjects.
Exposure: Participant self-reported physician diagnosis of OSA.
Main Outcomes and Measures: Rate of change in brain Aβ42, CSF TAU, PTAU, and CSF Aβ42
burden over time. Multi-level mixed effects linear regression models with randomly varying intercepts
and slopes were constructed to test whether the rate of change in biomarker data differed between subjects
with and without OSA. The final models were adjusted for age, sex, BMI, CPAP use, APOE e4 status,
and history of chronic medical conditions.
Results: The self-reported prevalence of OSA in the 3 study cohorts was as follows: NL (6%), MCI
(13%), AD (7%). Across all groups, mean ages of OSA+ and OSA- were 72.3 ±7.1 and 73.9 ±7.3
respectively. Females were 49% in the NL group, 40% in the MCI group, and 37% in the AD group. In
NL and MCI groups, the annual rate of AD biomarker burden change over time, indicated that OSA+
subjects experienced faster increase in brain Aβ-42 (B = - .06, 95% CI, -.09, -.04 for both), CSF TAU (B
= -2.89, 95% CI, -3.51 to -2.29 and B = -1.89, 95% CI, -2.91, -.87, respectively), CSF PTAU (B = -1.21,
95% CI, -1.71, -.74 and, B = -1.48, 95% CI, -2.05, -.94, respectively), and a faster decrease in CSF Aβ-42
(B = 3.93, 95% CI, 3.56, 4.31 and B = 2.69, 95% CI, 2.02, 3.36, respectively); compared to OSAsubjects, over the follow-up period.
Conclusion and Relevance: OSA appears to accelerate increases in brain amyloid deposition, CSF TAU
and PTAU and decreases in CSF biomarkers burden, over time, both in elderly Cognitive Normal and
MCI individuals. Clinical interventions aimed at OSA, such as treatment with CPAP or dental appliances,
in cognitive normal and MCI patients, could possibly slow the progression of cognitive impairment to AD
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INTRODUCTION
Obstructive Sleep Apnea (OSA) and Alzheimer’s disease (AD) are both common chronic disease
conditions in older adults. OSA affects between 19% and 57% of individuals aged over 65.1-4 By 2050,
the incidence of AD in the U.S is expected to approximate a million people each year, with a total
estimated prevalence of 11 to 16 million people.5 Both OSA and AD cause significant morbidity and
mortality to those afflicted,6-8 and have very high socio-economic burden worldwide.5,8-16 It is therefore
pertinent that preventive and/or treatment efforts targeting both disease conditions are consolidated to
create a better quality of life in older adults.
OSA is characterized by intermittent partial or complete breathing cessation during sleep,
occurring from narrowing of various upper airway sites.1 OSA related hypoxemia and sleep fragmentation
have been implicated as possible links between OSA and AD, with recent studies demonstrating
associations between OSA and AD biomarkers in cognitive normal (NL) and MCI older adults.17-21
Clearly distinguishing whether OSA individuals with normal cognition or MCI are at heightened risk to
develop AD is critical to our ultimate mission of preventing AD.
AD biomarkers serve as in-vivo indicators of particular AD pathologies.22-24 They can be used in
the clinical setting to predict future clinical course of AD. 25,26 PET amyloid imaging of significant Aβ
load and significant levels of cerebrospinal fluid (CSF) Aβ42 are robust predictors of the development of
AD in at risk populations’ i.e. cognitive normal to amnestic mild cognitive impairment (aMCI) and MCI
to AD.25,26 Aβ deposition commences many years prior to AD symptoms’ onset27,28 while MRI brain
imaging show abnormalities later in the disease trajectory.29 This suggests a time-dependent risk of
developing AD from amnestic MCI. Significant increases of CSF P-tau have been demonstrated in AD
patients compared with controls.30 P-tau in CSF is a measurable core marker of AD.31 Since crosssectional studies demonstrate that OSA is associated with AD biomarkers, we further examined OSA’s
effect on longitudinal changes of these biomarkers, especially since they have been shown to predict timeto-progression from MCI to AD.32 Demonstrating associations between OSA and AD-specific
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neuropathology changes, progression or worsening consolidates the evidence for a potential causal
relationship between OSA and AD.
METHODS
Data used in the preparation of this article were obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a
public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of
ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography
(PET), other biological markers, and clinical and neuropsychological assessment can be combined to
measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Thus
far, ADNI has recruited over 2,000 adults aged 55 to 90 years, consisting of cognitively normal (NL)
older individuals, people with early or late MCI, and people with early AD-dementia. Follow-up is at 6
month intervals with duration ranging from 2 to 3 years as specified in the protocols for ADNI-1, ADNI2, and ADNI-GO.
Study Participants
Participant data used for this study were based on medical history from baseline and follow-up
visits obtained from downloaded ADNI data on December 7, 2016. Study participants included 1,639
subjects (516 Cognitive Normal (NL), 798 MCI and 325 AD). Subjects missing important study covariates
were excluded in each of the study groups. Subjects having co-morbid sleep disorders, body mass index
(BMI) change greater than 5 between any follow-up visits, were further excluded, since disturbed sleep,
and BMI are known independent risk factor for cognitive decline and AD, and being overweight is
associated with SDB and AD.33 Other exclusions included subjects who indicated they have had previous
OSA surgery, and those who had a reversible diagnosis (i.e. they had an MCI or AD diagnosis at any time
point but an NL diagnosis or MCI diagnosis at their last visit, thereby allowing us to control for unspecified
diagnoses.
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OSA diagnosis
Presence or absence of OSA was self-reported (variable name: MHDESC). Patients with reported
“sleep apnea” or “OSA” were labeled OSA+ and the remaining participants were considered OSA−. To
ensure that patients were allocated into the correct groups, three physicians (R.O, S.A and O.B.) reviewed
medical history descriptions in the ADNI download, for OSA+ and OSA-.
NL, MCI and AD Diagnosis
ADNI criteria for subject classification is described elsewhere.34 In summary, NL subjects had no
memory complaints while MCI and AD subjects had memory complaints. NL and MCI scored between
24 – 30 on the Mini-Mental State Examination (MMSE) while AD subjects scored between 20 – 26. NL,
MCI and AD subjects had a Clinical Dementia Rating (CDR) score of zero, 0.5 with a mandatory
requirement of the memory box score being 0.5 or greater, and 0.5 or 1, respectively. In addition, MCI
subjects had to have largely intact general cognition and functional performance, and could not qualify for
dementia diagnosis.35 The diagnosis of AD was made using established clinical criteria.36 Patient
diagnosis was recorded at 6-month intervals for 24 months. Subjects were classified as converters if they
converted to AD between 12 months and 24 months and as stable if they did not convert by 24 months.
Florbetapir-PET Imaging Acquisition and Interpretation
ADNI Florbetapir summary data are updated regularly, and uploaded to LONI by the University
of California at Berkeley group.37,38 More information on the methods can be found at:
https://adni.loni.usc.edu/wp-content/uploads/2010/05/ADNI2_PET_Tech_Manual_0142011.pdf,
http://adni.loni.usc.edu/updated-florbetapir-av-45-pet-analysis-results/.
Cerebrospinal Fluid Methods (CSF)
CSF bio-specimen data collection are explained in detail at http://adni.loni.usc.edu/datasamples/biospecimen-data/ and (http://www.adni-info.org/index.php).
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Covariates/potential confounders
Covariates/potential confounders in our study include age, sex, educational status, smoking
status, body mass index (BMI), APOE4 status, hypertension, diabetes and history of cardiovascular
disease.
Data analysis
Given that ADNI data is unbalanced with unequal numbers of measurement for each study
participant, we used multi-level mixed effects linear regression models with normal errors39-41 for our
longitudinal analyses to examine the relationship between OSA and CSF P-tau, and Aβ-42 volumes, as
they provide a flexible and valuable tool for analyzing such unbalanced longitudinal data. Our method
allowed for incorporation of all the available information in the data, and possibly reduced or even
eliminated any bias resulting from an analysis confined to the complete cases.42
Specifically, to determine the specific type of modeling, we examined profile plots for the
biomarker data levels over time, by OSA status (=1 if OSA, =0 if non-OSA) using both the original data
and within-subject residuals. We also examined trajectory plots obtained by subtracting the baseline
measurement from the original measurements (i.e. dij = Yij − Yi1), and examined plots of mean and
variance of the biomarker data at each time point by OSA status. Further, using the slopes as summary
statistics, we conducted different formal tests to compare the two OSA statuses. Based on the above, our
assumption was that the rate of change of biomarker data is approximately linear over time, so we
proposed a parametric model with time as a continuous variable. Using PROC MIXED in SAS software;
we fit the models with randomly varying intercepts and slopes and allowed them to depend on exposure
group (i.e., OSA status). Based on the findings from above, we fit a random coefficients model for the
relationship between OSA status and time using unstructured covariance model. For finding a
parsimonious covariance structure, we fit as many different covariance models and conducted a likelihood
ratio test of each nested model using information criteria for non-nested models. Finally, using the
preferred covariance structure obtained above, we used PROC MIXED to construct a test of whether the
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rate of change in biomarker data differed between the two OSA groups. The final models were adjusted
for age, sex, BMI, CPAP use, APOE e4 status, and history of chronic medical conditions.
These analyses allowed us to examine whether there was significant variation between OSA and
non-OSA subjects in mean AD biomarker level at baseline (intercept), as well as whether significant
variation in the change in AD biomarker level over time (slope) occurred. Furthermore, the covariance
between the baseline AD biomarker level (intercept) and AD biomarker change over time indicated
whether OSA+ or OSA- subjects had experienced a faster increase or decrease in AD biomarker level
over time (significant slope). It also allowed for assessment of significant differences in the rate of change
in AD biomarker level between OSA+ and OSA- patient groups over time. Statistical analyses was
performed using SAS software (version 9.4; SAS Institute Inc., Cary, NC). For sensitivity analyses, we
attempted using the dichotomized brain Aβ level outcome (Aβ+ vs. Aβ-) and examined the rate of change
in AD biomarker level in these populations (SDB+/ Aβ+ vs. SDB-/ Aβ+; SDB+/ Aβ- vs. SDB-/ Aβ-; and
SDB+/ Aβ+ vs. SDB+/ Aβ-; SDB-/ Aβ - vs. SDB-/ Aβ+). However, power issues limited our analyses;
moreover, convergence issues did not permit any estimation with these categorical variables.
RESULTS
Demographic and Clinical Characteristics
Table 3.1 shows the demographic and clinical characteristics of study participants. Overall, the
mean ages of OSA+ and OSA- were 72.3 ±7.1 and 73.9 ±7.3 respectively. Forty-nine percent were female
in the NL group, while in the MCI and AD groups, females consisted of 40% and 37% of the participants
respectively. In the NL group, 6% were OSA+, while 13% of the MCI group and 7% of the AD group
were OSA+. Participants differed markedly in APOE4 status with 28%, 51% and 66% being APOE
positive in the NL, MCI and AD groups respectively. Participants were similar in age, educational status,
BMI, and chronic medical conditions across groups (i.e. NL, MCI and AD), however, within group
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differences (i.e. OSA+ vs. OSA-) existed on these characteristics. Mean follow up time for all participants
was 2.52 ±0.51 years.
Baseline AD Biomarker levels by clinical group and OSA status
Table 3.1 and Figure 3.1 show baseline CSF Aβ-42, TAU, PTAU and Brain Florbetapir PET
imaging levels by NL, MCI and AD group and OSA status without controlling for confounders. There
were significant differences in CSF Aβ-42 levels for both MCI (P =0.04), and AD (P <0.01) groups
respectively, with OSA+ participants having significantly higher levels at baseline. No significant
difference was seen in NL group by OSA status. Significant difference in TAU levels was seen for the
MCI patients (P =0.02), with OSA+ individuals having significantly lower levels. No significant
difference was seen in both the NL and AD groups. For PTAU levels, no significant difference was seen
across all groups. For Brain Florbetapir PET imaging levels, at baseline, there was significant differences
between OSA groups for both NL and MCI participants (P =0.02 for all), with OSA+ participants having
significantly lower brain Florbetapir levels. No difference was seen in AD group. For the MCI group, the
inclusion of an interaction term OSA*APOE4 was also significant (P =0.01).
Rate of Change in AD Biomarker by OSA status
Table 3.2 reports the covariance parameter estimates and between subject (i.e. OSA+ vs. OSA-)
variation in AD biomarker levels over time.
Brain Aβ-42 levels
In NL participants, there was significant variation by OSA status in the annual change in brain
Florbetapir PET volumes over time (slope) (mean SUVR; B = 0.06, p < .0001). The covariance between
the baseline brain Florbetapir level and the annual brain Florbetapir volume change over time was -.06,
indicating that OSA+ subjects experienced faster increase in brain Aβ-42 deposition over time (p < .0001)
when compared to OSA- subjects. In MCI participants, there was also significant variation by OSA status
in the annual change in brain Florbetapir volumes over time (slope) (mean SUVR; B = 0.08, p < .0001).
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The covariance between the baseline brain Aβ-42 level and the annual brain Aβ-42 volume change over
time was -.006, indicating that OSA+ subjects experienced faster increase in brain Aβ-42 deposition over
time (p < .0001) when compared to OSA- subjects. For the MCI group, the inclusion of an interaction
term OSA*APOE4 was also significant (P =0.01) with APOE4+/OSA+ individuals showing a faster
increase in brain Aβ-42 compared to APOE4-/OSA- patients. No significant variation in the change in
brain Florbetapir PET volumes by OSA status over time was seen for the AD group.
CSF Aβ-42, TAU and PTAU levels
For the NL and MCI groups, there was significant variation in the annual change in CSF Aβ-42
by OSA status (mean SUVR; B = -2.708, mean SUVR; B = -2.264, p < .0001 for all respectively) over
time. Significant differences in the annual change in TAU and PTAU levels over time (slope) were also
seen in both groups. Covariance parameters between the baseline CSF Aβ-42, TAU and PTAU volume
change over time indicated that OSA+ subjects experienced a faster decrease in CSF Aβ-42 and increases
in TAU and PTAU volumes over time (p < .0001 for all) compared to OSA- participants, in both the CN
and MCI groups (Table 3.2). No significant variations in the change in CSF Aβ-42, TAU and PTAU over
time was seen for the AD group.
DISCUSSION
Major findings from this study include the following:
i.

At baseline, OSA+ patients had significantly higher CSF Aβ-42 in the MCI group; and lower
brain Florbetapir PET in NL and MCI groups; and lower TAU levels in the MCI group,
compared to OSA- patients.

ii.

Longitudinally, there was significant differences in the annual rate of change in brain Florbetapir
PET, CSF Aβ-42, TAU and PTAU levels over the follow up period for the NL and MCI group

iii.

OSA+ subjects experienced significantly faster increase in brain Aβ-42, TAU and PTAU levels
and a faster decrease in CSF Aβ-42 over the follow-up period in both the NL and MCI groups.
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iv.

For the MCI group, APOE4+/OSA+ individuals showed a faster increase in brain Aβ-42
compared to APOE4-/OSA- patients

Baseline AD Biomarker levels by clinical group and OSA status
At baseline, the data showed that OSA+ patients had significantly higher CSF Aβ-42 and lower
brain Aβ-42 in NL and MCI groups, and lower TAU levels in the MCI group, compared to OSA- patients.
Theoretically, this may be attributed to slow wave sleep (SWS) occurring during non-rapid eye movement
(NREM) sleep, a known Aβ modulator.43-45 Sleep is involved in the clearance of Aβ,45 and fragmented
SWS limits brain Aβ clearance, thereby leaving higher levels that reflect in the CSF.46,47 At cross-section,
disrupted SWS has been shown to be associated with higher CSF Aβ-42 in middle-aged48,49 and older
adults.50 It is also important to note that CSF tau protein pathology and CSF Aβ-42 burden may not be
specific to AD in these participants.51 The effect of normal aging in NL subjects on CSF turnover and
brain Aβ-42 clearance is still not fully understood.52,53 Furthermore, cross-sectional data show little
evidence for an association between age and CSF Aβ-42.54,55 It is also noteworthy that the functional
significance of high CSF Aβ42 levels is not fully known.
Rate of Change in AD Biomarker by OSA status
The major objective of this study was to examine the effect of OSA on longitudinal changes in
brain amyloid deposition, and AD CSF biomarkers. There were significant differences in the annual rate
of change in brain Florbetapir PET, CSF Aβ-42, TAU and PTAU levels over the follow-up period for the
NL and MCI group, with OSA+ subjects experiencing significantly faster increase in brain Florbetapir
PET, TAU and PTAU levels and a faster decrease in CSF Aβ-42. The direction of these longitudinal
changes are in cognizance with emanating evidence-linking disturbed sleep, OSA with AD pathogenesis.
Self-reported sleep duration and quality has been shown to be associated with higher brain Aβ-42
burden.19 MCI individuals with higher apnea-hypopnea index and oxygen desaturation index
demonstrated higher brain Aβ-42 burden globally and regionally in the precuneus.20 A recent study by
Yun et al56 examined whether OSA increased brain amyloid burden relative to controls in middle-aged
172

participants from the Korean Genome and Epidemiology Study. After adjusting for potential confounders,
OSA patients had a higher brain amyloid burden in the right posterior cingulate gyrus and right temporal
cortex, relative to controls, suggesting that OSA may have been responsible for these findings. Bu et al.17
examined whether hypoxia indices in OSA was associated with serum amyloid (Aβ40, Aβ42), total tau
and phosphorylated tau 181 (P-tau 181) comparing their levels with controls. Results from this study
demonstrated significantly higher levels of serum Aβ40, Aβ42, total Aβ and P-tau 181 in OSA patients
compared to control. Hypoxia indices including apnea-hypopnea index, the oxygen desaturation index,
and the mean and lowest oxyhemoglobin saturations correlated positively with Aβ40, Aβ42, and total Aβ
in OSA patients, suggesting that hypoxia possibly effects AD pathogenesis. In a population of MCI
individuals, Liguori et al57 compared CSF β-amyloid42, tau proteins, and lactate levels in OSA versus
CPAP treated OSA and controls. Findings from the study demonstrated lower CSF β-amyloid42, higher
lactate levels and t-tau/ Aβ42 ratio compared to controls and CPAP treated OSA patients. Controls and
CPAP treated OSA MCI patients had similar AD biomarker levels. These findings suggest that OSA may
effect early AD biomarker changes that may be susceptible to CPAP treatment.
In our study, among MCI patients, APOE4+/OSA+ individuals showed a faster increase in brain
Aβ-42 compared to APOE4-/OSA- patients, suggesting that the APOE4 allele may be a moderator of the
association between OSA and AD. In a population of cognitive normal (NL) older adults, Osorio et al18
demonstrated an association between intermittent hypoxia and increases in CSF T-Tau, P-Tau and Aβ42
in ApoE3+, suggesting that hypoxia may be responsible for changes in the AD biomarkers in this
population. In ApoE4+ subjects, OSA severity tended towards lower CSF Aβ42 levels. There was no
difference in the rate of biomarker change in the AD group by OSA status. This may be because in AD
patients, risk profile is possibly linear with brain atrophy until it reaches a threshold thereby exhibiting a
ceiling effect at higher levels of brain Aβ.32 OSA’s effect as it relates to AD biomarker changes may
therefore be attenuated or have reached its maximum.
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Strengths and Limitations
Our study possesses several strengths including a well-defined cohort, and objective assessment
of CSF P-Tau, Hippocampal atrophy and β-amyloid burden, which allowed for a high degree of certainty
regarding measurement of our outcome.58 Furthermore, our statistical analytic methods were robust with
respect to unbalanced number of observations per subject over time. However, we were limited by our
measurement of OSA since this was self-reported. It is known that self-reported sleep measures can be
impacted by diminished cognition59 and in certain situations might not be correlated with objective
measurements using polysomnography or wrist actigraphy.60 Moreover any positive findings from our
study will need to be replicated using objective measures of sleep function. The ADNI racial demographic
is largely white; as such this limits the generalizability of our findings to other racial populations.
CONCLUSIONS
OSA appears to accelerate increases in brain amyloid deposition, CSF TAU and PTAU and
decreases in CSF biomarkers burden, over time, both in elderly Cognitive Normal and MCI individuals.
Sleep fragmentation and/or intermittent hypoxia from OSA are likely candidate mechanisms. Thus,
clinical interventions aimed at OSA, such as treatment with CPAP or dental appliances, in cognitive
normal and MCI patients, could possibly mitigate or slow the progression of cognitive impairment to AD.
Further research examining mechanisms underlying these observed effects are needed.
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Table 3.1: Descriptive Characteristics of Participants by Obstructive Sleep Apnea Status at
Baseline
Cognitive Normal
Characteristics
All
Number of participants (%)
516 (100)
Female gender, number (%)
253 (49)
Age, years, median (interquartile range)
74 (71, 78)
APOE positive, number (%)
145 (28)
Education, years, median (interquartile range)
16 (14, 18)
BMI (kg/m2)
27.2 ± 4.8
Hypertension, number (%)
251 (49)
Diabetes, number (%)
45 (9)
Thyroid Disease, number (%)
112 (22)
Respiratory Disease, number (%)
123 (24)

OSA487 (94)
241 (49)
71 (70, 78)
140 (29)
16 (14, 18)
27.1 ± 4.7
235 (48)
40 (8)
109 (22)
100 (21)

OSA+
29 (6)
9 (32)
71 (70, 76)
5 (17)
16 (15, 18)
29.8 ± 5.9
16 (55)
5 (17)
3 (10)
23 (79)

209 (155,
241)

226 (199, 259)

59 (45 83)
27 (20, 42)
1.1 (1.0, 1.2)

56 (48, 84)
27 (20, 32)
1.0 (1.0, 1.0)

OSA695 (87)
297 (43)
71 (70, 78)
368 (53)
16 (14, 18)
26.5 ± 4.4
337 (48)
57 (8)
133 (19)
133 (19)

OSA+
103 (13)
25 (25)
71 (70, 76)
42 (41)
16 (14, 18)
29.4 ± 5.3
58 (56)
18 (17)
23 (22)
62 (60)

153 (130,
209)

150 (128,
206)

169 (139, 214)

80 (54, 116)
36 (23, 51)
1.2 (1.0, 1.4)

81 (54, 122)
37 (23, 52)
1.2 (1.0, 1.4)

67 (51, 97)
32 (21, 44)
1.1 (1.0, 1.3)

OSA303 (93)
113 (37)
76 (71, 80)

OSA+
22 (7)
6 (27)
71 (64, 76)

210 (155,
241)

CSF-ABETA pg/ml median (interquartile range)

TAU pg/ml median (interquartile range)
59 (45, 84)
PTAU pg/ml median (interquartile range)
27 (20, 40)
Aβ, median (interquartile range)
1.1 (1.0, 1.2)
Mild Cognitive Impairment
Characteristics
All
Number of participants (%)
798 (100)
Female gender, number (%)
319 (40)
Age, years, median (interquartile range)
74 (68, 79)
APOE positive, number (%)
410 (51)
Education, years, median (interquartile range)
16 (14, 18)
BMI (kg/m2)
26.9 ± 4.6
Hypertension, number (%)
395 (49)
Diabetes, number (%)
75 (9)
Thyroid Disease, number (%)
156 (20)
Respiratory Disease, number (%)
195 (24)
CSF-ABETA pg/ml median (interquartile range)
TAU pg/ml median (interquartile range)
PTAU pg/ml median (interquartile range)
Aβ, median (interquartile range)

Alzheimer's Disease
Characteristics
All
Number of participants (%)
325 (100)
Female gender, number (%)
119 (37)
Age, years, median (interquartile range)
76 (71, 80)
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APOE positive, number (%)
Education, years, median (interquartile range)
BMI (kg/m2)
Hypertension, number (%)
Diabetes, number (%)
Thyroid Disease, number (%)
Respiratory Disease, number (%)
CSF-ABETA pg/ml median (interquartile range)
TAU pg/ml median (interquartile range)
PTAU pg/ml median (interquartile range)
Aβ, median (interquartile range)

216 (66)
16 (14, 18)
25.9 ± 4.6
165 (51)
32 (10)
65 (20)
67 (21)
132 (116,
151)
80 (54, 116)
42 (33, 61)
1.4 (1.3, 1.5)

198 (65)
16 (14, 18)
25.6 ± 4.3
149 (49)
30 (10)
61 (20)
52 (17)
115 (96,
182)
67 (51, 97)
41 (33, 61)
1.4 (1.3, 1.5)

18 (82)
16 (14, 18)
29.0 ± 6.8
16 (73)
2 (9)
4 (18)
15 (68)
115 (79, 151)
81 (54, 122)
54 (35, 66)
1.4 (1.3, 1.6)

Abbreviation: Aβ: amyloid beta, APOE: Apolipoprotein epsilon, BMI: body mass index, CSF: cerebrospinal fluid, TAU: tau
protein, PTAU: phosphorylated tau

Table 3.2 Covariance Parameter estimates and Between Subject variation in AD Biomarker
Deposition
Parameters

Estimate

95% CI

P-value

OSA+ vs. OSA- (Cognitive Normal Patients)
β-Amyloid Burden over time (slope)
β-Amyloid Burden over time (covariance)

0.06
-0.06

.02, .11
-.09, -.04

<.0001
<.0001

CSF Aβ-42 volume over time (slope)
CSF Aβ-42 volume over time (covariance)

-2.71
3.93

-3.11, -2.35
3.56 - 4.31

<.0001
<.0001

CSF TAU volume over time (slope)
CSF TAU volume over time (covariance)

3.68
-2.89

3.31 - 4.07
-3.51, -2.29

<.0001
<.0001

CSF PTAU volume over time (slope)
CSF PTAU volume over time (covariance)

1.22
-1.21

1.02 - 1.42
-1.71, - .74

<.0001
<.0001

OSA+ vs. OSA- (Mild Cognitive Impairment Patients)
β-Amyloid Burden over time (slope)
β-Amyloid Burden over time (covariance)
CSF Aβ-42 volume over time (slope)
CSF Aβ-42 volume over time (covariance)

0.08
-0.06
-2.62
2.69

.05, .12
-.09, -.04
-3.23, -2.03
2.02, 3.36

<.0001
<.0001
<.0001
<.0001

CSF TAU volume over time (slope)
CSF TAU volume over time (covariance)

2.21
-1.89

1.58, 2.86
-2.91, -.87

<.0001
<.0001

CSF PTAU volume over time (slope)
CSF PTAU volume over time (covariance)

1.74
-1.48

1.22, 2.27
-2.05, -.94

<.0001
<.0001

OSA+ vs. OSA- (Alzheimer's disease Patients)
β-Amyloid Burden over time (slope)
β-Amyloid Burden over time (covariance)

0.07
-0.29
182

-1.19, 1.33
-2.07, 1.49

0.33
0.31

CSF Aβ-42 volume over time (slope)
CSF Aβ-42 volume over time (covariance)

-1.11
-1.14

-3,31, 1.09
-3.38, 1.63

0.53
0.56

CSF TAU volume over time (slope)
CSF TAU volume over time (covariance)
CSF PTAU volume over time (slope)
CSF PTAU volume over time (covariance)

0.26
-0.15
0.94
-0.16

-1.02, 1,28
-1.94, 1.64
0.23, 1.65
-1.66, 1.34

0.47
0.47
0.11
0.11

Abbreviation: Aβ: amyloid beta, APOE: Apolipoprotein epsilon, BMI: body mass index, CSF: cerebrospinal fluid, TAU: tau
protein, PTAU: phosphorylated tau

Models were adjusted for age, sex, BMI, CPAP use, APOE e4 status, and history of chronic medical
conditions.
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Figure 3.1: Baseline Alzheimer Disease Biomarker burden and Brain
Aβ-42 levels in Cognitive Normal subjects by OSA status
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Figure 3.2: Baseline Alzheimer Disease Biomarker burden and Brain
Aβ-42 levels in Mild Cognitive Impairment subjects by OSA status
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Figure 3.3: Baseline Alzheimer Disease Biomarker burden and Brain
Aβ-42 levels in Alzheimer disease subjects by OSA status

186

SECTION 4
Obstructive Sleep Apnea: A Distinct Physiological Phenotypic Risk Factor in older adults with Cognitive
decline and Alzheimer’s disease
ABSTRACT
Introduction: Studies suggest that Obstructive Sleep Apnea (OSA) in the elderly may result in varying
functional outcomes relative to OSA in the middle-aged. Therefore, understanding and appreciating the
heterogeneity of OSA and its outcomes in distinct age groups especially at it relates to cognition,
subsequent cognitive decline and Alzheimer disease (AD), is critical in mitigating the deleterious effects
of OSA.
Methods: In this review, we integrated over 3 decades of research examining OSA and cognition; OSA
and subsequent cognitive decline; and OSA and AD, with particular focus in appreciating the
heterogeneity of OSA and its outcomes in distinct age groups. A systematic literature search of
bibliographic databases including PubMed/Medline, Embase, Psych INFO and Cochrane library for
clinical trials, was conducted to identify all eligible studies (published from their onset up until August
31, 2017) that examined associations between OSA and cognitive function, OSA and subsequent
cognitive decline, and OSA and AD
Results: Thirty-four studies examining the association between OSA and cognition, 7 studies examining
the association between OSA and subsequent cognitive decline, and 15 studies examining the association
of OSA and AD or AD pathology were identified by the literature search after applying specific inclusion
and exclusion criteria. The data suggests that OSA is associated with greater cognitive deficits in middle187

age adults than in older adults and the elderly; greater risk of subsequent cognitive decline in middle-aged
adults than in older adults and elderly; and in older adults with MCI rather than in healthy older adults,
OSA may be the critical correlate of cognition.
Conclusion: OSA may be age-dependent in older adults (60 – 70 years old) and the elderly (70 years and
above) and is associated with neurodegenerative diseases particularly, cognitive decline and AD. In the
middle-aged (30 – 60 years old), the data suggests that OSA may be age-related and presents with a
distinct phenotype, with cardiovascular, and possibly metabolic effects. Intermittent hypoxia and sleep
fragmentation are two main processes by which OSA induces neurodegenerative changes.

INTRODUCTION
Cognitive decline in older adults and Alzheimer’s disease (AD) both have debilitating effects on
individuals affected, with significant socioeconomic implications.1-4 It is well known that advanced age is
the most notable risk factor for cognitive decline and AD. With projected substantial increase in the
ageing population, it is pertinent that efforts directed at comprehending risk factors of cognitive decline
and AD be consolidated. There is increasing evidence in recent years linking cognitive decline and AD to
various sleep problems and disorders.5-8 Notably, the link between cognitive impairment and Obstructive
Sleep Apnea (OSA) is well-established,9-12 and recent evidence suggest that a longitudinal risk between
OSA, cognitive decline and AD exist.13-15 It is therefore vital to clearly understand the distinct and unique
relationship OSA has with cognitive decline and AD in the elderly as this will help inform prevention and
treatment strategies of both OSA and AD.

Age-related and Age-dependent OSA co-morbidities
Obstructive sleep apnea (OSA) is characterized by intermittent hypoxemia, sleep fragmentation
and intrathoracic pressure changes.16,17 OSA is an issue of public health significance, because it is highly
prevalent,18-21 results in serious morbidity and significant mortality, 22-26 and has a high socio-economic
188

impact.27,28 Studies suggest that OSA in the elderly may result in varying functional outcomes relative to
OSA in the middle-aged. Therefore, understanding and appreciating the heterogeneity of OSA and its
outcomes in distinct age groups is critical in mitigating the deleterious effects of OSA.
Bliwise et al.29 in their study using the Bay Area Sleep Cohort described two peak incidences of
OSA, one being age-dependent and the other being age-related. The concept describes OSA as an agedependent condition in the elderly, relative to OSA being an age-related condition in the middle-aged.
OSA affects 3–7% of the middle-aged population and becomes more prevalent with increasing age.20,30-37
In middle-aged individuals, Bliwise noted that OSA is thought to show an age-related occurrence
conferring a specific period of susceptibility,38,39 in association with disparate morbidities. Age-related
diseases and disorders are not particularly related to the process of aging, occurring at a distinctive
age/age-group and then lessening in frequency with increasing age (e.g. multiple sclerosis and
amyotrophic lateral sclerosis).29
Conversely, in the elderly, the prevalence of OSA ranges from 30-80%,32,40-46 contingent on the
definition of OSA. The significance of these high rates in the elderly is ambiguous; while certain studies
suggest reduced mortality with increasing age,47 others suggest otherwise.48 However, the pathogenesis of
OSA somewhat appears to involve normal aging with exponential increases in mortality and morbidity
with advancing age.49,50 This physiologic susceptibility with increased incidence with chronological age
suggests that OSA is age-dependent in the elderly. Mechanisms underlying how aging increases the risk
of OSA are not completely understood. The effects of advancing age are generally considered to function
with other physiologic systems experiencing aging.51,52 Notable factors in OSA pathogenesis during
aging include an extremely collapsible airway, limited upper airway dilator muscle activity, diminished
respiratory arousal threshold, and a precarious ventilatory control system.35,53,54 Furthermore, agedependent changes in lung function as reported in cross-sectional studies,55-57 are associated with
increments in OSA frequency.
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Much focus on OSA’s age-dependence in the elderly has been in cardiovascular outcomes
relative to cognitive outcomes. However, the various co-morbidities associated with increasing age in
OSA increases susceptibility to cognitive decline.58,59 Cardiovascular outcomes of OSA such as
hypertension, coronary heart disease, and congestive heart failure; 25,60,61 stroke; 62-64 multiple
inflammatory and metabolic effects including diabetes; 65-68 are associated with increased severity of
OSA, and may be more likely to occur in young and middle-aged (30 – 70 years), rather than older
populations.69-73 In young and middle-aged adults, substantive evidence exists establishing relationships
between OSA and cognitive function, including areas such as memory, motor, vigilance and executive
functions.74-76 Studies examining cardiovascular outcomes of OSA in the elderly show varying findings.
Some studies77-79 report increased mortality and incidence of stroke in older adults while other
studies47,48,80 report decreased mortality with age in OSA patients compared to the general population. In
the elderly, multiple studies demonstrate associations between OSA and cognitive decline.15,81-83 We
demonstrated that in the elderly, OSA patients had an earlier age of cognitive decline to MCI and to AD
than non-OSA controls,84 and showed that individuals with OSA were more than two times more likely to
have AD compared to non-OSA individuals in a recent meta-analysis.5 A meta-analysis of cross-sectional
studies also concluded OSA-AD associations, such that AD patients were at an increased risk of
presenting with OSA than cognitively normal individuals.85 Of particular concern is that longitudinal
studies also provide evidence of an association between OSA and cognitive decline. A 5-year prospective
study of older women (mean ±SD age: 82.3 ±3.2 years) found elevated oxygen desaturation index (≥15
events/ hr) to be associated with increased risk of developing mild cognitive impairment (MCI) or
dementia.15 In general, the literature regarding OSA, cognitive function, cognitive decline and AD have a
relationship with advancing age, suggesting that age may be an effect modifier of these association and
that OSA may present as a distinct physiologic phenotypic risk factor in older adults with cognitive
decline and AD.
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Review Objective
Recent narrative reviews on OSA, Cognitive Decline and AD described the cognitive profiles
found in association with OSA in children and adults (young, middle-aged and elderly adults);9,86
explored mechanisms, neurobiology and treatment for geriatric psychiatry audience; and discussed
probable explanatory mechanisms linking OSA, depression and cognitive dysfunction. 87-89 Other
narrative discussions focused on the probable explanatory mechanisms linking OSA to dementia.82
Previous systematic and meta-reviews focused on how OSA affects specific neurocognitive domains,
producing inconsistent74,90 and sometimes non-conclusive findings.12,91 The only meta-review focusing on
older adults reported a small association between OSA and cognitive dysfunction and suggested that some
individuals may be more at risk of adverse cognitive effects.92
In this review, we integrate over 3 decades of research examining OSA and cognition; OSA and
subsequent cognitive decline; and OSA and AD; with particular focus in appreciating the heterogeneity of
OSA and its outcomes in distinct age groups. We note that the data suggests that OSA may be agedependent in older adults (60 – 70 years old) and the elderly (70 years and above) and is associated with
neurodegenerative diseases particularly, cognitive decline and AD. In the middle-aged (30 – 60 years
old), the data suggests that OSA may be age-related and presents with a distinct phenotype, with
cardiovascular, and possibly metabolic effects. We also explore and describe possible mechanisms linking
OSA as a precipitator of AD pathogenesis especially in the elderly, by systematically reviewing clinical
and epidemiological evidence of such an association. Where findings are discrepant, we focus on
methodological differences among studies.
METHODS
Search strategy

A systematic literature search of bibliographic databases including PubMed/Medline, Embase,
Psych INFO and Cochrane library for clinical trials, was conducted to identify all eligible studies
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(published from their onset up until August 31, 2017) that examined associations between OSA and
cognitive function, OSA and subsequent cognitive decline, and OSA and AD. Our search strategy utilized
the combination of terms characterizing cognitive function, cognitive impairment, AD or AD pathology
as the dependent variables, OSA as the independent variable and a third set of terms specifying specific
study types including clinical and epidemiological studies. For the dependent variables, search terms
included cognition, cognitive function, executive function, neuropsychological function, cognitive
decline, mild cognitive impairment, Alzheimer’s disease, AD biomarkers and amyloid beta. For the
independent variable, search terms included sleep apnea; sleep disordered breathing and obstructive sleep
apnea. All terms were combined with the Boolean Logic operator OR, within each set, and the three sets
were combined using AND. Furthermore, we performed a manual search of references of included
articles to identify relevant references not identified by the automated search. Indexing and management
of the references was done using EndNote X7 (Thompson Reuters, New York, NY). This review was
conducted adhering to the preferred reporting items for systematic reviews and meta-analyses (PRISMA)
statement by Moher et al.93

Selection criteria
Eligible studies for this review had to meet the following selection criteria: 1) be original research
investigations examining associations between OSA and cognition, OSA and cognitive decline, and OSA
and AD; 2) conducted in humans; 3) include both healthy controls and OSA patients and conducted
between group comparisons. Studies without controls that conducted within group comparisons based on
OSA severity were also considered; 4) conducted in adults (young, middle-aged and older); 5) studies
examining cognition or cognitive decline as an outcome must have utilized objective neuropsychological
cognitive tests; 6) studies examining AD or AD pathology as an outcome must have utilized objective
measures; and 7) diagnosis of OSA must have been based on polysomnography. Excluded studies include
case reports, case series, narrative or systematic reviews, abstracts or editorials. Studies conducted in
OSA patients that did not include relevant cognitive parameters (i.e. executive, motor, verbal, attention,
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memory) and those that examined the effects of CPAP but did not include an examination of OSA vs.
control at baseline, were also excluded.

Reviewing Procedure and Data Extraction
Bibliographic data base searches were conducted first in May 2017. Another search was
conducted in August 2017 to identify manuscripts published between May and August 2017. Independent
examination of all titles and abstracts of identified eligible studies by the search strategy was performed
by two authors (OB and XX) using EndNote X7. Selected articles at this stage were further assessed by
retrieving and reading the manuscript’s full text. Identified articles for the review were assessed for
possible inclusion by the same two authors. Where there were discordant decisions regarding inclusion, a
resolution was reached by two other authors (XX and XX). Two authors (OB and XX) performed data
extraction for each reference. Extracted fields included authors, year of publication, study design, study
population, age, exposure and outcome assessment, statistical analytic methods used, covariates, and the
main findings of the study. Two other authors (XX and XX) resolved discrepancy in the information
extracted. Reviewers were not blinded to the funding, authors, or institutions. Figure 1 shows a summary
of the study selection and retrieval process.

Assessment of Study Quality
We assessed the quality of included studies in this review using an adaptation from the modified
version of the Newcastle-Ottawa scale (NOS) for quality assessment of the observational studies,94 with
addition of new items relevant to this review. Following adaptations from previous reviews, parameters
used for the quality assessment included well-specified hypothesis, study design type, appropriately
described sample, sample size, assessment and definition of OSA, cognitive impairment or AD, statistical
analytic methods used, and approach used to adjust for potential confounders. We utilized a star rating
system with increasing number representing increasing quality. Tables 1-3.
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RESULTS
OSA and Cognition (Cross-sectional studies)
Main findings
Table 4.1 summarizes the findings from 34 studies that examined the association of OSA and
cognitive function at a single time point. Most studies that were conducted in the middle-aged adults
consistently linked OSA and deficits in attention,95-99 memory,100-102 executive function,99,103,104 motor
function,99 reaction time,105 psychomotor vigilance106 and information processing speed.107 Explanations
and plausible mechanisms responsible for these findings in the middle-aged include daytime sleepiness or
drowsiness from fragmented sleep because of frequent apneic episodes,108-110 and hypoxia.111,112
Specifically, deficits of attention and memory may be due to fragmented sleep and excessive daytime
sleepiness,102,113 while motor function, executive function, reaction time and vigilance may be related to
the severity of hypoxemia.114-116 For example, studies where middle-aged adults with OSA who
complained of excessive daytime somnolence were compared to healthy controls, consistently showed
scores in memory and attention that were lower than normal.99,100,102 Furthermore, correlation analysis
revealed that daytime somnolence correlated with attention while nocturnal hypoxemia correlated with
executive function and visual-constructive abilities.99
Studies in the middle-aged that examined the effect of CPAP treatment on cognitive impairment
after both a short and long-term treatment period revealed conflicting results. Studies included in our
review administered CPAP and assessed for its effect after 3-months,96,97 6 months117 and 12 months.98
After 3-months of CPAP treatment, Canessa et al.96 observed significant improvements involving
memory, attention, and executive functioning in OSA patients, while Saunamaki et al.117 did not show
improvements in OSA patients’ visuospatial organizational skills or their mental set-shifting performance,
after a 6 months CPAP treatment. Variations in methods of assessing cognitive decline, and the possible
presence of confounding variables, such as rapid eye movement (REM) and slow-wave sleep (SWS)
occurring after first night of CPAP use could be responsible for the discrepant findings.
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Castronova et al.96 employed imaging techniques using diffused tensor imaging (DTI) to examine
changes in white matter integrity and cognition following CPAP treatment in severe OSA patients. Pretreatment OSA patients showed impairments in most cognitive areas, and diffuse reduction of white
matter integrity. Limited changes of white matter were seen after 3 months of CPAP. However, the
authors report an almost complete reversal of white matter abnormalities over the course of 12 months
CPAP treatment. In addition, significant improvements involving memory, attention, and executivefunctioning paralleled white matter changes after treatment. Other studies using imaging techniques
showed regions of diminished grey matter volume in the left hippocampus, frontal structures of the brain
and within more lateral temporal areas in patients with OSA after CPAP treatment.97,118,119 These findings
suggest that cognitive impairment seen in middle-aged patients with moderate to severe OSA is
associated with damage to brain tissue in areas involved in several cognitive tasks. In addition, nocturnal
intermittent hypoxia and fragmented sleep could be culprits in cognitive and brain structural deficits in
OSA.
Studies that restricted their populations to older adults or whose mean age occurred in that range
(i.e., ages 61 – 70) generally show weaker results with cognition where associations were identified.
Otherwise the plurality of findings in studies where potential confounders were accounted for were null
findings. First, consider evidence for hypoxia indices and executive, memory and attention. Boland et
al.120 in their study examined the effect of Respiratory Disturbance Index (RDI) values on attention,
executive function and memory in 1700 subjects free of clinically diagnosed SDB who underwent athome polysomnography (PSG) as part of the Sleep Heart Health Study (SHHS). This study controlled for
age, education, occupation, field center, diabetes, hypertension, body-mass index, use of CNS
medications, and alcohol drinking status, and found no association between the RDI and any of the three
cognitive function measures assessed. Foley et al.121 assessed the association between sleep-disordered
breathing and cognitive functioning in an elderly cohort of Japanese-American men and found no
association between sleep-disordered breathing and memory function, concentration, and attention.
Phillips et al.122 and Sforza et al.123 also had null findings between AHI findings and global cognition,
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attention, executive function, memory, language and motor functions. Dlugaj et al.124 examined the
association between Mild Cognitive Impairment (MCI) and MCI sub-types and SDB severity and found
no association. Except for Sforza and Dlugaj, the other studies made use of a healthy population and this
may have contributed to this finding.
On the contrary, other studies conducted in older adults showed associations between OSA and
delayed verbal memory,125,126 non-verbal IQ memory delayed recall,127 executive function, and
attention128,129 and decreased vigilance.130 As earlier specified most of these studies were only able to
demonstrate relatively weak associations. For example, Yesavage et al.,129 Terpening et al.,131 and Berry
et al.,127 demonstrated effects between hypoxia measures and cognitive measures that were minimally
significant. Perhaps OSA in older adults with MCI rather than in healthy older adults is the critical
correlate of cognition in older adults. Kim et al.132 specifically examined the effect of SDB in older adults
with MCI on language test performance. Individuals with MCI have an increased risk of developing AD.
Although the study found no differences between MCI and control groups on AHI and hypoxia measures,
higher AHI was associated with language test performance among individuals with MCI. These findings
possibly reflect frontal-subcortical pathology in patients with MCI suggesting that susceptibility to a
specific brain damage associated with OSA could increase the risk for AD.
Examination of studies conducted in the elderly (i.e. ages > 70 years) are also contradictory;
however, more recent studies tend to show associations between hypoxemia and executive function or
global cognition. Blackwell et al130 examined SDB and cognition in elderly men and adjusted for age,
race, education, BMI, lifestyle, comorbidities and medication use. Findings from the study showed
significant associations between SDB and cognition. Spira et al.133 conducted a similar study in elderly
women and determined whether the apolipoprotein E (APOE) e4 allele modifies the association. Results
showed that increased AHI was associated with decreased cognition and APOE4 increased this risk by
five times.
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OSA and Cognitive Decline (Longitudinal studies)
Main findings
Table 4.2 summarizes the only seven prospective epidemiological studies that have attempted to
answer this critical question. Six of the studies were in older adults and the elderly while one study
included a mixture of middle-aged, older adults and the elderly.
In older adults and elderly, OSA at baseline may be a weak predictor of cognitive decline. Only
two studies that included older adults and the elderly reported significant cognitive associations with OSA
that were mostly modest. Blackwell et al. conducted a population-based study in a setting that included
six centers in the United States. They included community-dwelling older men without cognitive
impairment at baseline, and followed them for approximately 3 years. Results from the study showed a
modest association between nocturnal hypoxemia and subsequent decline in cognition. Martin et al
utilized a subset of individuals enrolled in the PROgnostic indicator OF cardiovascular and
cerebrovascular events, study (PROOF). They assessed whether cognitive function changes occurred in
untreated elderly SBD patients and without dementia. After an 8-year follow-up, SDB showed a
minimally significant association with decline in the attentional domain and this was more evident in the
patients with an AHI > 30. There were no significant changes in the executive and memory functions over
the follow-up period. In this study chronic hypoxemia accounted for between 4–7% of variance in the
decline in attention. In contrast, Cohen-Zion et al in their study utilizing community-dwelling elderly
individuals with high risk for SDB found no association of hypoxia indices with cognitive decline after
controlling for oximetry, sleep and subjective report. However, a significant association existed between
increases in daytime sleepiness and declining cognitive function. In addition, Lutsey et al utilizing a
subset of individuals from The Atherosclerosis Risk in Communities (ARIC) study, who participated in
the Sleep Heart Health Study (SHHS), examined the effect of OSA and cognitive decline over a 15-year
follow-up. Overall, this study found no evidence that OSA severity, degree of nocturnal hypoxemia, sleep
fragmentation, or habitual sleep duration were associated with subsequent cognitive decline. The
relationship between midlife OSA and later life cognition was also null.
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Studies examining the relationship between OSA and Dementia outcomes tend to be more
consistent in their findings. Yaffe et al in their prospective study of SDB and cognition in elderly women
without dementia at baseline who were a substudy of the Study of Osteoporotic Fractures (SOF) followed
for approximately 5 years, found that elderly women had an 85% increased risk of developing
MCI/Dementia. In another study, Yaffe and her colleagues conducted a retrospective cohort study using
medical record data, and examined the relationship between a diagnosis of sleep disturbance and
dementia in elderly veterans. Sleep disturbance was significantly associated with an increased risk of
dementia and specifically, OSA demonstrated significant associations with increased risk of AD, Vascular
dementia and other dementias combined (frontotemporal dementia, senile dementia, or dementia not
otherwise specified). Furthermore, Chang et al in their retrospective matched-control cohort study that
utilized data from Taiwan’s Health Insurance Database estimated dementia risk in OSA versus non-OSA
patients in individuals 40 years and older, followed for 5 years. Results from the study showed a 70%
increased risk of developing dementia among OSA compared to non-OSA individuals. This study also
demonstrated gender-dependent, age-dependent and time-dependent associations of OSA and dementia.
OSA females were more like to develop dementia; OSA males aged 50-59 (middle-aged) had an
increased risk for developing dementia, while OSA females aged ≥ 70 years (elderly) had a greater risk of
developing dementia, and OSA patients were more likely to develop dementia in the first 2.5 years of
follow-up.
Summary, critique and future research directions
In middle-aged adults, cross-sectional studies mostly demonstrate that OSA is often associated
with cognitive decline. Longitudinal studies demonstrating that OSA can precede cognitive decline in
middle-aged adults are rare, however, the one study that examined this relationship, suggests so.
Nocturnal intermittent hypoxia and fragmented sleep could be culprits in cognitive and brain structural
deficits in middle-aged OSA patients. Studies utilizing brain-imaging techniques suggest that cognitive
impairment seen in middle-aged patients with moderate to severe OSA is associated with damage to brain
tissue in areas involved in several cognitive tasks including grey matter volume in the left hippocampus,
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frontal structures of the brain and lateral temporal areas. CPAP treatment seems to be beneficial however
over a long-term as one study reported an almost complete reversal of white matter abnormalities over the
course of 12 months CPAP treatment.
In older adults and elderly, cross-sectional studies have not consistently demonstrated OSACognition associations and studies that identified such only revealed relatively weak associations. This
distinction and pattern in OSA-Cognition associations in middle-aged, older adults and elderly provides
the foundation for envisioning age-related modification of OSA-cognition relationships. Most of the
studies that examined this relationship in healthy community older adults revealed null associations. On
the contrary, studies examining this association in older adult OSA patients with MCI consistently
showed significant associations of OSA with cognition, suggesting that perhaps OSA in older adults with
MCI rather than in healthy older adults is the critical correlate of cognition in older adults. Longitudinal
studies in older adults and elderly, suggest that OSA at baseline may be a weak predictor of cognitive
decline. However, longitudinal studies examining the relationship between OSA and Dementia outcomes
produced consistent significant findings. This evidence that OSA can possibly precede MCI/AD and that
perhaps OSA in older adults with MCI rather than in healthy older adults is the critical correlate of
cognitive decline in older adults, may indicate that the presence and deposition of the AD biomarker, beta
amyloid, may be a moderator in these relationships. We consider this theme in the remaining sections.
Methodological differences existed among studies reviewed and can be rightly viewed as
limitations in the field of OSA and AD research. Issues related to the single assessment of OSA in
longitudinal studies, absent or incomplete CPAP intervention information during follow-up, and the
possibility that the etiological timeframe relevant for the association between OSA and AD could be
outside the examined period, variability in ways in which cognition was assessed, and issues relating to
selection bias, are all opportunities for future improvements. Many studies utilized clinic patients. It is
clear that the likelihood of clinic attendance in such participants is associated with disturbed sleep.
Therefore, when analyses are conducted on only such participants, biased results are likely the outcome.
In addition, not all studies accounted for the possible role of depression and its symptoms, which may be
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important mediator or confounder of the association between disturbed sleep and cognition.134,135
Therefore, new research in the field should endeavor to separate causality relating to OSA, depression and
cognition.
Despite methodological strengths such as use of PSG sleep measures, and certain long followups, these were not all present in all studies, therefore limiting the strength of causal inferences that can
be made. Lastly, future studies should examine whether these associations are causal, focusing on the
mechanisms responsible for the somewhat different OSA effects seen at different ages or in different
populations.

OSA and Alzheimer’s disease (Cross-sectional studies)
Main findings
Studies examining any association between OSA and a diagnosis of AD were conducted in older
adults and the elderly since most AD diagnoses occur after age 65 (Tables 4.3 and 4.4). The scarcity of
epidemiological studies examining OSA and AD co-morbid associations was noteworthy. The five
studies included were conducted some 2 to 3 decades ago and had varying findings (Table 4.3). Two
studies136,137 demonstrated a significant association for OSA in AD patients relative to controls while
three of the studies had null associations. However, a recent meta-analysis of these studies concluded that
the aggregate odds ratio for OSA in AD vs. healthy control was 5.05 and homogeneous.85 Given the
cross-sectional nature of these analyses, the data cannot be interpreted as suggesting direction of causality
or temporality between OSA and AD. However, it does suggest the possibility of a reciprocal relationship
between these two disorders. OSA possibly facilitates progressive central nervous alterations and
excessive daytime sleepiness in patients and this further increases the risk of cognitive decline or AD
progression in older adults.86
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OSA and AD Pathology
Main findings
Cross-sectional studies
Observational studies of OSA and AD pathology are vital in establishing links between OSA and
AD. If the relationship between OSA and AD is causal then demonstrating AD-specific neuropathology
resulting from increased disease burden in OSA patients can be vital. Cross-sectional studies examining
this association were conducted mostly in older adults and the elderly. We identified two studies
conducted in middle-aged participants (Table 4.4). A recent study by Yun et al138 examined whether OSA
increased brain amyloid burden relative to controls in middle-aged participants from the Korean Genome
and Epidemiology Study. After adjusting for potential confounders, OSA patients had a higher brain
amyloid burden in the right posterior cingulate gyrus and right temporal cortex, relative to controls,
suggesting that OSA may have been responsible for these findings. In this study, examination of regional
differences in cortical thickness were not significant. Bu et al.139 examined whether hypoxia indices in
OSA was associated with serum amyloid (Aβ40, Aβ42), total tau and phosphorylated tau 181 (P-tau 181)
comparing their levels with controls. Results from this study demonstrated significantly higher levels of
serum Aβ40, Aβ42, total Aβ and P-tau 181 in OSA patients compared to control. Hypoxia indices
including apnea-hypopnea index, the oxygen desaturation index, and the mean and lowest oxyhemoglobin
saturations correlated positively with Aβ40, Aβ42, and total Aβ in OSA patients, suggesting that hypoxia
possibly effects AD pathogenesis.
In older adults, all cross-sectional studies examined demonstrated associations between OSA and
AD pathology (Table 3). Osorio et al140 examined whether an association existed between SDB severity,
cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers, and the APOE alleles in cognitively
normal older adults. Findings from the study demonstrated an association between SDB and CSF
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AD- biomarkers. They also found an association between intermittent hypoxia and increases in CSF TTau, P-Tau and Aβ42 in ApoE3+, suggesting that hypoxia may be responsible for changes in the AD
biomarkers in this population of cognitive normal older adults. In ApoE4+ subjects, the study did not
detect significant SDB group differences for Aβ42, T-Tau or P-Tau, though SDB severity tended towards
lower CSF Aβ42 levels. However, participants were at varying stages of preclinical disease amongst the
ApoE4+ subjects. A recent study by Liguori et al141 compared CSF β-amyloid42, tau proteins, and lactate
levels in OSA versus CPAP treated OSA and controls. All participants had MCI. Findings from the study
demonstrated lower CSF β-amyloid42, higher lactate levels and t-tau/ Aβ42 ratio compared to controls
and CPAP treated OSA patients. Controls and CPAP treated OSA MCI patients had similar AD
biomarker levels. These findings suggest that OSA may effect early AD biomarker changes that may be
susceptible to CPAP treatment. Furthermore, in the elderly MCI patients, Spira et al showed that greater
SDB severity was associated with greater brain amyloid burden

Prospective/Longitudinal studies
Lutsey et al142 examined whether diagnosed OSA in the middle-aged was associated with adverse
morphological brain changes 15 years later. They utilized participants from the Atherosclerosis Risk in
Communities Study (ARIC). After accounting for body mass index in a series of multivariate models,
OSA at mid-life was not associated with cerebral markers of dementia or White Matter Hyper intensity
brain volume or regional brain volume changes. This study’s strength is its length of follow-up, since
dementia is known to have a long preclinical duration and middle-aged individuals may represent the
etiological relevant phase, similar to other dementia risk factors including diabetes,143-145 hypertension,146149

and smoking.145,150 Also, use of community based participants rather than small sample sized clinic

participants is also a plus. However, various methodological concerns could have been responsible for
their findings. Selection bias issues could have occurred from loss to follow-up as a third of participants
did not attend follow-up for neurocognitive assessments. The study had relatively few diagnosed severe
OSA patients, necessitating lumping of moderate and severe OSA patients together, which could have
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attenuated any association that could potentially have occurred in severe OSA patients. The study also
did not account for CPAP use or treatment of OSA during the follow-up period. In contrast, Osorio et al14
using Alzheimer’s Disease Neuroimaging Initiative (ADNI) data examined whether SDB was associated
with an earlier onset age at MCI or AD. The study also determined whether CPAP treatment delayed MCI
or AD onset. Findings showed that in all population subsets examined, SDB patients had an earlier onset
age to MCI or AD-dementia. CPAP use also delayed the age of MCI onset. This study utilized a welldefined longitudinal cohort; however, study limitations include the self-reported SDB and CPAP status.

Randomized Controlled Trials
The most effective treatment for OSA is continuous positive airway pressure (CPAP). With
CPAP treatment, OSA patients without dementia show an increase in slow wave sleep (SWS) and rapid
eye movement (REM) sleep.151-154 However, what is the effect of CPAP on sleep parameters and
cognition in AD patients with OSA? All four RCTs identified in this review included elderly participants
(mean age > 70) and reported significant improvements in deep sleep,155 mood,156 cognition,156,157 and
daytime sleepiness158 in OSA patients with AD (Table 4.4). For example, in a randomized placebocontrolled trial, Cooke et al examined the effect of CPAP on sleep parameters in AD patients with OSA.
The researchers administered 3 weeks of CPAP treatment and compared the outcome with 3 weeks
placebo CPAP in patients with AD and OSA. Results from the study showed significant improvements in
SWS after one night with the improved effect extending for three weeks. Chong et al also examined the
effect of CPAP treatment on daytime sleepiness and found a significant reduction in patients with mildmoderate AD with SDB after CPAP treatment. Examining the effects of CPAP on cognition in AD
patients, Ancoli-Israel et al157 compared CPAP treatment for three weeks versus placebo CPAP for three
weeks and found significant cognitive improvements. In addition, post-hoc analyses showed
improvements in episodic verbal learning and memory, executive functioning such as cognitive
flexibility, and mental processing speed.
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A limitation identified in these RCTs include the issue of power to detect meaningful changes
across treatment arms. Some studies were underpowered and as such could not make definitive statements
specific to improvements within certain cognitive constructs. Other limitations include examination of
sleep parameters post-hoc while the study was powered for changes in cognition, inability to make causal
inferences due to non-random group assignment (continued use versus discontinuation of CPAP), limited
validation of ESS in elderly patients with AD, and issues with generalizability. Despite these limitations,
there is sufficient evidence to conclude that CPAP treatment may be effective in improving cognition in
OSA patients with AD.
Summary, critique and future research directions
In older adults and the elderly, cross-sectional studies suggest the possibility of a reciprocal relationship
between OSA and AD. The aggregate odds ratio in older adults, for OSA in AD vs. healthy control was
5.05 and homogeneous as demonstrated in a recent meta-analysis. OSA patients have an increased risk of
cognitive decline as shown in the above in the OSA and Cognition section, and cognitive decline
increases the risk for AD. Methodological concerns relating to these studies include the fact that
participants were mostly probable AD, because of the clinical and cognitive presentations of the enrolled
patients and the lack of reported neuroimaging or biomarkers data. Participants were also significantly
more educated which could have been responsible for the null findings seen in some studies. Higher
educational level and cognitive reserve are known protective risk factors for OSA induced cognitive
decline.86,159 Other studies failed to control for demographic and other possible confounders of the
association between OSA and AD. For example, Smallwood et al.160 failed to account for gender
differences in their sample. Women were significantly higher in their sample, which could have been
responsible for their null findings since studies suggest that OSA is more prevalent in men and increases
with age.161
In middle-aged, older adults and elderly individuals, cross-sectional data consistently suggests
that there is an association between OSA and preclinical-AD in the cognitively normal. Studies
consistently demonstrated OSA associations with AD biomarkers including higher levels of serum Aβ40,
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Aβ42, total Aβ and P-tau 181 in OSA patients compared to control, with APOE possibly acting as an
effect modifier. Although determination of the causal relationships and directionality of these associations
is limited in these studies, it is possible that OSA increases the risk for preclinical AD or vice versa.
Prospective studies examining whether OSA accelerates amyloid deposition and effects regional
brain morphological changes that contribute to the development or progression of Alzheimer’s disease are
sparse in all age groups. The two prospective studies examined had contradictory findings. Both studies
also had their strengths and weaknesses (see section on OSA and AD Pathology/Prospective studies).
Therefore, future research is needed in the field to address the temporal nature of OSA-AD relationship
and the possible mechanisms underlying the relationship.
Evidence from RCTs provide an insight into the possibility of causal associations between OSA
and AD and are somewhat compelling. All RCTs were conducted in the elderly, and showed that CPAP
treatment not only improved sleep parameters in AD patients with OSA, such as improved SWS, and
excessive daytime sleepiness, it also increased cognitive function including areas such as episodic verbal
learning and memory, executive functioning such as cognitive flexibility, and mental processing speed.
Such compelling is the evidence such that effects were seen with a single night of CPAP treatment. These
findings clearly provides evidence that AD patients (particularly mild to moderate AD) with OSA can
benefit from CPAP treatment. It is also important to note that studies have shown that management of AD
with donepezil improved various hypoxia and sleep duration measures, suggesting that the cholinesterase
inhibitor improves subjective measures of OSA independently, 162,163 therefore highlighting the potential
reciprocal relationship between sleep and AD.
Future RCTs need to include dose-response studies stratified not only to the mild, moderate, and
severe categories of OSA, but also to include categories addressing duration of disease, extent of
intermittent hypoxemia extent, fragmented sleep severity, and presence of comorbidities. Issues with
design and sample size of double-blinded, placebo controlled clinical trials addressing the effect of CPAP
exist and need to be improved. Furthermore, as Pan et al164 noted in their review, non-inferiority trials
utilizing sleep apnea dental devices or other non-PAP therapeutics will also be beneficial.
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DISCUSSION
Altogether, over three decades of research has investigated OSA-cognition, OSA-cognitive decline
and OSA-AD associations in the middle-aged, older adults and elderly. The data suggests the following:
-

OSA is associated with greater cognitive deficits in middle-age adults than in older adults and the
elderly;

-

OSA is associated with greater risk of subsequent cognitive decline in middle-aged adults than in
older adults and elderly;

-

OSA in older adults with MCI rather than in healthy older adults may be the critical correlate of
cognition in older adults, therefore suggesting that presence or absence of amyloid burden might
act as a moderator in these relationships. This could be responsible for findings showing
increased amyloid deposition in older MCI patients with higher AHI but not in cognitive normal
controls165

-

There is a link between OSA and AD biomarkers of neurodegeneration (e.g. Aβ40, Aβ42, total
Aβ and P-tau 181) and subsequent cognitive decline, in the middle-aged, older-adults and even in
elderly cognitive normal individuals.

We believe that this distinct pattern observed in OSA-Cognition and OSA-AD biomarker associations in
middle-aged, older adults and elderly provides the foundation for envisioning age-related modification of
OSA-cognition relationships.
A pertinent question arises from the findings: why are OSA-cognitive associations particularly
pronounced in the middle-aged and less so in older adults or the elderly? Several studies suggest that the
link between sleep and cognition weakens with increasing age because the aging brain is unable to
adequately and efficiently facilitate specific sleep supported cognitive processes.166-171 If this is true, then
it could have been responsible for the null or weaker results with cognition where associations were
identified in older adults and the elderly in this review. It also implies that improving duration and quality
of sleep in older adults and the elderly may not improve cognitive dysfunction because of diminished
neural plasticity, increased neuronal loss and atrophy, neuroendocrine changes, and nocturnal hypoxia
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that occurs as one ages.172 These neurobiological changes seen in older adults and the elderly may also
compromise memory consolidation processes despite possible preservation of slow wave sleep amplitude
and density. Scullin and Bliwise in their review make the case that functional weakening of the brain in
their support of sleep-specific cognitive processes as we age, that hippocampal—neocortical
consolidation will not occur regardless of slow wave sleep quantity, if the hippocampus, neocortex, or
hippocampal—neocortical connections are greatly impaired in aging.170,173
Another pertinent question from the above is what mechanisms underlie the subsequent cognitive
decline in the middle-aged, even when no OSA-cognition associations are seen in older adults and the
elderly? Scullin and Bliwise highlight the possibility of disturbed sleep causing changes in sleep
modulated cognitive functions across the lifespan such that there is weakening of and/or compensation
attempts incited at sleep-cognition links. They note that studies demonstrate increases in insulin, cortisol,
blood pressure, proinflammatory cytokines and sympathetic tones, during acute or chronic sleep
restriction states,174,175 all of which possibly hasten cognitive aging.176 In addition, experimental studies
show that restriction of sleep in young animals can increase beta amyloid burden,177,178 and cause protein
misfolding,179 therefore compromising consolidation of memory.180,181 The prolonged accumulation over
time of beta amyloid and protein misfolding in the young and middle-aged further results in irreversible
neurodegeneration,182 thereby suggesting that sleep disturbances could possibly underlie subsequent
cognitive decline, even when no sleep-cognition associations are expressed in older adults and the
elderly.172
In middle-aged OSA individuals with cognitive deficits and particularly in OSA elderly AD
patients, randomized placebo controlled clinical trials provide promising findings of improvement of
cognitive deficits that range from attention and vigilance to memory and executive function. Although
CPAP improved hypoxia and other sleep measures relative to pre-CPAP indices, treated OSA patients
demonstrate comparable level of performance in certain areas such as working memory storage functions,
but still show deficits in other areas such as working memory.157,183 Furthermore, intricate
neuropsychological measures of attention, psychomotor speed and executive function tend to improve
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only minimally since intermittent hypoxia upregulates death of neurons and hypertrophy of astrocytes in
the hippocampus and parietal cortex.184-186 The literature suggests that deprived sleep negatively affects
the prefrontal cortex (PFC) which largely controls executive function.187,188 Maillet and Rajah189 in their
review found that task performance matched between age groups yielded negative associations between
regional PFC and activity in older adults, however, the reverse was the case between volume and right
lateral PFC, when older adults performed worse than younger adults did. In addition, several studies
showed that in healthy older adults, PFC activity is positively related to grey matter volume in the medial
temporal lobe, but the reverse was observed in MCI and AD patients. In older adults, prefrontal sleep
spindles that facilitates hippocampal episodic learning are markedly reduced, and the increase in disturbed
sleep further compromises cognition.190,191 Therefore, OSA worsens metabolic injury192 that is particularly
resplendent in middle-aged, and exacerbates neuronal injury and facilitates memory and cognitive
impairment,193-197 that is particularly resplendent in older adults and the elderly.
Recent exciting trends in the literature point to a link between OSA and AD biomarkers of
neurodegeneration and subsequent cognitive decline, in the middle-aged, older-adults and even in elderly
cognitive normal individuals. This finding across our entire examined age spectrum poses a thought
provoking question as to why this is so. The data suggests that intermittent hypoxia and sleep
fragmentation are two main processes by which OSA induces neurodegenerative changes. Chronic
intermittent hypoxia, hypercapnia and hypertension in OSA can induce neuronal damage, including
axons,198 white matter,199 and reduced Diffusion tensor imaging based mean diffusivity in multiple brain
regions.200 Multiple studies also show grey matter loss in OSA patients compared to controls.119,201,202 As
a result of the pathophysiological effect of hypoxia precipitating hypertension,203-206 hypoperfusion,207-209
impaired glucose metabolism,210-212 and adverse cardiovascular,213,214 and metabolic consequences,215,216
beta amyloid deposition,217-220 and tau hyperphosphyrylation,212,221-224 ultimately these effects lead to
cognitive decline and progress to AD. In addition, inflammation,210,221-224 and oxidative stress,225,226
upregulate neurocognitive impairment in OSA and sustained OSA-cognitive dysfunction overlay with
that seen in AD-associated cognitive decline.82
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CONCLUSION
OSA may be age-dependent in older adults (60 – 70 years old) and the elderly (70 years and
above) and is associated with neurodegenerative diseases particularly, cognitive decline and AD. In the
middle-aged (30 – 60 years old), the data suggests that OSA may be age-related and presents with a
distinct phenotype, with cardiovascular, and possibly metabolic effects. Intermittent hypoxia and sleep
fragmentation are two main processes by which OSA induces neurodegenerative changes.
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Table 4.1: Literature Search Terms for the Systematic Review of Obstructive Sleep Apnea, Cognition and
Alzheimer’s disease

Obstructive Sleep Apnea
Related
Sleep apnea
OR Obstructive Sleep Apnea
OR Obstructive Sleep Apnea
Syndrome
OR Sleep Disordered Breathing
OR OSA
OR OSAH
OR Obstructive Sleep Apnea
Hypopnea Syndrome
OR Respiratory Disturbance
Index
OR Apnea Hypopnea Index
OR Hypoxia
OR Sleep Apnea Syndromes
OR Sleep Apnea, Obstructive
OR Sleep Apnea, Central
OR Anoxia

Cognition and Alzheimer's
Disease Related
Alzheimer's disease Dementia
OR Cognitive Decline

Alzheimer's disease
pathology related
Amyloid beta
OR Amyloid beta
deposition/generation
OR Cognitive Impairment
OR Alzheimer's disease
pathogenesis
OR Mild Cognitive Impairment OR Amyloid Precursor
(MeSH)
Protein
OR MCI
OR Amyloid cascade
hypothesis
OR aMCI
OR Inflammation
OR Cognition
OR P-Tau
OR Alzheimer (MeSH)

OR Phosphorylated Tau

OR Cognitive function
OR Neuropsychological
function
OR Executive function

OR Hippocampal atrophy
OR Apolipoprotein E
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OR APOE4
OR CSF-Tau
OR CSF-PTau

Table 4.2: Descriptive Study Characteristics and Main Findings: Obstructive Sleep Apnea, Cognition, Cognitive Decline and Alzheimer’s disease
(Cross-sectional studies)
Authors,
Year
Published

Study Design,
Setting (Study
Quality)

Subjects
Controls
N

Age

OSA+
N

Gender

Age

SDB Severity

Cognitive Domains

Adjusted
Variables

Major Findings

Reaction time

Age, AHI,
SaO2min/mean,
T90, BMI

OSA individual’s ≥ 50
had decreased reaction
times. This effect was
not seen in those <50.

Global function,
attention, memory,
executive function

Age, education

OSA individuals had
significantly impaired
cognitive performance

Age, education

▪ At baseline OSA
assoc. with
↓neurocognitive
function
▪OSA group had
improved
neurocognitive
function after 3 months
of CPAP
▪OSA assoc. with
structural deficits

Age, education

▪OSA associated with
over recruitment of
brain regions in
working-memory task
▪Decreases in
activation after
treatment

Middle Aged (30-60)

Alchantis et
al., 2008

Cross-sectional,
sleep clinic

41

49 (33-63)

Bawden et
al., 2011

Cross-sectional

20

27.6 (8.7)

Canessa et
al., 2011

Castronovo et
al., 2009

Controlled clinical
trial

Controlled clinical
trial

15

14

42.15
(6.64)

42.15
(6.64)

58

49 (3265)

N/A

AHI: range
31-137
OSAS;
Range=1-7
NC

17

41.4
(13.0)

N/A

AHI: 515/>15-30/
>30

17

14

44 (7.63)

43.93
(7.78)

All men

All men

234

AHI: ≥ 30

AHI > 30

Memory, executive
functions, attention,
constructional
abilities, abstract
reasoning, vigilance,
ESS

Working memory,
Brain activation
(fMRI)

Castronovo et
al., 2014

FeriniStrambi et al.,
2003

HrubosStrom et al.,
2012

Kim et al.,
2007

Kloepfer et
al., 2009

Mathieu et
al., 2008

Prospective clinical
study

Case-control, sleep
clinic

Cross-sectional,
community

Cross-sectional,
community

15

23

N/A

N/A

42.15
(6.64)

55.8 (5.4)

N/A

N/A

13

23

290

611

43.23
(7.63)

56.6 (6.1)

48.2
(11.2)

All men

40M6F

162M
129F

AHI:<15/ ≥15

AHI:
median=2.8;
range=0-121

22M
13F

Clinical
diagnosis:
AHI >5 and
questionnaire

26 M
2W

AHI: 51(4)
OSAS
younger;
43(4) OSAS
older

47.4(5.6)

15

46.4 (5.9)

Cross-sectional,
sleep clinic

Younger:
12
Older:
18

Younger:
38.9 (2.2)
Older:
62.5 (1.8)

Younger:
14
Older:
14

Younger:
37.7 (2.0)
Older:
62.3 (2.0)
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Memory, Executive
function

Age, sex,
education

▪Average oxygen
saturation was the
indicator of obstructive
sleep apnea severity
most strongly assoc.
with cognitive function

Vigilance

BMI,
caffeine/alcohol
consumption,
smoking status,
stimulants before
testing

▪SDB related with
diminished vigilant
attention performance

Age, sex, IQ

▪Moderate OSA assoc.
with impairment of
procedural and verbal
declarative memory

Age, education

▪No Group-by-Age
interaction for
cognitive performance.
▪Main effects for both
Group and Age

AHI:
Controls: <5,
OSA: ≥5-40

Processing speed,
language, executive
function, motor
learning

346 M
265 W

20

Age, education

▪ 15 days of CPAP
treatment returned
visuospatial and motor
skills to normal ▪CPAP
did not improve
executive function/
constructional abilities

AHI ≥ 30

Global function,
memory, attention,
vigilance, abstract
reasoning, visuospatial, verbal

Range:
35-74

Cross-sectional

Age, education

▪After 12 months of
CPAP treatment,
almost a complete
reversal of white
matter abnormalities
was seen ▪Significant
improvements in
neuropsychological
function

Memory, global

Attention, Executive
Function, Memory

Naegele et
al., 1995

Naegele et
al., 2006

Nikodemova
et al., 2013

Quan et al.,
2006

Cross-sectional

Cross-sectional

Cross-sectional,
community

Cross-sectional,
community

17

49 (3)

17

49 (3)

95

47.4

95

48

AHI <5

AHI 5-14

AHI ≥
15

Total

n: 1,148
age: 52.1
(9.9)

n: 399
age: 56.4
(9.6)

n: 298
age: 56.6

n: 1,845
age: 53.9
(10.1)
age range:
30-81

74

57.4(9.2)

67

59.4 (9.2)

All men

144M46F

1,081 M
F

84M
57F

236

RDI > 10

RDI ≥ 10

Attentional capacity,
memory efficiency,
long-term memory,
frontal lobe function

Memory

AHI: <5/514/≥ 15

Memory, Executive
function

AHI: ≤5

Attention and
vigilance, processing
speed, executive
function, motor
learning, visuospatial
ability, memory

Age, education,
verbal IQ

▪Memory deficits were
associated with the
number of apneas and
hypopneas per hour of
sleep ▪Typical frontallobe related
abnormalities were
associated with levels
of nocturnal
hypoxemia

Age, education

▪OSA associated with
impaired episodic
memory, overall
procedural memory
performance, specific
working memory
capabilities ▪No
impairment of
maintenance,
recognition, or
forgetfulness

Age, sex,
education, BMI

▪No significant
association between
SDB and cognitive
performance in
APOE4- ▪AHI ≥15,
APOE4+ associated
with ↓cognitive
function

Age, sex,
education

▪No significant impact
of OSAH and
neuropsychological
function ▪↑hypoxemia
associated with ↓motor
and processing speed

Salorio et al.,
2002

Saunamaki,
Himanen, et
al., 2009

Saunamaki et
al., 2010

Saunamaki,
Jehkonen et
al., 2009

Cross sectional

Controlled clinical
trial

Controlled clinical
trial

Controlled clinical
trial

24

15

17

20

44.2(8.5)

44
Range:
30-63

44Range:
30-63

43
Range:
29-63

28

15

20

40

44.0 (7.9)

50
Range:
37-59

50 Range:
37-65

47
Range:
28-65

34M
18F

All men

All men

All men
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Hypoxic
episodes: 520/21-35/>35
episodes per
hour

AHI:≤5/> 10

AHI:≤5/> 10

AHI:≤5/> 10

Long-term Learning
and Memory,
Executive control

WAIS-R

WAIS-R; Short term
memory, working
memory, verbal
fluency, visuomotor
tracking, visuospatial
organization

WAIS-R; Verballybased cognitive
abilities, visuallybased cognitive
abilities,

Sex, education, IQ

▪OSA individuals
exhibited poorer recall,
less efficient semantic
clustering, poorer use
of semantic cues
▪Other than letter
fluency, deficits were
not observed in general
executive control

Age, education

▪OSAS associated with
mild visually based
cognitive dysfunction
and reduced amount of
sleep in the right
hemisphere even after
CPAP

Age, education,
IQ

▪OSAS showed poorer
performance on
executive tests ▪OSAS
did not show any
improvement on
executive or
visuospatial function
even after long-term
CPAP treatment

Age, education

▪OSAS had lower setshifting and
analysis/synthesis
performance than
controls ▪Based on
normative data, most
had normal, while
others had more
serious deficits

Sharma et al.,
2010

Cross-sectional

25

45.6 (6.2)

50

43 (7.5)

63M
12F

AHI > 30

Alertness, working
memory, response
inhibition, problem
solving, executive
function

Age, sex,
education

▪OSA subjects had
significantly impaired
performance on tests
on alertness, working
memory, response
inhibition, problem
solving, executive
function ▪Significance
disappeared after
adjusting for delayed
information processing

Age, education,
sleep apnea
severity

▪↑RDI related to↓
verbal delayed recall
memory
▪↑sleep fragmentation
and hypoxemia
associated with↓ verbal
delayed recall memory
▪Cognitive benefits
with CPAP compliance

Older Adults (61-70)
Noncompliant

Aloia et al.,
2003

Cross-sectional,
clinic

Berry et al.,
1990

Cross-sectional,
sleep clinic

Boland et al.,
2002

Dlugaj et al.,
2014

Cross-sectional,
community

Cross- sectional,
population-based

Compliant

6

64.8 (2.6)

6

64.8 (6.4)

12

68.4 (2.2)

8

68.6(4.8)

N/A

N/A

1700

62 (range
52-75)

AHI <15

AHI 15-29

AHI ≥
30

Total

n: 327
age: 65.79
(7.41)

n: 143
age:
62.17
(7.31)

n: 1323
age:
62.94
(7.23)

n: 1793
age: 63.79
(7.45)

N/A

RDI: 51(20)
OSAS
compliant;
46(22) OSAS
noncompliant

Attention, Executive
Function,
Construction, Motor
Speed, Memory,
Language

Men only

AHI: 28(12)
OSAS;
3(3)NC

Global, IQ, Memory

▪OSAS: ↓nonverbal IQ
and nonverbal memory
delayed recall

837M923W

RDI median
range: .4-23

Attention, Executive
Function, Memory

age, education,
occupation, field
center, diabetes,
hypertension,
body-mass index,
CNS meds,
alcohol use

919M
874F

AHI; <15/1529/ ≥ 30

Memory, executive
function

Age, sex,
education
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▪No relationships

▪SDB not associated
with MCI or MCI
subtypes (amnestic and
non-amnestic)

Foley et al.,
2003

Cross-sectional,
community

N/A

N/A

Ju et al., 2012

Case-control, sleep
clinic

21

68.7 (5.5)

Kim et al.,
2011

Cross-sectional,
clinic

Lutsey et al.,
2016

Cross-sectional

Phillips et al.,
1992

Cross-sectional,
community

N/A

521

N/A

N/A

60.7 (5.1)

N/A

382

Combined
exposure
and
controls:
68(1.8)

Casecontrol(convenience
sample),
community

N/A

Cross-sectional,
sleep clinic

N/A

Sforza et al.,
2010

Cross-sectional,
community

Terpening et
al., 2015

Yesavage et
al., 1985

Men only

71% had
AHI≥5; 19%
had AHI ≥ 30

Global, Attention,
Executive Function,
Construction,
Memory, Language

Age, education,
marital status

▪No relationships

68(4.4)

37M
26F

AHI: Controls
:< 15. OSA:
<15.3*

General
cognitive/intellectual
ability, executive
function

Age, sex,
education, BMI

▪Significant findings
with delayed recall and
executive function

67.4 (3.8)

42M
18W

AHI: 13(12)
MCI;15(14)
NC

Executive function,
Language, Memory,
Visuospatial
construction

718

Range:
79-97

42

30

445

92

62(4.9)

435M
531W

64.2 (8.6)

44M
48W

445

Combined
exposure
and
controls:
68(1.8)

343M
484W

N/A

40

63.5 (8.9)

19M21F

N/A

41

69.5 (6.5)

Men only

Elderly (>70)
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▪↑AHI associated with
language with MCI

AHI (<5/514.9/1529.9/≥30)

Global

Age, sex, field
center, education,
alcohol intake,
smoking, physical
activity, APOE4,
BMI, CRP, CVD
comorbidities

AHI: 3(4)

Global, IQ, Attention,
Executive Function,
Memory, Language,
Motor

None

▪No relationship
between AHI and
cognition

Global, Attention,
Executive Function,
Memory, Language

gender, BMI,
diabetic status,
hypertension,
education level,
anxiety and
depression scores,
ESS, blood
pressure, selfreported sleep
time

▪No relationships

AHI: 20(15);
53% had
AHI≥15

Processing speed

RDI: 26(30);
73% had
RDI>5

Attention, Executive
Function, Memory

▪OSA category and
additional indices of
sleep were not
associated with change
in any cognitive test

▪Findings significant**

Age, depression,
education, typical
sleepiness/fatigue

▪RDI associated with
attention and executive
function

Blackwell et
al., 2011

Hayward et
al., 1992

Spira et al.,
2008

Cross-sectional,
population-based

Cross-sectional,
community

Cross-sectional,
community

N/A

N/A

391

N/A

N/A

82.7 (3.3)

2,909

96

57

76 (6)

78 (3.9)

83.6 (4.3)

Only men

21 M
75 W

Women
only

Age, race, clinic,
BMI, IADL, CVD
comorbidities,
antidepressant
use,
benzodiazepine
use, depressive
symptoms,
education, alcohol
use, smoking,
physical activity,
self-reported
health

▪↓ time in REM, ↑ time
in Stage 1 sleep, and
↑nocturnal hypoxemia
are associated with
poorer cognition

AHI: <5/514/≥ 30

Global, Executive
Function

RDI: 6(6)

Attention, Executive
Function, Memory,
Language, Motor

Age, education

▪RDI not associated
with memory, verbal,
or motor factors
▪RDI associated with
cerebral efficiency
factor

Global, Executive
Function

Age, Education,
SSRI (BMI and
functional
impairment were
found to not have
a significant
impact on results)

▪↑AHI&↑hypoxemia&
↑central apnea
associated with
cognition
▪APOE4+ associated
with 5x risk of
cognitive impairment

AHI: <30/≥
30

Abbreviations: a, adjusted; Aβ40/42, amyloid beta-40/42; AD, Alzheimer’s disease; AFCFT, alphabetic fluency and category fluency tasks; AHI ≥ 15, apnea hypopnea index of 15 or more events per
hour of sleep; APOE, apolipoprotein epsilon4; BVRT, Benton visual retention test; c, crude; CAR, circadian activity rhythms; CASI, cognitive abilities screening instrument; CERAD, consortium to
establish a registry for Alzheimer’s disease; CPRS, comprehensive psychopathological rating scale; CSF, cerebrospinal fluid; CVLT, California verbal learning test; DSM-IIIR/IV-TR, diagnostic and
statistical manual of mental disorders; third edition/fourth edition, text revised; EDS, Excessive daytime sleepiness; ESS, Epworth sleepiness scale; GBSRT, Grober and Buschke selective reminding
test; HAM-D, Hamilton Depression Rating Scale; HR, hazard ratio; ICD-9/10, international classification of diseases ninth/tenth edition AD criteria; IQCODE, informant questionnaire on cognitive
decline in the elderly; MMSE, mini mental state examination; MRI, magnetic resonance imaging; N, number of participants; NA, not applicable; N/A, not available; NINCDS-ADRDA, national institute
of neurological and communicative disorders and stroke and the Alzheimer’s disease and related disorders association; NINDS-AIREN, national institute of neurological disorders and stroke and
association internationale pour la recherche et l’enseignement en neurosciences vascular dementia criteria; OR, odds ratio; PSG, polysomnography; PSQI, Pittsburgh sleep quality index; P-tau,
phosphorylated tau; RBANS, repeatable battery for the assessment of neuropsychological status; RR, relative risk; SDB, sleep disordered breathing; SPMSQ, short portable mental status questionnaire;
TONI, test of nonverbal intelligence; Trails B, trail making b test; TST, total sleep time; T-tau, total-tau; WAIS-III, Wechsler adult intelligence scale third version; WASO, wake after sleep onset;
WHIIRS, women’s health initiative insomnia rating scale; WMS-R, Wechsler memory scale-revision; w/o, without.
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Table 4.3: Descriptive Study Characteristics and Main Findings: Obstructive Sleep Apnea, Cognition, Cognitive Decline and Alzheimer’s disease
(Longitudinal studies – older adults mainly)

Authors,
Year
Published

Blackwell et
al., 2015

Study
design,
setting
(study
quality)

Longitudinal,
community
based

Chang et al.,
2013

Longitudinal,
community
based

Cohen-Zion
et al., 2001

Longitudinal,
Community

Lutsey et al.,
2016

Longitudinal

Subjects
Controls
N

1,504

7,070

Age

75.8
(5.3)

55.5
(4.78)

OSA+
N

1,132

1,414

46

Age

Gender

SDB
Severity

Men
only

ODI: <15,
≥15
AHI: <15,
≥15)

55.5
(4.93)

M:
5,034
F:
3,450

Not
specified;
clinical
diagnosis
(according to
the
guidelines of
the AASM)

80(3)

7M
39 W

RDI: 10(9)

435M
531W

AHI: <5/514.9/ 1529.9/ ≥30

76.4
(5.2)

N/A

N/A

521

60.7
(5.1)

445

62(4.9)

N/A

N/A

599

67.0 (1)

Cognitive
Domains

Adjusted Variables

Major Findings

Global

Age, site, race, BMI,
education, depressive
symptoms, CVD
comorbidities, Parkinson's
disease, IADL,
benzodiazepine use,
antidepressant use, selfreported health, physical
activity, alcohol intake,
smoking

▪No significant association
between AHI and cognitive
decline in older communitydwelling men
▪Modest association of
nocturnal hypoxemia with
global cognitive decline

Age, sex, CVD
comorbidities, urbanization
level, income

▪ Hazard ratio of dementia is
1.44 times greater for patients
with SA than for the
comparison group
▪SA is an age, time, and gender
dependent risk factor for
dementia

Global

Age, education

▪↑EDS associated with global
cognitive decline over 3 years
follow-up ▪Hypoxemia and RDI
not associated with cognition

Global

Age, sex, field center,
education, alcohol intake,
smoking, physical activity,
APOE4, BMI, CRP, CVD
comorbidities

▪OSA category and additional
indices of sleep were not
associated with change in any
cognitive test

Dementia
diagnosis

Global
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Martin et al.,
2015

Longitudinal,
population
based

224M
335W

Yaffe et al.,
2011

Longitudinal,
Community

Women
only

Men
Only

Yaffe et al.,
2015

Longitudinal

193

######

82.1(3.2)

68.5

105

13,480

82.6(3.1)

66.9

Age, sex, education, followup length, BMI, ESS, CVD
comorbidities, anxiety,
depression

▪Abnormal breathing events
associated slightly with decline
in attentional domain
▪No association with changes in
executive and memory function

AHI: ≥15

Global,
Attention,
Executive
Function,
Memory

Age, race, BMI, education,
smoking, diabetes,
hypertension, antidepressant
use, benzodiazepine use,
non-diazepam anxiolytics use

▪SDB: ↑hypoxemia had ↑risk of
developing MCI or dementia
over 5 year follow-up▪Sleep
fragmentation and duration not
associated with cognition

Not
specified;
clinical
diagnosis

Dementia
(classified using
International
Classification of
Disease, Ninth
Revision codes)

Age, CVD comorbidities,
obesity, depression, income,
education

▪Those with a sleep disturbance
had a 27% increased risk for
dementia (HR: 1.27)

AHI: <15/
15-30/ >30)

Abbreviations: a, adjusted; Aβ40/42, amyloid beta-40/42; AD, Alzheimer’s disease; AFCFT, alphabetic fluency and category fluency tasks; AHI ≥ 15, apnea hypopnea index of 15 or more events per
hour of sleep; APOE, apolipoprotein epsilon4; BVRT, Benton visual retention test; c, crude; CAR, circadian activity rhythms; CASI, cognitive abilities screening instrument; CERAD, consortium to
establish a registry for Alzheimer’s disease; CPRS, comprehensive psychopathological rating scale; CSF, cerebrospinal fluid; CVLT, California verbal learning test; DSM-IIIR/IV-TR, diagnostic and
statistical manual of mental disorders; third edition/fourth edition, text revised; EDS, Excessive daytime sleepiness; ESS, Epworth sleepiness scale; GBSRT, Grober and Buschke selective reminding
test; HAM-D, Hamilton Depression Rating Scale; HR, hazard ratio; ICD-9/10, international classification of diseases ninth/tenth edition AD criteria; IQCODE, informant questionnaire on cognitive
decline in the elderly; MMSE, mini mental state examination; MRI, magnetic resonance imaging; N, number of participants; NA, not applicable; N/A, not available; NINCDS-ADRDA, national institute
of neurological and communicative disorders and stroke and the Alzheimer’s disease and related disorders association; NINDS-AIREN, national institute of neurological disorders and stroke and
association internationale pour la recherche et l’enseignement en neurosciences vascular dementia criteria; OR, odds ratio; PSG, polysomnography; PSQI, Pittsburgh sleep quality index; P-tau,
phosphorylated tau; RBANS, repeatable battery for the assessment of neuropsychological status; RR, relative risk; SDB, sleep disordered breathing; SPMSQ, short portable mental status questionnaire;
TONI, test of nonverbal intelligence; Trails B, trail making b test; TST, total sleep time; T-tau, total-tau; WAIS-III, Wechsler adult intelligence scale third version; WASO, wake after sleep onset;
WHIIRS, women’s health initiative insomnia rating scale; WMS-R, Wechsler memory scale-revision; w/o, without.
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Table 4.4 Descriptive Study Characteristics and Main Findings: Obstructive Sleep Apnea, and Alzheimer’s disease/AD Pathology
Subjects
Authors, Year
Published

Study
Design

N

Age
(Mean ±
SD)

Gender

OSA
assessment

Alzheimer's disease
assessment

Adjusted Variables

Major findings

OSA and AD
Hoch et al.,
1986

Crosssectional

80

71.5 (8.1)

33 M
57 F

AHI

DSM-III

None

Significant association

Hoch et al.,
1989

Crosssectional

27

74.5 (5.1)

7M
20 F

AHI

NICNDS-ADRDA,
DSM-III

N/A

No association between OSA
and dementia

Reynolds et
al., 1985

Crosssectional

69.7 (6.8)

19 M
42 F

AI, AHI

DSM 3, Hamilton
rating, Folstein
score, and a
modified Hachinski
Ischemia score

Gender

Significant association between
sleep apnea and dementia in
women

N/A

No association between OSA
and dementia

Age, sex

61

Reynolds et
al.,1987

Crosssectional

30

73.3 (9.1)

3M
12 F

24 Chanel
polygraphs

DSM 3, Hamilton
rating, Folstein
score, and a
modified Hachinski
Ischemia score

Smallwood et
al., 1983

Crosssectional

55

Range: 2381 years

45 M
10 F

AHI

DSM 3, neurological
examination

No relationship between
dementia and apnea severity

OSA and AD pathology

Bu et al., 2015

Crosssectional

Ligouri et al.,
2017

Crosssectional

94

43.62
(9.78)

67M
27F

50

66.96
(7.98)

33M
17F

AHI, ODI,
MSaO2,
LSaO2

Amyloid beta levels

Age, sex

Significant association between
hypoxia and amyloid levels

AHI

CSI classified by
subjective memory
decline, cognitive
performance

Age, education

Significant association between
OSA and CSF AD biomarkers
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Lutsey et al.,
2017

Osorio et al.,
2014

Prospective

Crosssectional

312

95

Osorio et al.,
2015

Prospective

2,285

Yun et al.,
2017

Crosssectional

38

61.7 (5.0)

67.6

56.7 (4.0)

145M
167F

37M58F

M: 18
F: 20

Neurocognitive
exam, brain MRI

age, sex, field center,
education, physical
activity, ethanol intake,
smoking status, leusire
time physical activity,
and APOE e4 risk
allele, BMI

No relationship between midlife OSA and dementia

AHI

Neuropsychological
test battery

Age, BMI, CSF internal
batch, time interval
between sleep study and
lumbar puncture,ApoE4
status

Significant association between
SDB and AD CSF biomarkers

Self reported

Self-report;
diagnosis by
clinician

AHI

Neuropsychological
test battery

AHI, SHHS
Sleep Habits
Questionnaire

APOE e4 status, sex,
education, BMI,
depression,
cardiovascular disease,
hypertension, diabetes,
and age
Age, sex, education,
APOE genotype, status
of sleep duration,
hypertension, diabetes,
BMI, exercise,
depressive mood,
smoking, and alcohol
drinking

Significant association between
SDB and earlier age at
cognitive decline

Significant association between
OSA and amyloid deposition

Random Control Trials
Ancoli-Israel
et al., 2008

RCT

52

78.2 (7.2)

39M
13F

Rechtschaffen
and Kales
criteria

Nueropsychological
test battery

None

CPAP improved some
cognitive functioning

Chong et al.,
2006

RCT

39

78.0 (7.04)

29M
10F

RDI

NINCDS-ADRDA
criteria

None

CPAP reduces sleepiness in
those with AD and OSA

Cooke et al.,
2009a

RCT

52

77.8 (7.3)

39M
13F

Rechtschaffen
and Kales
criteria

NINCDS-ADRDA
criteria, MMSE

None

After one night of tCPAP use:
deeper sleep, affects for three
weeks

Cooke et al.,
2009b

RCT

10

75.7 (5.9)

7M
3F

AHI, PSQI,
ESS, FOSQ

Neuropsychological
test battery

None

Sustained CPAP use associated
with less cognitive decline
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Spira et al.,
2014

RCT

13

71.6 (7.8)

7M
6F

AHI, ODI

Neuropsychological
tests, GDS, CDR

None

SDB severity associated with
amyloid deposition

Abbreviations: a, adjusted; Aβ40/42, amyloid beta-40/42; AD, Alzheimer’s disease; AFCFT, alphabetic fluency and category fluency tasks; AHI ≥ 15, apnea hypopnea index of 15 or more events per
hour of sleep; APOE, apolipoprotein epsilon4; BVRT, Benton visual retention test; c, crude; CAR, circadian activity rhythms; CASI, cognitive abilities screening instrument; CERAD, consortium to
establish a registry for Alzheimer’s disease; CPRS, comprehensive psychopathological rating scale; CSF, cerebrospinal fluid; CVLT, California verbal learning test; DSM-IIIR/IV-TR, diagnostic and
statistical manual of mental disorders; third edition/fourth edition, text revised; EDS, Excessive daytime sleepiness; ESS, Epworth sleepiness scale; GBSRT, Grober and Buschke selective reminding
test; HAM-D, Hamilton Depression Rating Scale; HR, hazard ratio; ICD-9/10, international classification of diseases ninth/tenth edition AD criteria; IQCODE, informant questionnaire on cognitive
decline in the elderly; MMSE, mini mental state examination; MRI, magnetic resonance imaging; N, number of participants; NA, not applicable; N/A, not available; NINCDS-ADRDA, national institute
of neurological and communicative disorders and stroke and the Alzheimer’s disease and related disorders association; NINDS-AIREN, national institute of neurological disorders and stroke and
association internationale pour la recherche et l’enseignement en neurosciences vascular dementia criteria; OR, odds ratio; PSG, polysomnography; PSQI, Pittsburgh sleep quality index; P-tau,
phosphorylated tau; RBANS, repeatable battery for the assessment of neuropsychological status; RR, relative risk; SDB, sleep disordered breathing; SPMSQ, short portable mental status questionnaire;
TONI, test of nonverbal intelligence; Trails B, trail making b test; TST, total sleep time; T-tau, total-tau; WAIS-III, Wechsler adult intelligence scale third version; WASO, wake after sleep onset;
WHIIRS, women’s health initiative insomnia rating scale; WMS-R, Wechsler memory scale-revision; w/o, without.

245

Identification

Figure 4.1: Study retrieval and selection for Obstructive Sleep Apnea, Cognitive Decline and/or
Alzheimer’s disease Review
Studies identified through database searching (n = 2717)
(PubMed=1,112, Embase = 1,164, Web of Science = 285, Psych Info = 103, Cochrane library = 53

Duplicates removed
(n =1029)
Studies after duplicates removed
(n = 1,688)

Screening

Studies screened for titles
(n = 1,688)

Studies excluded
(n =784)

Studies screened for abstracts

Studies excluded
(n = 711)

(n = 904)

Eligibility

Full-text articles assessed
for eligibility
(n =193)

Full-text articles excluded, with
reasons (n = 141)
-

Included

Article identified
from reference
search
(n = 5)

Studies included in
systematic review
(n = 57)
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Review article (n = 15)
OSA not assessed (n =
32 )
Relationship not
studied (n = 40)
Not peer reviewed (n =
15 )
Alzheimer not
examined (n = 24)
Duplicate studies (n =
15)

248

249

APPENDIX C
IRB LETTER

10/20/2017
Omonigho Bubu, MD, MPH
Epidemiology and Biostatistics
4202 East Fowler Ave.
Tampa, FL 33612
RE:
IRB#:
Title:

Not Human Subjects Research Determination
Pro00032613
Obstructive Sleep Apnea and the risk of Alzheimer’s disease

Dear Dr. Bubu:
The Institutional Review Board (IRB) has reviewed your application. The activities presented in
the application involve methods of program evaluation, quality improvement, and/or needs
analysis. While potentially informative to others outside of the university community, study
results would not appear to contribute to generalizable knowledge. As such, the activities do not
meet the definition of human subject research under USF IRB policy, and USF IRB approval and
oversight are therefore not required.
While not requiring USF IRB approval and oversight, your study activities should be conducted
in a manner that is consistent with the ethical principles of your profession. If the scope of your
project changes in the future, please contact the IRB for further guidance.
If you will be obtaining consent to conduct your study activities, please remove any references to
"research" and do not include the assigned Protocol Number or USF IRB contact information.
If your study activities involve collection or use of health information, please note that there may
be requirements under the HIPAA Privacy Rule that apply. For further information, please
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contact a HIPAA Program administrator at (813) 974-5638.
Sincerely,

E. Verena Jorgensen, M.D., Chairperson
USF Institutional Review Board
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